<SEC-DOCUMENT>0001731122-20-000807.txt : 20200806
<SEC-HEADER>0001731122-20-000807.hdr.sgml : 20200806
<ACCEPTANCE-DATETIME>20200806160815
ACCESSION NUMBER:		0001731122-20-000807
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		40
CONFORMED PERIOD OF REPORT:	20200630
FILED AS OF DATE:		20200806
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		201081634

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e2054.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:avxl="http://anavex.com/20200630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2020_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_avxl_anavex.com_20200630 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20191001_20200630 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0wOS0zMA== -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DDocumentFiscalYearFocus_2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:CurrentFiscalYearEndDate">--09-30</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2019-09-30" id="xdx2ixbrl0056" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0275" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-01to2020-06-30" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-01to2020-06-30" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0434" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-06-30" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0462" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0465" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0468" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0469" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0470" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember" id="xdx2ixbrl0476" unitRef="USD" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="avxl-20200630.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-10-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-29</xbrli:startDate>
        <xbrli:endDate>2020-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-19</xbrli:startDate>
        <xbrli:endDate>2015-10-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_903_edei--DocumentType_c20191001__20200630_zGIjp6YidOt7"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_906_edei--DocumentQuarterlyReport_c20191001__20200630_z0mSCyCYihW6"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span><span style="font: 10pt Times New Roman, Times, Serif"><b>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_905_edei--DocumentPeriodEndDate_c20191001__20200630_ze4EMVGmN7m3"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, 2020</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_904_edei--DocumentTransitionReport_c20191001__20200630_zpQLqPl5NLlc"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font: 10pt Times New Roman, Times, Serif"><b>
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_901_edei--EntityFileNumber_c20191001__20200630_zRGoyJl1ZFv1"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20191001__20200630_z5Po5OtV6Qsd"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20191001__20200630_zFt1SzRUkYma"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20191001__20200630_zOifIxr74Bwc"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction
    of</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation or
    organization)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90D_edei--EntityAddressAddressLine1_c20191001__20200630_z3K4UqkRWdn2"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityAddressAddressLine1">51 West 52nd Street</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressAddressLine2_c20191001__20200630_zhylTZla4qY8"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityAddressAddressLine2">7th Floor</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressCityOrTown_c20191001__20200630_zpTFaQ7LfCzf"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20191001__20200630_zBLaW3cU11Mb"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressCountry_c20191001__20200630_zXTqsp1oiRya"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">USA</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20191001__20200630_zpLu9M1Ryj4k"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">1-<span id="xdx_908_edei--CityAreaCode_c20191001__20200630_z1n3OV0VV6N5"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90D_edei--LocalPhoneNumber_c20191001__20200630_zHFaNrnL7D3g"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_edei--Security12bTitle_c20191001__20200630_zkwl4EbCRdy1"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--TradingSymbol_c20191001__20200630_zXALEOn7y6z9"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 34%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--SecurityExchangeName_c20191001__20200630_znQ48q0ckWL6"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The NASDAQ Stock Market LLC</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#9746;<span style="font: 10pt Times New Roman, Times, Serif"><b>
<span id="xdx_903_edei--EntityCurrentReportingStatus_c20191001__20200630_za6Ww756jaMa"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#9744;  No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#9746;<span style="font: 10pt Times New Roman, Times, Serif"><b>
<span id="xdx_909_edei--EntityInteractiveDataCurrent_c20191001__20200630_zZLw7c4rVB41"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#9744;  No</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 27%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</span></td>
    <td style="width: 3%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;&#160;
    &#160;</span></td>
    <td style="width: 41%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 26%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityFilerCategory_c20191001__20200630_zzDLSDk1QSge"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" name="dei:EntityFilerCategory">Accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="width: 3%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#9744;</td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntitySmallBusiness_c20191001__20200630_zkzWoS6uB8V5"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth
    company</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20191001__20200630_zKGNw1dPGqL1"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#9744;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&#9744;<span style="font: 10pt Times New Roman, Times, Serif"><b>
 Yes&#9746;  <span id="xdx_907_edei--EntityShellCompany_c20191001__20200630_zEnRuAk0mZW8"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_iI_c20200806_zNDoEGe87m64"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2020-08-06" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,190,619</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of common stock outstanding as
of August 4, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS </b></span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part1">PART I - FINANCIAL INFORMATION</a></span></td>
    <td style="width: 10%; text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item1">Item 1. FINANCIAL STATEMENTS</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">19</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item3">Item 3. Quantitative and Qualitative Disclosures about Market Risks.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item4">Item 4. Controls and Procedures.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#part2otherinfo">PART II &#8211; OTHER INFORMATION</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#legalproceedings">Item 1. Legal Proceedings.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#itemn1a">Item 1A. Risk Factors.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#unregistered">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#defaults">Item 3. Defaults Upon Senior Securities.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#minesafety">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#otherinfo">Item 5. Other Information.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#exhibits">Item 6. Exhibits.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#signatures">SIGNATURES</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="part1"></span><b>PART
I - FINANCIAL INFORMATION</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="item1"></span><b>Item
1. FINANCIAL STATEMENTS</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0; text-transform: uppercase; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0; text-transform: uppercase; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0; text-transform: uppercase; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">June
30, 2020 and September 30, 2019</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_111_z2K7QEDTAM19" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" id="xdx_49B_20200630_zQR7W15JOH5d" style="font-weight: bold; text-align: center">June 30,</td><td>&#160;</td>
    <td colspan="3" id="xdx_49D_20190930_ztdZwpfMCAuj" style="text-align: center"><b>September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--AssetsAbstract_iB_zJuU3CwWIkEj" style="vertical-align: bottom; background-color: White">
    <td>Assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zWPAqeCiXPcl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Current</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">&#160;</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzjgC_zNFKUpnxeFi3" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 12px">Cash and cash equivalents</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,619,145</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,185,630</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--IncomeTaxesReceivable_i02I_maCzjgC_zSombPsxc5J1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12px">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,547,972</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,642,745</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--PrepaidExpenseCurrent_i02I_maCzjgC_zOAJCuFYLRck" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12px">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">438,631</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,998</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--DeferredCostsCurrent_i02I_maCzjgC_zG2WTfmhSUia" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12px">Deferred costs</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,508</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0056">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--AssetsCurrent_i02TI_mtCzjgC_maCzLps_zHKZ6IbPN5Xg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total Current Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,630,256</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,329,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--Assets_i01TI_mtCzLps_zfvEnzECAfv2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,630,256</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,329,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zCjiCFpxDV0c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities and Stockholders' Equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--LiabilitiesCurrentAbstract_i01B_zIs8w0e9vRik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current Liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AccountsPayableCurrent_i02I_maCzBSA_zs40fQVDx6cg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12px">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,980,204</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523,332</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzBSA_z2O5aTCR9Wfj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12px">Accrued liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,968,994</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,516,342</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--LiabilitiesCurrent_i02TI_mtCzBSA_maCzUVd_ztoSyDR80I0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,949,198</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,039,674</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--CommitmentsAndContingencies_i01I_zrSsXTu0oMHg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Commitments and Contingencies - Note 5</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12px">Authorized:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 24px"><span id="xdx_909_eus-gaap--PreferredStockSharesAuthorized_iI_c20200630_zmiJ23NxrQq" title="Preferred stock, authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20190930_z1bVAj2KqLp9" title="Preferred stock, authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> preferred stock, par value $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200630_zhAqkgBSbDo" title="Preferred stock, par value (in dollars per share)"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20190930_zdoPzUoTLmqc" title="Preferred stock, par value (in dollars per share)"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_maCz8c3_c20200630_zHaEoffsybrf" title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-06-30" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" id="xdx_98E_eus-gaap--PreferredStockValue_i01I_pp0p0_d0_c20190930_z2RHtnyxKcS9" style="display: none; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-09-30" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 24px"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20200630_zjo23j5XvuHi" title="Common shares, authorized"><span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20190930_z8Evdjjnqfd" title="Common shares, authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> common stock, par value $<span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200630_zkrkZRjxY6p6" title="Common shares, par value (in dollars per share)"><span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20190930_z7fdbkwIN4h3" title="Common shares, par value (in dollars per share)"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12px">Issued and outstanding:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 24px"><span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20200630_zsWqWrHd8kq6" title="Common shares, issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20200630_zVswoHyjD3Oa" title="Common shares, outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,082,291</ix:nonFraction></ix:nonFraction></span></span> common shares<br /> &#160;(September 30, 2019 - <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20190930_zf6gILV0EJ0k"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20190930_zW9Oh0EarMr7"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,251</ix:nonFraction></ix:nonFraction></span></span>)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CommonStockValue_i01I_pp0p0_c20200630_zdDa2JJ2DBL3" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,083</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--CommonStockValue_i01I_pp0p0_maCz8c3_c20190930_z6lGxfFbVvI7" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maCz8c3_zfGMySEiMEd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additional paid-in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,332,979</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCz8c3_zml2C4oxhnC6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Accumulated deficit</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,712,004</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40C_eus-gaap--StockholdersEquity_i01TI_mtCz8c3_maCzUVd_zmjeqMjV4UPg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,681,058</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzUVd_zgfC4N5rSgs1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">&#160;Total Liabilities and Stockholders' Equity</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,630,256</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,329,373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the three and nine months ended June 30, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_113_z2LAjoy6I1q4" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_497_20200401__20200630_zVi2yKYwoZV6" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20190401__20190630_zDfhOb27OISi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_492_20191001__20200630_zE7hOD4Z02h5" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20181001__20190630_zYBxYSQITeM3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td><b>&#160;</b></td>
    <td colspan="7" style="text-align: center"><b>Three months ended June 30,</b></td><td><b>&#160;</b></td>
    <td colspan="7" style="text-align: center"><b>Nine months ended June 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td><td style="font-weight: bold; padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><b>2020</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td></tr>
<tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zp4Bre6zH1lf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maCz9Tu_zhfPiYwMSjie" style="vertical-align: bottom; background-color: White">
    <td style="width: 40%; text-align: left">General and administrative</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,381,477</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,388,729</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,453,654</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,211,287</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz9Tu_zBuEZElIRWLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Research and development</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,725,002</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,758,446</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,126,717</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,549,442</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--OperatingExpenses_i01NT_di_mtCz9Tu_msCzrnw_zlMY9aMMHjP7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total operating expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,106,479</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,147,175</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,580,371</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,760,729</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zY8MXuffSKZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expenses)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--NonOperatingIncomeFromGrant_i01_d0_maCzW6n_zGToqKDKss8a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Grant income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-04-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,888</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,999</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzW6n_zzvw9rB3BSJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development incentive income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,319,913</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,980,456</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,727,007</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--InterestIncomeExpenseNet_i01_maCzW6n_zYRmsJYvf8T3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest income, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,096</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,838</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">172,996</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,103</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_d0_maCzW6n_zHVehTUjotd5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gain on settlement of accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2020-04-012020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,978</ix:nonFraction></td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-10-01to2020-06-30" format="ixt:zerodash" decimals="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,978</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzW6n_zxu16Zgb16A7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Foreign exchange gain (loss), net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">248,665</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,546</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,182</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,854</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01T_mtCzW6n_maCzrnw_zFcBU5iZXcO3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total other income, net</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,624,674</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">644,549</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,279,158</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,148,233</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_i01T_mtCzrnw_maCzalv_z2gQ9IJvL2m6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss before provision for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,481,805</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,502,626</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,301,213</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,612,496</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzalv_zlLs7twYlHCh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax expense, current</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,817</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,300</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,031</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,065</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtCzalv_zozc9Xh8Qoq9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss and comprehensive loss</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,521,926</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,688,561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_ze61gOYzykR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net Loss per share</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zcKdoxAbjTOa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 12px">Basic and diluted</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.35</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.43</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB_ztCzJaIgSuol" style="vertical-align: bottom; background-color: White">
    <td>Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_zxWrj7HtIWbl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 12px">Basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,105,399</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,622,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,401,387</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,691,921</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the nine months ended June 30, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_308_112_zQj4HVhpMEug" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_49C_20191001__20200630_zMk3zC0taug8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2020</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" id="xdx_498_20181001__20190630_zJgU3VZ8Qgi8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2019</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: right">&#160;</td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zMfaXDvBhLke" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash Flows used in Operating Activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_i01_maCzetA_zqh19j25tJ4j" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Net loss</td><td style="width: 8%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 12%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,688,561</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr id="xdx_40B_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zChLi3XGzG6h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operations:</td><td style="color: red; font-weight: bold">&#160;</td>
    <td style="color: red; font-weight: bold; text-align: left">&#160;</td><td style="color: red; font-weight: bold; text-align: right">&#160;</td><td style="color: red; font-weight: bold; text-align: left">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="color: red; text-align: right">&#160;</td><td style="color: red; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maCzetA_zy1aFrZJmza5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12px">Stock-based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,194,343</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zFDmTdZy7cu3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in non-cash working capital balances related to operations:</td><td style="color: red; font-weight: bold">&#160;</td>
    <td style="color: red; font-weight: bold; text-align: left">&#160;</td><td style="color: red; font-weight: bold; text-align: right">&#160;</td><td style="color: red; font-weight: bold; text-align: left">&#160;</td><td style="color: red">&#160;</td>
    <td style="color: red; text-align: left">&#160;</td><td style="color: red; text-align: right">&#160;</td><td style="color: red; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzetA_zDCKwm7ShVv8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12px">Incentive and tax receivables</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">905,227</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,780,150</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzetA_zKIw6WQ9Xupa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 12px">Prepaid expenses and deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">62,367</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">829,576</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzetA_z1KE1ydfIGAa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 12px">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">456,872</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">267,061</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzetA_zClIDQjC3R3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 12px">Accrued liabilities</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,452,652</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">184,920</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i02T_mtCzetA_maCzYmC_zH6R1gH7Z9ej" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in operating activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,032,274</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,992,811</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_zlNiM0r6kKGi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash Flows provided by Financing Activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzRzW_zaTajhfmbDg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issuance of common shares</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,490,297</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,361,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msCzRzW_zDmmPLEzIM27" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Deferred financing charges</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,508</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzRzW_maCzYmC_zhFlir5QN8ve" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,465,789</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,311,379</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCzYmC_zsqsCGvwqauj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in cash and cash equivalents during the period</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,433,515</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,681,432</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--Cash_iS_zJg4gtZVZ11f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of period</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,185,630</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,930,638</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Cash_iE_zFp0v4bSvij2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,619,145</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,249,206</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the three months ended June 30, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_114_zlAq3fXhQuQc" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zJ8HSnB9yhYi" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvIKsv4FChWj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_custom--CommonSharesToBeIssuedMember_z7Rp6XP7Wr9e" style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zNNv4jPfQ1ik" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_4B7_zv69gQCsnGtj" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">Additional
                                            Paid-in</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center">Common Shares to be</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Par Value</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">Issued</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43E_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zoJADHIGuO1f" style="vertical-align: bottom; background-color: White">
    <td style="width: 43%">Balance, April 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVngDKh7qOz2" title="Balance Beginning (in shares)" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">58,664,946</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,958,462</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td><td style="width: 1%">$</td>
    <td style="text-align: right; width: 6%; vertical-align: top"> <span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">147,225,382</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,791,746</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zrlNjgdfi5U3" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkz3QBlyGF7l" title="Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,400,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,123,405</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0275">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0276">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,124,805</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_zStKyfriCd0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMfBjgBeQHui" title=" Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptions_zr7LHHkiZazi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued pursuant to cashless exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0kY3KKpgBZj" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zJFggSDLEClf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251,129</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,251,129</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_z9HMOvWPors1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding-bottom: 2pt; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,486,622</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43C_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zGKGRih6cR03" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziDCLPA0lRI2" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,082,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,332,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; vertical-align: top"> <span style="-sec-ix-hidden: xdx2ixbrl0310">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,712,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,681,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20190401__20190630_eus-gaap--StockholdersEquity_iS_zJvb1n8dDzs4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, April 1, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zatSdU92VMzi" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48,173,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,696,975</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>$</td>
    <td style="text-align: right; vertical-align: top"> (<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_custom_CommonSharesToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">292,700</ix:nonFraction></td>
    <td>)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">121,268,416</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,184,034</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued under 2015 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--StockIssuedDuringPeriodValueAcquisitions2_iP3us-gaap--SharesOutstanding_zmf2yQMGYArl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesAcquisitions2_iP3custom--StockIssuedDuringPeriodValueAcquisitions2_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zucBERo6p8K9" style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesAcquisitions2" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,619,403</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,833,451</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,700</ix:nonFraction></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,128,770</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_iP3us-gaap--SharesOutstanding_zI1p6Yuf05jk" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_iP3custom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgON9ksTuPX6" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,070</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zmuGO2WSvFj7" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxC9U3LMgjMc" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,400</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0339">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,775</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_zp2k7MtfYol9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaKerBfagMIi" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">328,157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">328</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0347">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zsMmtCNQfAga" style="vertical-align: bottom; background-color: White">
    <td>Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,234,204</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,234,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_zgmBDeAtAyk6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="border-bottom: Black 1pt solid; padding-bottom: 1pt"></td>
    <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"> <span style="-sec-ix-hidden: xdx2ixbrl0358">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,521,926</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,521,926</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_43B_c20190401__20190630_eus-gaap--StockholdersEquity_iE_zaQe4UwZ7wUl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefnqJ4LSr3d" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,509,871</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,511</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,927,688</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="border-bottom: Black 2.5pt double; padding-bottom: 2.5pt">$</td>
    <td style="border-bottom: Black 2.5pt double; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">127,790,342</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,188,857</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the nine months ended June 30, 2020 and 2019</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Common Stock</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">Additional
                                            Paid-in</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="display: none; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="display: none; vertical-align: top; text-align: center">Common Shares to be </td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">Accumulated</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Shares</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Par Value</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Capital</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; display: none; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; vertical-align: bottom; text-align: center">Issued</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Deficit</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_434_c20191001__20200630_eus-gaap--StockholdersEquity_iS_ztZ0wpYTbfxl" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%">Balance, October 1, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuhrSMh7NRGi" style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,652</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td><td style="display: none; width: 1%">&#160;$</td>
    <td style="display: none; vertical-align: top; padding-left: 40pt; text-align: right; width: 6%"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued under 2019 Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_zCcOyI8gwJ56" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyC1Wn1D2vel" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,364,584</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,482,932</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0379">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,490,297</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_zY3QgxTomHF1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZW1Tk3VcFii" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,465</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptions_zet4JhG04chf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued pursuant to cashless exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwPSMYaZ1ae6" title="Shares issued pursuant to cashless exercise of options (in shares)" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">721</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfOptions" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zQSGwPKTQjj2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,216,306</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_zjOLhE2TjIA8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,315,244</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_434_c20191001__20200630_eus-gaap--StockholdersEquity_iE_zInAoqleviji" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20191001__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQWVRTDZBuh4" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,082,291</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,083</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">178,332,979</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;$</td>
    <td style="display: none; vertical-align: top; padding-left: 40pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">153,712,004</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,681,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43C_c20181001__20190630_eus-gaap--StockholdersEquity_iS_zcFR7qZhxUfj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance, October 1, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHsiqq1ofGD1" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,933,472</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">129,377,542</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;$</td>
    <td style="display: none; vertical-align: top; padding-left: 40pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">107,101,781</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,321,696</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued under 2015 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--StockIssuedDuringPeriodValueAcquisitions2_zj2D5eRyPXHj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesAcquisitions2_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzxXGbfolaf2" title="Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)" style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesAcquisitions2" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,848,995</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,849</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,192,755</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueAcquisitions2" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,197,604</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_znEoxlUMZroc" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGIKV1qgP2Q4" title="Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,701</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0434">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shares issued under 2019 purchase agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_z7ZlnersjqWl" style="vertical-align: bottom; background-color: White">
    <td>&#160;&#160;Purchase shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHaYmzN1i2hc" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,400</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,163,775</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_zcmLWfLJehb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;&#160;Commitment shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKC8o2NXDyv9" style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">328,157</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">324</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">324</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrants_iP2us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ze6Q2wqfFvX2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued pursuant to cashless exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_iP2us-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmxW6v6yUXc" title="Shares issued pursuant to cashless exercise of warrants (in shares)" style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">546</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zHDi8Knhf8L6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Share based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0462">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,194,343</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0465">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,194,343</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--NetIncomeLoss_zOBsaRkgIPij" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0468">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0469">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="display: none; text-align: right; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0470">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,688,561</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,688,561</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_436_c20181001__20190630_eus-gaap--StockholdersEquity_iE_zYmcPtOQN7Nk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance, June 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20181001__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z94FxWrWfC23" title="Balance Ending (in shares)" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,509,871</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,511</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,927,688</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td>&#160;</td><td style="display: none; padding-bottom: 2.5pt">&#160;$</td>
    <td style="display: none; text-align: right; padding-left: 40pt; vertical-align: top"><span style="-sec-ix-hidden: xdx2ixbrl0476">&#8212;</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">127,790,342</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,188,857</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zQlXHVUG8wTg" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note
1 &#9;<span style="text-decoration: underline"><span id="xdx_825_zIzBfC2Q1yPc">Business Description and Basis of Presentation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX&#174;2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
results for the nine months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year
ending September 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>

<ix:exclude><p id="xdx_237_zmi5p1cwXSb1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_238_zXkvxIR1Btu4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23B_zRyZIrvmMg5i" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zgGLo7a2rlDl" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zJv2jVNNiPq8" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zhxYXUzOWrjj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zUTUZVkhlkXc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_zquFZrexR6pi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to
curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition
for the year ending September 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the President of the United States signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#8217;s interim condensed consolidated financial statements.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_233_z2sloxM301Me" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_239_ziPHHDUTJ3k6" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_z6kX0VfBzZl9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zjHI20qSH6x1" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zBDPqJ8KDVjg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zFUlpmPFRdG9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z5m8dIBVgSv7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zjicnBxozp32" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="text-align: justify; margin-right: 0; margin-left: 42.55pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Adjustment
of Prior Period Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">As
previously disclosed in Note 1 to the Company&#8217;s consolidated financial statements included in the Company&#8217;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial. These adjustments
were identified in connection with the preparation of the consolidated financial statements for the year ended September 30, 2019
and related to the timing of recognition of research and development incentive income. Previously the Company accounted for research
and development incentive income when received in cash. During the year ended September 30, 2019, based on a continuing assessment
regarding the Company&#8217;s eligibility for the incentive programs under which it was receiving such income, the Company determined
that the income should have been accrued and recorded in the period in which the qualifying research and development expenditures
were incurred.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
interim condensed consolidated financial statements for the three and nine months ended June 30, 2020 have been similarly adjusted
to reflect the adjusted research and development incentive income for the three and nine months accordingly in the amount of $<span id="xdx_900_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20190401__20190630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentsIncentiveIncome" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">552,335</ix:nonFraction></span>
and $<span id="xdx_904_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20181001__20190630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="avxl:ResearchAndDevelopmentsIncentiveIncome" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,477,007</ix:nonFraction></span>, respectively and should be read in conjunction with Note 1 to the Company&#8217;s consolidated financial statements
for the year ended September 30, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Principles of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_233_zsS3g2YNCIY" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23C_ztjbh4e9k3ce" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zWn4edavJeMd" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zZW3bDPFKGFj" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zrOciyzZMtq8" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zORUG0ZFdj7l" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zI8J0ZwrC4Wf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - &#9;quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active &#9;&#9;markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - &#9;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2020, loss per share excludes <span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200630_pii" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,576,266</ix:nonFraction></span> (September 30, 2019 &#8211; <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" contextRef="From2018-10-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,812,933</ix:nonFraction></span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

<ix:exclude><p id="xdx_23E_zfGkOOYmlTG9" style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_234_zg0NGfuu7LJi" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_230_zqR0q5hMHuv5" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zyOUuqyrV589" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_233_zzZckQ5YQyWb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqagfZL73Wy6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
2&#9;<span style="text-decoration: underline"><span id="xdx_82E_z85hjqJ0aMAj">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znN3K39uB8bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, &#34;Simplifying the Accounting for Income Taxes (ASC 740)&#34;, which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_231_zSNi2cvwZLP3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_23E_zzxgVob5rpB6" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_233_zvyqRY11AEmh" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_znI2i9or6DM2" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_233_zGjJAzSsa99" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_zTNvxEt29vYe" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_z3NUlhABfVhb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zDlL81fO1162" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_809_ecustom--OtherIncomeDisclosureTextBlock_zeLtjRD503Ad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
3&#9;<span style="text-decoration: underline"><span id="xdx_825_zxassuBqGV39">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
Income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_900_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,886</ix:nonFraction></span>. The grant was received in
equal quarterly installments over a period of two years commencing during the year ended September 30, 2018 in exchange for a
commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the three and nine months ended June 30, 2020, the Company recognized $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20200401__20200630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span title="Grant income"><span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_zzQ6UnSjeSfa"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">149,888</ix:nonFraction></span></span>, respectively (2019: $<span title="Grant income"><span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_c20190401__20190630_zehAlWHgYVT8"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,944</ix:nonFraction></span></span>
and $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20181001__20190630_pp0p0" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,999</ix:nonFraction></span>, respectively) of this grant on its statement of operations within grant income. As at June 30, 2020, the Company
had recognized the full amount of grant funding.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;).&#160;Research and development incentive income
during the three and nine months ended June 30, 2020 and 2019 represents the receipt by the Company&#8217;s Australian subsidiary,
of the Australian research and development incentive credit, (the &#8220;ATO R&amp;D Credit&#8221;), as well as receipt by the
Company of the New York City Biotechnology Credit (&#8220;NYC Biotech credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company recorded research and development incentive income of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630_zIgqvw7r8Uwc" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,319,913</ix:nonFraction></span> (AUD
<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630__srt--CurrencyAxis__currency--AUD_zRFY0EmyPBc3" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-04-012020-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,923,000</ix:nonFraction></span>) and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,980,456</ix:nonFraction></span> (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2018-10-012019-06-30_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,471,000</ix:nonFraction></span>), respectively (2019: $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20190401__20190630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">552,335</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,727,007</ix:nonFraction></span>, respectively) in respect of the ATO R&amp;D
Credit for eligible research and development expenses incurred during the period (2019: In respect of the ATO R&amp;D Credit for
eligible research and development expenses incurred during the period and the NYC Biotech credit).</span></p>

<ix:exclude><p id="xdx_238_zdzwKSVQ5pl1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_23F_zY5JmCfP3FMa" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_237_zDXxt38DIqe9" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_232_zT2pCGayMrv8" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zm6lafmShzZ5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="avxl:EquityOfferingAgreementsTextBlock"><p id="xdx_80C_ecustom--EquityOfferingAgreementsTextBlock_zfIUaaCpRYtc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
4&#9;<span style="text-decoration: underline"><span id="xdx_824_z5LW55hRLcJ2">Equity Offering Agreements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into an Amended and Restated&#160;Sales Agreement dated May 1, 2020 (the &#8220;Sales Agreement&#8221;) with
Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company
may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> from time to time through the
Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zVfgMLXdiCy3" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2019-10-012020-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. As of June 30, 2020, no shares had been sold pursuant to the Offering.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $<span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $<span title="Total number of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time over a <span id="xdx_905_ecustom--AgreementTerm_dtM_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7MmdbFAlQ6f" title="Agreement term"><ix:nonNumeric contextRef="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt-sec:durmonth" name="avxl:AgreementTerm">36</ix:nonNumeric></span>-month period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended June 30, 2019, the Company issued an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,872,696</ix:nonFraction></span> shares of common stock under the 2015 Purchase
Agreement, including <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,848,995</ix:nonFraction></span> shares of common stock for an aggregate purchase price of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,197,604</ix:nonFraction></span> and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,701</ix:nonFraction></span> commitment shares.
At June 30, 2020 and September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.</span></p>

<ix:exclude><p id="xdx_23D_znmzg3rY6DGd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_23A_zvsyxOdGipSa" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_zmoWVV0gJfx9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_z11MNE28IjPf" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zJhMU061vWii" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zA5P21kfyBPj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z58UFiiVuSWc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
4&#9;<span style="text-decoration: underline">Equity Offering Agreements</span> &#8211; Continued</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zca3CL4XlbPa" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction></span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, as amended on July 1, 2020 (the &#8220;Amendment Date&#8221;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $<span title="Total number of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the <span id="xdx_907_ecustom--AgreementTerm_dtMp_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBxgIhrXnQY1" title="Agreement term"><ix:nonNumeric contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt-sec:durmonth" name="avxl:AgreementTerm">36</ix:nonNumeric></span>-month anniversary of June
12, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price"><ix:nonNumeric contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" name="us-gaap:UnrecordedUnconditionalPurchaseObligationDescription">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,016,457</ix:nonFraction></span> shares
of Common Stock, representing <span id="xdx_903_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXmKUzpOCcwh" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.99</ix:nonFraction></span>% of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#8217;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#8217;s outstanding shares of Common Stock at any given time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,383</ix:nonFraction></span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended June 30, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,431,049</ix:nonFraction></span> (2019: <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z0O1oNJCqhY9" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">703,157</ix:nonFraction></span>) shares of common
stock under the 2019 Purchase Agreement, including <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,364,584</ix:nonFraction></span> (2019: <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">375,000</ix:nonFraction></span>) shares of common stock for an aggregate purchase
price of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,490,297</ix:nonFraction></span> (2019: $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,163,775</ix:nonFraction></span>) and <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,465</ix:nonFraction></span> (2019: <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">328,157</ix:nonFraction></span>) commitment shares. At June 30, 2020, an amount of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,875,198</ix:nonFraction></span>
remained available under the 2019 Purchase Agreement, as amended.</span></p>

<ix:exclude><p id="xdx_232_zVhqQqqYBt1a" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_233_zwRIEPbMqFR6" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_234_zGtvHn6me1R1" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zZIpluR60kQ7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zPmUf2Ifb2Ai" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zXBwNjwP3ydh" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_z6t9SlQ454v" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_z3AXoOb8dNzg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5 &#9;<span style="text-decoration: underline"><span id="xdx_82E_zQuSaGcTyW5k">Commitments and Contingencies</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>a)</i></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Leases
                                         </span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company incurred office lease expense of $<span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,554</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,469</ix:nonFraction></span>, respectively
(2019: $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20190401__20190630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,546</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20181001__20190630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,807</ix:nonFraction></span>, respectively).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span><span style="font-size: 10pt"><br /></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zZWKgXFSWzT6" summary="xdx: Disclosure - Commitments and Contingencies (Details)" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B6_zn2zABSpv8jk" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 35%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_ziqb9BiyeLV3" title="Share Purchase Warrants Balance, at beginning" style="width: 20%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3JnLXGCxB3l" title="Weighted Average Exercise Price Balance, at beginning" style="width: 20%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3bxlKyoKPB3" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2019-10-012020-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXh8ABBOisha" title="Weighted Average Exercise Price Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2019-10-012020-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z0sX98riAYsd" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zTGK6luJQFc1" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8A3_zA2ymSIfOUE3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2020, the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zLDXHvnaDEi2" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_z6nL5KtxiWed" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Number</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Exercise Price</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Number" style="width: 12%; text-align: left"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Exercise Price" style="width: 12%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td title="Expiry Date" id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zxZCX8kPYXRb" style="width: 56%; text-align: right"><ix:nonNumeric contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 30, 2021</ix:nonNumeric></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Number" style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zzBBoNDn6kaj" style="text-align: right; padding-bottom: 1pt"><ix:nonNumeric contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630_pii" title="Number" style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



</ix:nonNumeric><p id="xdx_8A1_zraAxYp4CsLc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"></p>

<ix:exclude><p id="xdx_238_zJdAJtcIWNp2" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zJvRJ0kuWiCf" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_234_zBEV4717TYWg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23D_zngpU4pnWji8" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zym42qcH1zec" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_ztbmbLKfGrw9" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zKyee6qEnYb7" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zkbXhmzMBwcb" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zbsV0NXpJzi6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5 &#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; Continued</span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zvetVnH6S6Ce" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the
&#8220;2015 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan is <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member" title="Description of grant option"><ix:nonNumeric contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction> </span>additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"><ix:nonNumeric contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2019Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</ix:nonNumeric></span></span></p>

<ix:exclude><p id="xdx_235_zkusUagDY4R" style="font: 10pt Arial, Helvetica, Sans-Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div id="xdx_231_zCFqPPUlKUrf" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23A_z6KjWfuJcy3d" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zy4YYzrWNRP7" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23D_zNJBi5kE1YCc" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_ziJR5GWDQMUi" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zS4GnU2IBnS9" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zFZZRgpkbuPd" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5&#9;<span style="text-decoration: underline">Commitments and Contingencies</span> &#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><p id="xdx_233_zQnoDlbjbPfl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;e)
Stock-based Compensation Plan - (Continued)&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zDwKSMAkTh8e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>&#160;</p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zVxhk4ylQtie" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span id="xdx_8B1_zU7BoFNDLJTf" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Grant Date Fair Value ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate intrinsic value
    ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 32%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         September 30, 2019</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zNpPtqZQ9cM9" title="Options Outstanding at beginning" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,462,933</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrgt4hrjcQb8" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.58</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 13%; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zojP64cEmKH8" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 1pt solid; width: 13%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,115,032</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRrVn3O8MER" title="Options Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,695,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUYkLwAkzy1h" title="Weighted Average Exercise Price Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zI05EiVc7nhk" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOq12yM1C5dj" title="Options Forfeited" style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,332</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCDVrzUaXet4" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMp17Cuyenmk" title="Options Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQGq44vAnB" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zsY9J8uI8cq3" title="Options Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zskENi1W2Ndj" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyGaUEQJF8Ha" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,818,714</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVQgEmFvYhy5" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,284,183</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4p8P2cxHTc3" title="Weighted Average Exercise Price Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.67</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgVoSUSIbc5" title="Aggregate intrinsic value Exercisable at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,366,473</ix:nonFraction></span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><p id="xdx_8A8_zFroywHDE9c5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at June 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zLf59z9vH5cd" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,251,129</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200630_zfrDE5KDVRvh" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,216,306</ix:nonFraction></span>,
respectively (2019: $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20190401__20190630_zX06LvO8MMj5" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,234,204</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20181001__20190630_zkHo8rdFi9x5" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,194,343</ix:nonFraction></span> respectively) in connection with the issuance and vesting &#9;of stock options and
warrants in exchange for services. These amounts have been included in general and &#9;administrative expenses and research and
development expenses on the Company&#8217;s interim condensed consolidated statements of &#9;operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zbZwBCbJCER6" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zAFP6YFvHpw5" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Three months ended June 30,</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Nine months ended June 30,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">General and administrative</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">575,451</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-04-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">579,636</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,863,869</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,586,223</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">675,678</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-04-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">654,568</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,352,437</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,608,120</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,251,129</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,234,204</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,216,306</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,194,343</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_8AD_zmmI9ahJzyV1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_90F_ecustom--RemainingAllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" title="Remaining stock based compensation"><ix:nonFraction name="avxl:RemainingAllocatedShareBasedCompensationExpense" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,858,000</ix:nonFraction></span> in stock-based compensation is expected to be recorded over the remaining vesting period &#9;of
such options through fiscal 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2019-10-01to2020-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5XfDOXZ76L9" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20191001__20200630_zj8evM8GyvQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20181001__20190630_zLYDbvHNkIS2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zUBTrSrAcebb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_zMdHMs6CGSt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.57</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.91</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_407_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zTZvz2UAK5m3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2019-10-01to2020-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.53</ix:nonNumeric></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2018-10-012019-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.59</ix:nonNumeric></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_zLNt6k3EXijf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97.80</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">105.96</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_uPure_zk0oLLbp6t8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-01to2020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-10-012019-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A0_z7WTMrNZJ5Z6" style="margin-top: 0; margin-bottom: 0"></p>

</ix:nonNumeric><p id="xdx_81A_zNPaRZjAQyw4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="item2"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</b></span></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Forward-Looking
Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained
in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone
events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;suggest,&#8221;
&#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to successfully
    conduct clinical and preclinical trials for our product candidates;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to raise
    additional capital on favorable terms and the impact of such activities on our stockholders and stock price;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the impact of the
    COVID-19 outbreak and its effect on us;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to generate
    any revenue or to continue as a going concern;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to execute
    our research and development plan on time and on budget;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our products ability
    to demonstrate efficacy or an acceptable safety profile of our product candidates;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain
    the support of qualified scientific collaborators;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability, whether
    alone or with commercial partners, to successfully commercialize any of our product candidates that may be approved for sale;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to identify
    and obtain additional product candidates;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our reliance on
    third parties in non-clinical and clinical studies;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend
    against product liability claims;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to safeguard
    against security breaches;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to obtain
    and maintain sufficient intellectual property protection for our product candidates;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply
    with our intellectual property licensing agreements;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to defend
    against claims of intellectual property infringement;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to comply
    with the maintenance requirements of the government patent agencies;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our ability to protect
    our intellectual property rights throughout the world;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    anticipated start dates, durations and completion dates of our ongoing and future clinical studies;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
    anticipated designs of our future clinical studies;</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    anticipated future regulatory submissions and our ability to receive regulatory approvals to develop and market our product
    candidates; and</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 28px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
    anticipated future cash position.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have based these forward-looking statements largely on our current expectations and projections about future events, including
the responses we expect from the U.S. Food and Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and
financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and
clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form
10-K filed with the Securities and Exchange Commission on December 16, 2019. These risks are not exhaustive. Other sections of
this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business and financial performance.
Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it
is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot
assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual
results could differ materially from those projected in the forward-looking statements. Except as required by applicable laws
including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Anavex&#8221;
mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
Current Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data
from clinical studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the
treatment of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
lead compound, ANAVEX<sup>&#174;</sup>2-73, is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and
potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
total portfolio currently consists of five programs. To prioritize the allocation of our resources, we designate certain programs
as core programs and others as seed programs. We currently have two core programs and three seed programs. Our core programs are
at various stages of clinical and preclinical development, in neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes key information about our programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Sans-Serif; margin: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><b><img src="image_001.jpg" alt="" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which
is an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional
regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order
to validate the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University,
a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73
target engagement or receptor occupancy (RO) with S1R in the brain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><img src="image_002.jpg" alt="" />&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cellular
Homeostasis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases
like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.
In neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance,
i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific
Biomarkers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
full genomic analysis of Alzheimer&#8217;s disease (AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification
of actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. It is expected that <i>excluding</i> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores. The consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73,
which are considered independent of AD pathology, as well as multiple endpoints and time-points, provides support for precision
medicine clinical development of ANAVEX<sup>&#174;</sup>2-73 by using genetic biomarkers identified within the study population
itself to target patients who are most likely to respond to ANAVEX<sup>&#174;</sup>2-73 treatment in AD as well as indications
like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome (RTT) in which ANAVEX<sup>&#174;</sup>2-73 is currently studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Clinical
Studies Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Alzheimer&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for
ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s patients. This open-label randomized trial met both primary and
secondary endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients.
ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress
levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&#8217;s
disease. In October 2017, we presented positive pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 2a study, which
established a concentration-effect relationship between ANAVEX<sup>&#174;</sup>2-73 and study measurements. These measures obtained
from all patients who participated in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker
signals of brain activity. Additionally, the study appears to show that ANAVEX<sup>&#174;</sup>2-73 activity is enhanced by its
active metabolite (ANAVEX19-144), which also targets the sigma-1 receptor and has a half-life approximately twice as long as the
parent molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2016, we received approval from the Ethics Committee in Australia to extend the Phase 2a clinical trial by an additional
108 weeks, which had been requested by patients and their caregivers. Subsequently, in May 2018, we received approval from the
Ethics Committee in Australia to further extend the Phase 2a extension trial for an additional two years. The two consecutive
trial extensions have allowed participants who completed the 52-week PART B of the study to continue taking ANAVEX<sup>&#174;</sup>2-73,
providing an opportunity to gather extended safety data for a cumulative time period of five years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we presented new long-term clinical data for ANAVEX<sup>&#174;</sup>2-73 in a presentation at the 2018 Clinical Trials
on Alzheimer&#8217;s Disease (CTAD) Meeting. At 148 weeks into the five-year extended Phase 2a clinical study, data confirmed
a significant association between ANAVEX<sup>&#174;</sup>2-73 concentration and both exploratory functional and cognitive endpoints
as measured by the Alzheimer&#8217;s Disease Cooperative Study-Activities of Daily Living&#160;(ADCS-ADL)&#160;evaluation and
the Mini Mental State Examination (MMSE), respectively. The cohort of patients treated with higher ANAVEX<sup>&#174;</sup>2-73
concentration maintained ADCS-ADL performance compared to the lower concentration cohort (p&lt;0.0001). As well, the patient cohort
with the higher ANAVEX<sup>&#174;</sup>2-73 concentration performed better at MMSE compared to the lower concentration cohort (p&lt;0.0008).
A significant impact on the drug response levels of both the SIGMAR1 (p&lt;0.0080) and COMT (p&lt;0.0014) genomic biomarkers,
identified and specified at week 57, was also confirmed over the 148-week period. Further, ANAVEX<sup>&#174;</sup>2-73 demonstrated
continued favorable safety and tolerability through 148 weeks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease commenced
in August 2018, which is independent of the ongoing Phase 2a extension study. The Phase 2b/3 study will enroll approximately 450
patients for 48 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial is currently taking
place in Australia; however, additional regions are being added. The ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 study design incorporates
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. Primary and secondary endpoints
will assess safety and both cognitive and functional efficacy, measured through Alzheimer&#8217;s Disease Assessment Scale &#8211;
Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and function (CDR-SB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2019, we initiated a long-term open label extension study of ANAVEX&#174;2-73, entitled the ATTENTION-AD study, for patients
who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last two years
and will give patients the opportunity to continue their treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Rett
Syndrome </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental
disease. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017,
we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly
instalments which commenced during fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
first Phase 2 study, which commenced in March 2019, is taking place in the United States and is a randomized double-blind, placebo-controlled
safety, tolerability, pharmacokinetic and efficacy study of oral liquid ANAVEX<sup>&#174;</sup>2-73 formulation to treat Rett syndrome.
Pharmacokinetic and dose findings will be investigated in 31 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73-specific
genomic precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73
under a voluntary open label extension protocol. Primary and secondary endpoints include safety as well as Rett syndrome conditions
such as cognitive impairment, motor impairment, behavioral symptoms and seizure activity. The ANAVEX<sup>&#174;</sup>2-73 Phase
2 Rett syndrome study designs incorporate genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase
2a Alzheimer&#8217;s disease study. The study completed enrollment in June 2020 and topline results are expected in late 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2019, we commenced the second Phase 2 study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the
AVATAR study. This study is taking place in Australia and United Kingdom using a convenient once-daily oral liquid ANAVEX<sup>&#174;</sup>2-73
formulation. Similar to the United States-based Phase 2 study for Rett syndrome, the study will evaluate the safety and efficacy
of ANAVEX<sup>&#174;</sup>2-73 in approximately 33 patients over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73
specific precision medicine biomarkers. All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73
under a voluntary open label extension protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the third study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the EXCELLENCE
study. This Phase 2/3 study in pediatric patients with Rett syndrome is using a convenient once-daily oral liquid ANAVEX<sup>&#174;</sup>2-73
formulation. The study will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in at least 69 pediatric patients,
aged 5 to 18, over a 12-week treatment period incorporating ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers.
All patients who participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label
extension protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Parkinson&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
September 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s disease, which demonstrated
significant improvements on all measures: behavioral, histopathological, and neuroinflammatory endpoints. The study was funded
by the Michael J. Fox Foundation. Additional data was announced in October 2017 from the model for experimental parkinsonism.
The data presented indicates that ANAVEX<sup>&#174;</sup>2-73 induces robust neurorestoration in experimental parkinsonism. The
encouraging results we have gathered in this model, coupled with the favorable profile of this compound in the Alzheimer&#8217;s
disease trial, support the notion that ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for Parkinson&#8217;s
disease dementia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2018, we initiated a double-blind, randomized, placebo-controlled Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
Disease Dementia (PDD), which will study the effect of the compound on both the cognitive and motor impairment of Parkinson&#8217;s
disease. The Phase 2 study enrolled approximately 120 patients for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73
doses or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporates genomic precision medicine biomarkers identified
in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The study has completed enrollment and topline results are forthcoming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Frontotemporal
Dementia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the First-in-Human Phase 1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71, for the treatment of Frontotemporal
Dementia (FTD), for which ANAVEX<sup>&#174;</sup>3-71 was previously granted orphan drug designation by the FDA. ANAVEX<sup>&#174;</sup>3-71
is an orally administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative
diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying
activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits,
amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Phase 1 clinical trial is taking place in Australia and will be a prospective double-blind, randomized, placebo-controlled study.
A total of at least 36 healthy male and female subjects will be included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71
will be administered in order to evaluate the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<sup>&#174;</sup>3-71 and
the effects of food and gender on its PK in healthy volunteers. This study is expected to be followed by longer duration dosing
including FTD patients and incorporating exploratory efficacy and disease biomarker measures<span style="color: #1F1F1F">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical study indications,
and several other compounds in different stages of clinical and pre-clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
proprietary SIGMACEPTOR&#8482; Discovery Platform produced small molecule drug candidates with unique modes of action, based on
our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial
apoptosis and other related cellular processes, in order to ensure survival and replication. Hence, it is possible that S1R could
play a role in modulating the cellular response to viral infection and ameliorate pathogenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compounds
that have been subjects of our research include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
<i>(blarcamesine)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related improvements in an array
of behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org,
ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which
advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment
with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome
disease mouse. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age
was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular coordination, balance,
motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome
disease model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. The studies will be conducted in a range of patient age demographics and geographic regions, as
more fully described above under <i>Clinical Studies Overview &#8211; Rett Syndrome</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome
and infantile spasms, respectively. In November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease
(RPD) designation for the treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the
development of treatments for rare pediatric diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Further,
in February 2020, the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the
treatment of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of new
drugs to address unmet medical needs in the treatment of serious and life-threatening conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
Parkinson&#8217;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal
model of Parkinson&#8217;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological,
and neuroinflammatory endpoints. In July 2018 the Company received approval from the Spanish Agency for Medicinal Products and
Medical Devices (AEMPS), to initiate its Phase 2, double-blind, placebo-controlled 14-week trial of the safety and efficacy of
ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson&#8217;s disease dementia. The Phase 2 study commenced in October 2018
and has enrolled 120 patients, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses or placebo, in approximately
24 clinical study sites across Spain and Australia. The study has completed enrollment and topline results are expected by forthcoming.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Alzheimer&#8217;s disease (AD) animal models, ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral
evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent
affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576,
ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of oxidative stress
in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently
amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals,
regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some
subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
ANAVEX<sup>&#174;</sup>2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers
between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety
and tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug,
the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the
body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several
Alzheimer&#8217;s disease studies, and the Technical University of Dresden.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s
disease. The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73
in 32 patients with mild-to-moderate Alzheimer&#8217;s disease. ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors,
which have been shown in preclinical studies to reduce stress levels in the brain believed to restore cellular homeostasis and
to reverse the pathological hallmarks observed in Alzheimer&#8217;s disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Phase 2a study met both primary and secondary objectives of the study.&#160;The 31-week&#160;preliminary exploratory&#160;safety
and&#160;efficacy data from the&#160;Phase 2a study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s&#160;patients, with most
receiving also donepezil, the current standard of care, demonstrated&#160;favorable&#160;safety, maximum tolerated&#160;dose,
positive dose response, sustained efficacy response through 31 weeks for both cognitive and functional measures, as well as&#160;positive
unexpected therapeutic response events. ANAVEX<sup>&#174;</sup>2-73 continued to demonstrate a favorable adverse event (AE) profile&#160;through
31 weeks in a patient population of elderly Alzheimer&#8217;s patients with varying degrees of physical fragility. The most common&#160;side
effects across all AE categories tended to be of mild severity grade 1 and were resolved with dose reductions that were&#160;anticipated
within the adaptive design of the study protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Through
57 weeks, Alzheimer&#8217;s patients taking a daily oral dose between 10mg and 50mg of ANAVEX<sup>&#174;</sup>2-73 was well tolerated.
There were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing
of ANAVEX<sup>&#174;</sup>2-73 throughout the 57-week study, continued significant improvements from baseline of cognitive, functional
and behavioral scores in a group of patients were observed, respectively. This data was analyzed using refined mathematical modeling
methods in conjunction with the detailed pharmacokinetic (PK) information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2017, we presented positive PK and PD data from the Phase 2a study, which established a concentration-effect relationship
between ANAVEX<sup>&#174;</sup>2-73 and study measurements. These measures, obtained from all patients who participated in the
entire 57 weeks, include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<sup>&#174;</sup>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Pre-specified
exploratory analyses included the cognitive (MMSE) and the functional (ADCS-ADL) changes from baseline. A continued stabilization
of both cognitive and functional measures in patients treated with ANAVEX<sup>&#174;</sup>2-73 was observed. This correlation was
positive within all measured scores (MMSE, ADCS-ADL, Cogstate, HAM-D and EEG/ERP).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to
ANAVEX<sup>&#174;</sup>2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73.
Results showed that study participants without the SIGMAR1 (rs1800866) variants, which is about 80 percent of the population worldwide,
demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation may enable a precision
medicine approach, since these signatures can now be applied to neurological indications tested in clinical studies with ANAVEX<sup>&#174;</sup>2-73
including Alzheimer&#8217;s disease, Parkinson&#8217;s disease dementia and Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. This Phase
2b/3 study design incorporates inclusion of genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73
Phase 2a study. The Phase 2b/3 study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different
ANAVEX<sup>&#174;</sup>2-73 doses or placebo, commenced in October 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data also validates ANAVEX<sup>&#174;</sup>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s
disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development
of audiogenic seizures. &#160;The results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed
in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data on ANAVEX<sup>&#174;</sup>2-73 related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system
neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex
(&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the
body with a high incidence of seizures. The new preclinical data demonstrates that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly
increases survival and reduces seizures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>3-71</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>3-71
is a clinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation,
which has been shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71
is a CNS-penetrable potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses
against the major Alzheimer&#8217;s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies,
and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive
therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related diseases given its ability to enhance neuroprotection
and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant
reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In
April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of Frontotemporal dementia
(FTD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
pathological conditions ANAVEX<sup>&#174;</sup>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis)
without causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and
Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that
in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the first Phase 1 clinical trial of&#160;ANAVEX<sup>&#174;</sup>3-71, for the treatment of Frontotemporal
Dementia (FTD). The study is taking place in Australia and is more fully described above under <i>Clinical Studies Overview &#8211;
Frontotemporal Dementia</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1-41</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1-41
is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration
or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and impairs cell
viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme that plays
a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates learning,
emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1066</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral
measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1037
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
compounds are in the pre-clinical and clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our
programs and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license,
or otherwise transfer our intellectual property to further our goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Target Indications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have developed compounds with potential application to two broad categories and several specific indications. including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Central
Nervous System Diseases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Alzheimer&#8217;s
    disease &#8211; In 2019, an estimated 5.8 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s
    Association<sup>&#174;</sup> reports that by 2025, 7.2 million Americans will be afflicted by the disease, about a 24 percent
    increase from currently affected patients. Medications on the market today treat only the symptoms of Alzheimer&#8217;s disease
    and do not have the ability to stop its onset or its progression. There is an urgent and unmet need for both a disease modifying
    cure for Alzheimer&#8217;s disease as well as for better symptomatic treatments.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Parkinson&#8217;s
    disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
    and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the
    neurotransmitter dopamine. Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically middle-aged
    and elderly people. The Parkinson&#8217;s disease market is expected to expand to $3.2 billion by 2021, according to business
    intelligence provider GBI Research.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Rett
    syndrome - Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain
    develops, including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis.
    It is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because
    males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating
    ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments,
    affecting nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat,
    sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000
    females.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depression
    - Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment
    for depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately
    75% of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration
    and generic competition.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Epilepsy
    - Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient
    signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease
    Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured,
    with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs.
    Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional
    anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Neuropathic
    Pain &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in
    any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well
    to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category
    of membrane stabilizing drugs or antidepressants.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Malignant
    Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
    melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor,
    adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma
    market is expected to grow to $4.4 billion by 2022.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prostate
    Cancer &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
    system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.
    Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellspacing="0" cellpadding="0" style="width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#183;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pancreatic
    Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of
    pancreatic cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according
    to the American Cancer Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment
    of pancreatic cancer in the United States and five largest European countries will increase to $2.9 billion by 2021.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b><i>&#160;</i></b></span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Patents,
Trademarks and Intellectual Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
hold ownership or exclusive rights to nine U.S. patents, ten U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73 and certain anticholinesterase inhibitors composition and
method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73 directed to a novel and synergistic
neuroprotective compound combined with donepezil and other cholinesterase inhibitors.&#160; This patent is expected to expire
in June 2034, absent any patent term extension for regulatory delays. We own two issued U.S. patents each with claims directed
to crystalline forms of ANAVEX<sup>&#174;</sup>2-73. The first of these two patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s
disease using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The
second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and
methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent
any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods and dosage forms for treating
seizures, the dosage forms containing a low-dose anti-epilepsy drug combined with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its
active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144. This patent is expected to expire in October
2035, absent any patent term extension for regulatory delays. We also own an issued U.S. patent that claims methods for treating
a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144,
and/or ANAVEX<sup>&#174;</sup>1-41, another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73. This patent is expected
to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own one issued U.S. Patent
with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73. This patent is expected
to expire in February 2030, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own one issued patent with claims directed to methods for treating or preventing pain with ANAVEX<sup>&#174;</sup>1066. This
patent is expected to expire in November 2036, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
regard to ANAVEX<sup>&#174;</sup>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to
the ANAVEX<sup>&#174;</sup>3-71 compound and methods of treating various diseases including Alzheimer&#8217;s with the same. These
patents are expected to expire in April 2030, and January 2030, respectively, absent any patent term extension for regulatory
delays. We also own exclusive rights to related patents or applications that are granted or pending in Australia, Canada, China,
Europe, Japan, Korea, New Zealand, Russia, and South Africa, and are expected to expire in January 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own other patent applications directed to enantiomers, formulations and uses that may provide additional protection for one
or more of our product candidates.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual
property rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and
confidential information by means of carefully considered processes of communication and the sharing of information, and by the
use of confidentiality and non-disclosure agreements and provisions for the same in contractor&#8217;s agreements. While no agreement
offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical
questions for which important legal principles are unresolved. For more information regarding challenges to our existing or future
patents, see &#8220;Risk Factors&#8221; &#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities
and Exchange Commission on December 16, 2019.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial
Highlights</b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
expenses for the third quarter of fiscal 2020 were $8.1 million, compared to $7.1 million for the comparable quarter in fiscal
2019. The operating expenses include an aggregate of $1.3 million, as compared to $1.2 million in the third quarter of fiscal
2019, in non-cash charges.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss for the third quarter of fiscal 2020 was $6.5 million, or $0.11 per share, as compared to $6.5 million, or $0.13 per share
in the comparative quarter of fiscal 2019.&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Revenue</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Three
and nine months ended June 30, 2020 compared to three and nine months ended June 30, 2019</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Total
operating expenses for the third quarter of fiscal 2020 were $8.1 million, compared to $7.1 million for the third quarter of fiscal
2019. Total operating expenses for the nine-month period ended June 30, 2020 were $23.6 million compared to $22.8 million for
the same period in fiscal 2019. This represents an increase of $1.0 million for the three-month period and $0.8 million for the
nine-month period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">General
and administrative expenses were $1.4 million for the three months ended June 30, 2020, as compared to $1.4 million for the third
quarter of fiscal 2019. General and administrative expenses decreased by $0.7 million to $4.5 million for the nine-month period
ended June 30, 2020, as compared to $5.2 million for the applicable prior year period. The decrease in general and administrative
expenses was primarily related to a decrease in stock option compensation charges of $1.0 million period over period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses were $6.7 million for the three months ended June 30, 2020 compared to $5.8 million in the comparable
quarter of fiscal 2019. Research and development expenses increased by $1.6 million to $19.1 million for the nine-month period
ended June 30, 2020, as compared to $17.5 million for the applicable prior year period. &#160;The increase is related to an increase
in clinical trial activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
income (net)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
net amount of other income was $1.6 million as compared to $0.6 million for the three-month period ended June 30, 2020 and $3.3
million for the nine-month period as compared to $2.1 million for the comparable nine-month period in fiscal 2019. The increase
in other income in the third quarter of fiscal 2020 is due to an increase in research and development incentive income in the
three and nine months ended June 30, 2020, as compared the three and nine months ended June 30, 2019, as a result of increased
clinical trial activities in Australia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity
and Capital Resources</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Working
Capital</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">June
    30, 2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">September
    30, 2019</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify"><span style="font-size: 10pt">Current Assets</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">31,630,256</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">25,329,373</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">Current Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">6,949,198</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">5,039,674</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font-size: 10pt">Working Capital</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">24,681,058</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">20,289,699</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font-size: 10pt"><br />
<span style="font-family: Times New Roman, Times, Serif">At June 30, 2020, we had $27.6 million in cash and cash equivalents,
an increase of $5.4 million from September 30, 2019. The principal reason for this increase is due to cash received from financing
activities of $20.5 million from the issuance of shares of common stock under the 2019 Purchase Agreement (as defined below),
offset by cash used in operations of $15.0 million.</span></span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
Flows</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">Nine months ended June 30,</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">2020</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">2019</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: justify; padding-left: 5.4pt"><span style="font-size: 10pt">Net cash flows used in operating
    activities</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">(15,032,274</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">(15,992,811</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font-size: 10pt">Net cash flows from financing activities</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">20,465,789</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">14,311,379</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font-size: 10pt">Increase (decrease) in cash and cash equivalents</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">5,433,515</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">(1,681,432</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
</table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
flow used in operating activities</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities for the first nine months in fiscal 2020 was $15.0 million, compared to $16.0 million during
the comparable period of fiscal 2019. The principal reason for this decrease in net cash used in operating activities in the current
period is due to the receipt of an increased amount of research and development incentive income during the period, as compared
to the comparable period.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
flow provided by financing activities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
provided by financing activities for the first nine months in fiscal 2020 was $20.5 million, attributable to cash received from
the issuance of common shares at various market prices under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
provided by financing activities for the first nine months in fiscal 2019 was $14.3 million, attributable to cash received from
the issuance of common shares at various market prices under the 2015 Purchase Agreement and the 2019 Purchase Agreement.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Other
Financing</b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, we entered into the 2019 Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital
Fund, LLC (&#8220;Lincoln Park&#8221;), as amended on July 1, 2020 (the &#8220;Amendment Date&#8221;), pursuant to which Lincoln
Park committed to purchase up to $50,000,000 of our common stock. Concurrently with the execution of the 2019 Purchase Agreement
in 2019, we issued 324,383 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common
stock under the 2019 Purchase Agreement and shall issue up to 162,191 shares pro rata, when and if Lincoln Park purchases, at
our discretion, the $50,000,000 aggregate commitment. The purchase shares that may be sold pursuant to the 2019 Purchase Agreement
may be sold by us to Lincoln Park at our discretion from time to time until July 1, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
may direct Lincoln Park, at our sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of common
stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the even we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional purchases. The purchase price
of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares at the
time of sales as described in the Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2020, approximately $24.9 million in shares of our common stock remained available for purchase by Lincoln Park under
the 2019 Purchase Agreement.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Controlled
Equity Offering Sales Agreement </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1 2020, we entered into an Amended and Restated&#160;Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp;
Co. (&#8220;Cantor Fitzgerald&#8221;) and SVB Leerink LLC (&#8220;Leerink&#8221;) and together as Sales Agents, pursuant to which
we may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $50,000,000 from time to time through
the Sales Agents (the &#8220;At-the-Market Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales
Agents may sell shares of common stock by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to
make any sales of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering
upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agents on a commercially reasonable
efforts basis consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations
and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have agreed to pay the Sales Agents commissions for their services of 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement.&#160; We have also agreed to provide the Sales Agents with customary indemnification and contribution
rights. At June 30, 2020, no shares had been sold pursuant to the At-the-Market Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
expect that we will be able to continue to fund our operations through existing cash and cash equivalents on hand and through
equity and debt financing in the future. If we raise additional financing by issuing equity securities, our existing stockholders&#8217;
ownership will be diluted. Obtaining commercial loans, assuming these loans would be available, would increase our liabilities
and future cash commitments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the Lincoln Park financing and the At-the-Market Offering, there can be no assurance that additional
financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we
are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale
down some or all of our research and development activities or perhaps even cease the operation of our business.</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Off-Balance
Sheet Arrangements</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>CRITICAL
ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">We
prepare our interim condensed consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America, and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue
and expenses, and the related disclosures of contingent liabilities. We base our estimates on historical experience and other
assumptions that we believe are reasonable in the circumstances. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Other
than as described in Note 2 &#8220;Recent Accounting Pronouncements&#8221; to our Interim Condensed Consolidated Financial Statements
included herein, there have been no significant changes in the critical accounting policies and estimates described in our Annual
Report on Form 10-K for the year ended September 30, 2019 as filed with the SEC on December 16, 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.3in; margin-right: 0; margin-left: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Please
refer to Note 2 &#8220;Recent Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements
included in this Form 10-Q.</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="item3"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
3. Quantitative and Qualitative Disclosures about Market Risks.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="item4"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
4. Controls and Procedures.</b></span></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Disclosure
Controls and Procedures </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rule 13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
and procedures were effective as of June 30, 2020.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter ended June 30, 2020, there were no changes in our internal control over financial reporting identified in management&#8217;s
evaluation pursuant to Rules 13a 15(d) or 15d 15(d) of the Exchange Act during the period covered by this Form 10-Q that materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="part2otherinfo"></span><span style="font-family: Times New Roman, Times, Serif"><b>PART
II &#8211; OTHER INFORMATION</b></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="legalproceedings"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
1. Legal Proceedings.</b></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="itemn1a"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
1A. Risk Factors.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no material changes to the risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report
on Form 10-K for the fiscal year ended September 30, 2019 filed with the SEC on December 16, 2019 except for the following new
risk:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
COVID-19 coronavirus could adversely impact our business, including our clinical trials, and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19
coronavirus has spread to multiple countries, including the United States, Australia and European and Asia-Pacific countries,
including countries in which we have planned or active clinical trial sites. As the COVID-19 coronavirus continues to spread around
the globe, we may experience disruptions that could potentially impact our business and clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, the spread of COVID-19 coronavirus has had and may continue to severely impact the trading price of shares of our common
stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact
our business, including our clinical trials, and financial condition will depend on future developments, which are highly uncertain
and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak,
travel restrictions and social distancing in the United States and other countries, business closures or business disruptions
and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the information set forth in this Form 10-Q, you should carefully review and consider the risk factors discussed in
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 filed
with the SEC on December 16, 2019. These risks could materially and adversely affect our business, financial condition, and results
of operations. The risks described in herein and in our Form 10-K are not the only risks we face. Our operations could also be
affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.
There have been no material changes in the significant factors that may affect our business and operations as described in &#8220;Risk
Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="unregistered"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</b></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="defaults"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
3. Defaults Upon Senior Securities.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="minesafety"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
4. Mine Safety Disclosures</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="otherinfo"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
5. Other Information.</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">None</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: justify"><span style="font-size: 10pt"><span id="exhibits"></span><span style="font-family: Times New Roman, Times, Serif"><b>Item
6. Exhibits.</b></span></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    </b></span><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif"><b>Number </b></span></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font-size: 10pt"><br />
    <span style="font-family: Times New Roman, Times, Serif"><b>Description</b></span></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Articles
    of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm" style="-sec-extract: exhibit">Articles of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 filed on May 9, 2019)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm" style="-sec-extract: exhibit">Bylaws (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm" style="-sec-extract: exhibit">Articles of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated by reference to our Current Report on Form 8-K filed on January 25, 2007)</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(31)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Rule
    13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2054ex_311.htm">Certification of Christopher Missling, PhD.</a></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">31.2*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2054ex_312.htm">Certification of Sandra Boenisch</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(32)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
    1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">32.1*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2054ex_321.htm">Certification of Christopher Missling, PhD and Sandra Boenisch.</a></span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(101)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>
<p style="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><span style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-transform: uppercase; text-align: center"><span style="font-size: 10pt"><span id="signatures"></span><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><span style="font-size: 10pt">Date: August 6, 2020</span></td>
    <td style="width: 34%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 33%"><span style="font-size: 10pt"><b>ANAVEX LIFE SCIENCES CORP.</b></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt"><i><span style="text-decoration: underline">/s/Christopher Missling, PhD</span></i></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Christopher Missling, PhD</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</span></p>
</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 33%"><span style="font-size: 10pt">Date: August 6, 2020</span></td>
    <td style="width: 34%"><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt"><i><span style="text-decoration: underline">/s//Sandra Boenisch</span></i></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Sandra Boenisch, CPA, CGA</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">Principal Financial Officer</span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>e2054ex_311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
31.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2020 of Anavex Life Sciences Corp. (the
&ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 6, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/Christopher
Missling, PhD </U><BR>
Christopher Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</FONT></P>
<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>e2054ex_312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
31.2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended June 30, 2020 of Anavex Life Sciences Corp. (the
&ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt 30.6pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 6, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/Sandra
Boenisch</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandra
Boenisch, CPA, CGA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
Financial Officer, Treasurer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial and Accounting Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>e2054ex_321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
32.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months
ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned,
in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: August 6,
    2020</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/<U>s/Christopher
    Missling, PhD </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling,
    PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Chief Executive
    Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/Sandra Boenisch</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch,
    CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial
    Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial
    and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (1 PP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "B@YP<=:XN+42=&_=7MY-K5THAF@60EH79OG(0\(5&['3IWZT =I
M17 RZMJT</VHR7:_8=/E2Z@QEF(8KYF!_& %?CJ":M17LYNSLO[AM1%Q;JMM
MYA*M$8HRY*= .7.[CD=>U ':45PBW]RRJ?M]R-2%I9M;0>8?WK,#NRG0@]SC
MCU&*;=7^H7,.I22-J,45S$]S9.KF,)L.T!=ISAD*O@]\T =[17,V3^5XONK1
M[LE(E0012WC[R-F3A#P_?D\_E734 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %&><45RUWHUS=>([V]VB-(EC:)PA\R0A&!16SPN3R,4
M =1D8SD8I<CUKSR'1;VTT^""YM25\^WE<)9F2,+Y#*<Q G+!OO'W4UJK:KG4
MEETV=[Z02&UG$!P(S'A%#?P8'&W@Y[=Z .NHKB[NRGUB"&,6]ZD36UM"Y*-$
MRLLR%B,X.0.<^U0O::[<)=%[:9;H27"[T.T2?NHE#*<\;MK8]"?:@#NJ*X^_
ML3J%A'I^BZ7):PR.99C(K6P#(HV=LD[RAZ<[#6AH=S<M?W1O+2YAFN1%)AHF
MV B)0PW=!\P/>@#H**** "BBB@ HHHH **** "BBB@ HHHH *,XZT5B^)+&;
M4(+&&&&*4?:U9Q,A= NUN6 (R,X_'% &U17&MHVJ6RW,$-Q));QO9K\T19I@
MA3<P;=QT]^E0FRU%VOI+ZUN(K?4U\US$#,T;(X\L-'CH4P&49SM([T =OD<<
MCGI2UQ^EV\QUNUN+O3U@'V:-(U6Q9E4AY>5;_EEP5.#ZX[5JNJIXSAE6WN,O
M9O&\PC<QYW(5&[[HX#4 ;=%%% !1110 4444 %%%% !1110 445E>(K::[T9
MX((EE=IH?D==RD"12=P[C .?:@#5HKB[K0]4MH+ZWLY_D.G,HQ 2K.SR-L3Y
MOEP& '7C%+/::E+J=W>36MPEG=I)9L87)E2(+\C!,<'<'.<_\M!0!V61C.1S
M2YYQ7#VMK,;_ $U[C3U2VA$J(5TUBK?.A#>7_P LB>>3Z$UL:M&D_B'3HQ9S
M!XV65KQ8&8  D",,!QD_>S@8^O !T%%%% !1110 4444 %%%% !1110 445G
M:_#+<>'M1A@0O-);NJ*.I)4X% &CUHKE%T/4;*[A6TGCB#1W#OY=N3%&6\L!
M%7=Q]TGKUSTS5.VM=82?3[Q[*7R[2"*S<"0B0HR#S&"8Y^<H<Y_Y9F@#MLC&
M<C%+FO/UL)5CLH38N;*WN6Q*^FLS2@Q8R\77<#QOQ@]:W?%-NUS#:+;VSR7"
MR*\>VW9C@,I*AQ_JB<?>/:@#HZ*** "BBB@ HHHH **** "BBB@"F;>^R<7Z
M ?\ 7 ?XTGV>_P#^?]/^_ _QJX3@$^E<S;ZYJ]XK/;643H#CA3Q^M<F)QE/#
MN,9W;=[65]C:E0E53<>G<VOL]_\ \_Z?]^!_C1]GO_\ G_3_ +\#_&LO^T=?
M_P"@?'_WR?\ &C^T=?\ ^@?'_P!\G_&L/[4I?R2_\!9I]4GW7WHU/L]__P _
MZ?\ ?@?XT?9[_P#Y_P!/^_ _QK+_ +1U_P#Z!\?_ 'R?\:/[1U__ *!\?_?)
M_P :/[4I?R2_\!8?5)]U]Z-3[/?_ //^G_?@?XT?9[__ )_T_P"_ _QK+_M'
M7_\ H'Q_]\G_ !H_M'7_ /H'Q_\ ?)_QH_M2E_)+_P !8?5)]U]Z-3[/?_\
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M5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\
M^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :
M/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_
M +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP
M/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q
M?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_
MQH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__
M ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\
MRLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_
M .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!
M_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__
M )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\
MC_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M
M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_
M _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'
M_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C
M_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_
M /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?
M5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K
M3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]
M^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV
M>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(
M_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A
M*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\
M3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P
M?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW
M_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/
ML]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U
M2O\ RLO?9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X
M2K3_ .[-_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z
M?]^!_C5'_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?
M9[__ )_T_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-
M_P!\C_&C^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'
M_A*M/_NS?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T
M_P"_ _QH^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C
M^T\'_P _%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS
M?]\C_&C_ (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QH
M^SW_ /S_ *?]^!_C5'_A*M/_ +LW_?(_QH_X2K3_ .[-_P!\C_&C^T\'_P _
M%]X?5*_\K+WV>_\ ^?\ 3_OP/\:/L]__ ,_Z?]^!_C5'_A*M/_NS?]\C_&C_
M (2K3_[LW_?(_P :/[3P?_/Q?>'U2O\ RLO?9[__ )_T_P"_ _QI4@O0ZEKU
M64'D>2!D?G5%/%&G.X7]ZN3C)48'ZULJP90RD%2,@CO711Q5&O?V4D[=C.I2
MG3^-6%HHHK<S"BBB@ HHHH 1_N-]*Y_PE_QXS_\ 73^@KH'^XWTKG_"7_'C/
M_P!=/Z"O-Q'^_4?27Y(ZZ7^[U/E^IT-%%%>D<@4444 %%%% !1110 4444 %
M%%% !1110!SMO_R.=S_N?^RK715SMO\ \CG<_P"Y_P"RK715YN6?#5_QR_,Z
ML7O#_"@HHHKTCE"BBB@#@_$G_(;G_P" _P#H(JM+IS1):,9 ?/(##'W"<$ _
M@0:N:_Y?_"0R>;GR]R;L=<8&:B;54G,OG0(@,BRH8UYRI[\_W<BO@*\*+Q%;
MVCUYG;[V_P#@?,^EI.:I0Y5T156VB%W+;RS."KE%*1[BQSCIFGW6GB!)6BE,
MPCE\HX7OMR?\*L)<6$=W/<K+<>8Y8H3$/D)/7KR<9J#[8+:S>"TGF#&4/OQM
M)&W&.#ZUFZ=",6I6ZZIW?EU+YJC:M_7X#SIL<9F\V=PL3(OR1;B2PSTS1;:6
M+F2 +/M6;S,,R]-OK]:F.IQ.]R1/<0F5HV#HN2=JX.>?6HH[Z&..-,R-L29=
MV.3OZ'K6G+A%);6]?[WK_+Y$7K6\_P#@>G<BM=.DN'N59O+\A6+9&<L,\?H:
M);***"-C,YED17"B+Y1GMNS5DZK$6C.Q@6C8S$#[TA7:#]/\344]Y%-:PH+B
MX'EQHIAV_(2._7^E2X850:B[O7^MUZ>I2E5<M=$.DTJ..7_CZS&DWE2LR;-O
M<D>O -0/9Q1V:W#3L/-W&(>7D$ XP3V-2WVHK>I.LC2-B;? 6[*>H/Z4VVNK
M>WM)%WS.9(RK0%1L+'HV<]OIFE-89S<8I6L];O\ *_Z];^01]KRIO?\ KR_K
M\2*WM89+5YYK@Q*KA!A-W)&?7VJ8:2YD,9E3/FI&I_A8,"0V:BMY;8V+V]PT
MJYE$@**#G (QR?>II+Z"=)(W61(R\>T+@D(JD?GTJ:<</R1YK7]7Y[]NG_!'
M)U+NW];?\$8MC ]Q)&MQ)MCC9WS"0PP>F,T6]@MU>/#%,0BKG?(FWGH!CW)
MJR-3A#J/.G+"%H_M&T!\DC'?MCUJ+[?'!$XB)N)9) SO.O8#COZUHX85--VM
MU^[;=]>WWD\U7;^O78ABLD-HUQ/,T2AS& (RV& [^E$EI%%:1RM-)YDD8<*(
MLKR<8+9JTE_:)>/=*\ZF0[I( H*/D<CKTSFH9KR*:QBB%Q.A2(*80OR$Y)]?
MZ5+IX=0=K-V?7\=U]WX,:E4;6_\ 7R,^BBBO-.H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M_0==-F
MPMKDDP$\-_<_^M6!75:!H&-MY>)[QQG^9KTLJAB98E?5]UOVMYG)C)4E2?M3
MIP00"#D&EHHK]"/F0HHHH **** $?[C?2N?\)?\ 'C/_ -=/Z"N@?[C?2N?\
M)?\ 'C/_ -=/Z"O-Q'^_4?27Y(ZZ7^[U/E^IT-9NOZNF@Z)=:D\+SF%1LAC^
M]*Y("H/<L0/QK2KG/$^BW^O7FDV\-RUK96\YNIYXBOF!T'[H ,""-Q).1_"*
M](Y"O?>/=/L-,T'49(96M-6=5,BD?Z."N2S^P/!].:N7/BF"TL]>N9+:3&DR
M>5M# F=C&CJ%]"2X4>]<_8^"[ZWNK;3[O9>Z1;WMS('F<;GAGA8,I4 #B1V'
M'8U4L_!&OK"=,N;_ !:'5A=&]C<&5H(8D$ *L""VY5SG/W,]Z .GTKQ=!JEQ
MI$8M9(5U.T>>)W8?+(A >$C^\N3_ -\GTJC_ ,)O<W5S%!IFAO>-,]R(F-TD
M:O'"ZH7R>Q9C@>@S67<^#]?L]-OX=+NDFO+;4!J&EW-RP!+2*1,CA0 !\SG@
M<[AZ5+J_@QHWT&*WT2UUBRTZQDMFAN)_*^<^7A^AR3M;/UH U;OQJ+"XGL;K
M3)4U0>0+6T$JDW7F\?(W3"L&#'L%SW%95K\3/M/Q"D\-'2]L D:%+@3 LSKG
M/RX]5/&<@$'H:EU#P_KU_JL6OI%!;7NE+&FF68FW(R$#SP[8_B'R ]M@/>NL
M72-/COWU2/3K8:@R\S"-0Y.,?>QGL!F@#.TKQ)<WFMMI6H:/-IUPUL;J'?,D
MF^,,%.=OW6!*\<]>M1^)O$FH^'H+B[30S=V,$7F-.+M(R3_="GDG. /4FLO1
M=)U^ZO[^?7[+[-=7R;&O;2_YMXU.4BB 4$#DDG.223Z :=_X?N;F;1-/$TLV
MEVLYNKJ2YF+RRLG,2'/4;CN/^X!0 77BF[L-3L8+S0YX;2[GCM5N3.A(E=<@
M; <E0>"?;.,<UTM<+K/AS4M4\5VM]%I-G:SVUW'(FKI=DR>2OWD\O;U9=RD9
MQ@YS7=4 %%%% '.V_P#R.=S_ +G_ +*M=%7.V_\ R.=S_N?^RK715YN6?#5_
MQR_,ZL7O#_"@HHHKTCE"BBB@"I-IEE<2M++;H[MU8]ZC_L73O^?2/]:Y/6[B
M==9N$260#<, ,?2JLPU*!E67[0A<X7)/)]*^7K9K052:>'O9M-Z=_3J>O#!U
M'&+]I:Z_KJ=M_8NG?\^D?ZT?V+IW_/I'^M<0AU&2=H$,YE3.Y QR,=:1GOT\
MS>TZF/ ?)/RYZ9K/^UL/:_U;\%_D7]2J;>U_K[SN/[%T[_GTC_6C^Q=._P"?
M2/\ 6N)QJ0<)^_WEM@7<<[L9Q]<4P2WS E7G.&"'!/WCT'UXH>;8=:/#?@O\
M@^I5?^?O]?>=S_8NG?\ /I'^M']BZ=_SZ1_K7%.NIQS)"WV@2/\ =7)R:&74
MUG2$_:!(_*KD_-]*?]J4/^@7\%_D+ZG4_P"?O]?>=K_8NG?\^D?ZT?V+IW_/
MI'^M</$]_,5$;S'<XC!W$#<>U._XF)@:8&<Q+G+[CBDLUP[5UAOP7^0?4JBT
M]K_7WG;?V+IW_/I'^M']BZ=_SZ1_K7$P_P!HW*%H3<2*IP2I)YIBR7S#Y6G/
MS[.I^]Z?6C^UL/9/ZMOY+_(?U*I_S]_K[SN?[%T[_GTC_6C^Q=._Y](_UKB_
M*U7SO*VW'F;=VW)Z>M,)U 3-#NG\Q%W,NXY QG--YI06^%_!?Y"6#J/_ )>_
MU]YV_P#8NG?\^D?ZT?V+IW_/I'^M<1$=1GC:2(SNB]6!.!2D:D+?SR9Q%C=O
M+'&/6DLUH-76%T]%_D'U*I>WM?Z^\[;^Q=._Y](_UH_L73O^?2/]:XF$:E<1
MF2'[1(@."5)/-$(U*X4M#Y[A3@D,>#Z4UFE!VMA=_)?Y \'46]7^OO.V_L73
MO^?2/]:/[%T[_GTC_6N&>:]CC21Y)E1\[6+'!QP:>@U*1D5/M!+KO49/*^OT
MI+-L.W98;\%_D/ZE56OM?Z^\[;^Q=._Y](_UH_L73O\ GTC_ %KB9/[1B$A<
MS@1XWG<?ESTS3HX]4F&8Q<-D \,>AZ4UFE!OE6%U]%_D+ZG4M?VO]?>=I_8N
MG?\ /I'^M']BZ=_SZ1_K7$3-J%N,S-,@SC)8]<9IDLU["^R629'P#AF.>:F6
M;X>.^&2^[_(:P-5[5?Z^\[K^Q=._Y](_UH_L73O^?2/]:P-(M!>V/G33W&_>
M5^60BM%=$B;_ );W7_?TUZM&*K4U4CAXV>NZ_P#D3BJ/V<G%U'=?UW+W]BZ=
M_P ^D?ZT?V+IW_/I'^M4I=(M8(S)+<72H" 3YI[\4T:99XE+SW:"-L-F4_@?
MH:MTTG9T(?>O_D1*3:NJC^Y_YE_^Q=._Y](_UH_L73O^?2/]:HC3=..?].N.
M%W']^>!2#3=-)(%]<''7$YXI<B_Y\0^]?_(CN_YY?<_\R_\ V+IW_/I'^M']
MBZ=_SZ1_K5$Z9IP('VVXR?\ IN:<^DV$?W[NY'./]<>M/V:_Y\0^]?\ R(7?
M\\ON?^9<_L73O^?2/]:/[%T[_GTC_6J/]FZ;@G[;<8!P?WQX-']FZ;C)OK@<
MXYF(YI<B_P"?$/O7_P B%W_/+[G_ )E[^Q=._P"?2/\ 6C^Q=._Y](_UJA_9
MVF[=WVZXQ_UV-+_9NFY ^W7&3TS.>:.2/_/B'WK_ .1"[_GE]S_S+W]BZ=_S
MZ1_K1_8NG?\ /I'^M<5?2S6]_<0QSR[(Y"JY<YQ5?[9<_P#/>3_OHUY$\WPL
M).+PZT]/\CMC@:TDFJC_ !_S.]_L73O^?2/]:/[%T[_GTC_6N"^V7/\ SWD_
M[Z-'VRY_Y[R?]]&I_MK"?] Z_#_(?U"M_P _'^/^9WO]BZ=_SZ1_K1_8NG?\
M^D?ZUP7VRY_Y[R?]]&C[9<_\]Y/^^C1_;6$_Z!U^'^0?4*W_ #\?X_YG>_V+
MIW_/I'^M']BZ=_SZ1_K7!?;+G_GO)_WT:/MES_SWD_[Z-']M83_H'7X?Y!]0
MK?\ /Q_C_F=[_8NG?\^D?ZT?V+IW_/I'^M<%]LN?^>\G_?1H^V7/_/>3_OHT
M?VUA/^@=?A_D'U"M_P _'^/^9WO]BZ=_SZ1_K1_8NG?\^D?ZUP7VRY_Y[R?]
M]&C[9<_\]Y/^^C1_;6$_Z!U^'^0?4*W_ #\?X_YG>_V+IW_/I'^M']BZ=_SZ
M1_K7!?;+G_GO)_WT:/MES_SWD_[Z-']M83_H'7X?Y!]0K?\ /Q_C_F=[_8NG
M?\^D?ZT?V+IW_/I'^M<%]LN?^>\G_?1H^V7/_/>3_OHT?VUA/^@=?A_D'U"M
M_P _'^/^9WO]BZ=_SZ1_K1_8NG?\^D?ZUP7VRY_Y[R?]]&C[9<_\]Y/^^C1_
M;6$_Z!U^'^0?4*W_ #\?X_YG>_V+IW_/I'^M']BZ=_SZ1_K7!?;+G_GO)_WT
M:/MES_SWD_[Z-']M83_H'7X?Y!]0K?\ /Q_C_F=[_8NG?\^D?ZT?V+IW_/I'
M^M<%]LN?^>\G_?1IT=_=1R*ZW$F5.1\QH6=83KAU^'^0?4*W_/S\_P#,[O\
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M.'_E.E_X2^;_ )]H_P S1_PE\W_/M'^9KFJ*/[7QW_/Q_A_D'U'#_P ITO\
MPE\W_/M'^9H_X2^;_GVC_,US5%']KX[_ )^/\/\ (/J.'_E.E_X2^;_GVC_,
MT?\ "7S?\^T?YFN:HH_M?'?\_'^'^0?4</\ RG2_\)?-_P ^T?YFC_A+YO\
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MUV5[^R?WO_(X&8RS10H8\")-@([\D_UI;AI;FX,K18) &!TX ']*[W^U=/\
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M^P?]]BC^U=/_ .?V#_OL55J__04O_ 8_YDWI_P#/E_>SG'UYG";K+E)/,4@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME_[Z7_"C^P<7Y?>']HT//[CC:*[+_A%]._Y[R_\ ?2_X4?\ "+Z=_P ]Y?\
MOI?\*/[!Q?E]X?VC0\_N.-HKLO\ A%]._P">\O\ WTO^%'_"+Z=_SWE_[Z7_
M  H_L'%^7WA_:-#S^XY6RLIKZX6&%<L>I[ >IKOM-TZ+3;40QG+'EV/<T:?I
MUMIT)2W&=W)<\DU<KZ#*LJCA%[2>LW^'H>9C,8ZSY8_"%%%%>T< 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>?/(,-.3E*F[OU-XYM**251:>@G_  A[_P#/XO\ W[_^O1_PAS_\_B_]^_\
MZ]+_ &YX/_Z"4'_?Y_\ &C^W/!__ $$H/^_S_P"-3_J]A?\ GT_OE_F/^UY_
M\_%^ G_"'/\ \_B_]^__ *]'_"'/_P _B_\ ?O\ ^O2_VYX/_P"@E!_W^?\
MQH_MSP?_ -!*#_O\_P#C1_J[A?\ GT_OE_F']KS_ .?B_ 3_ (0Y_P#G\7_O
MW_\ 7H_X0Y_^?Q?^_?\ ]>E_MSP?_P!!*#_O\_\ C1_;G@__ *"4'_?Y_P#&
MC_5["_\ /I_?+_,/[7G_ ,_%^ G_  A[_P#/XO\ W[_^O1_PAS_\_B_]^_\
MZ]+_ &YX/_Z"4'_?Y_\ &C^W/!__ $$H/^_S_P"-'^KV%_Y]/[Y?YA_:\_\
MGXOP$_X0]_\ G\7_ +]__7JU;>')K:"6'S[>6*4@NLL)(..G>JW]N>#_ /H)
M0?\ ?Y_\:/[<\'_]!*#_ +_/_C6E+(Z%&:G3@TUUO+_,B>:.I'EG--?(U;:P
MOK2,QP3VJ(6+;1"< GK@;N*F\G5/^?NV_P"_)_\ BJQ/[<\'_P#02@_[_/\
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MW_?QO\:/[)LO^>3?]_&_QH NT52_LFR_YY-_W\;_ !H_LFR_YY-_W\;_ !H
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M_P"@-8_]^%_PK8HK#VD^[.GV-/\ E7W&/_PBGA__ * UC_WX7_"C_A%/#_\
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M%%%>:>N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9WB3_GM!_P!^11_M?]W\1?[#_>_ 9_PK3Q-_SZ1_]_D_QH_X5IXF_P"?2/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH ;("8G ZE37CWA3Q!J7A2TN;1]
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MP"?PJ'4]+;2VV/>VD\@<QR1P2%FC8=0<@?F.*%AKNRJ,'B[*[HH]>_LKX?\
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M&4@J1D$=#7E5Z$J,K2/;PV)A7AS1^[L+1116!TA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>AI:#T- 'SQHU
M[!8:G?RS^65:UFC5)5)5V(X4@>M:5OXH@MK*"XFA6>[:=7\F!_)6".+_ %:X
MP<@EF./SJ&;P)XF:9V&E2X+$CYU_QIG_  @7B?\ Z!,O_?:_XU]#)T9.[DOO
M/E8K$05HQ?W,T;?7=-TJ9(K26*2T?4)78^7F2&)T4!E)&5923T_NU6?4-.F\
M.VV@RWJ[%\UUN5#824.Q3<,<JRG\"<U7_P"$"\3_ /0)E_[[7_&C_A O$_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3O\ GYN?S7_"C_A ]._Y^;G\U_PH VDLHY,[-0NFQZ39I_\ 9W_3Y>?]_?\
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MV_PKS2B@#TO^U-'_ .@U<_\ ?;?X4?VIH_\ T&KG_OMO\*\THH ]+_M31_\
MH-7/_?;?X4?VIH__ $&KG_OMO\*\THH ]+_M31_^@U<_]]M_A1_:FC_]!JY_
M[[;_  KS2B@#TO\ M31_^@U<_P#?;?X4JZEI#,%&M7&2<<R$?TKS.B@#V :<
M",B]O,?]=?\ ZU+_ &=_T^7G_?W_ .M7'^%O%/D;+"_?]UTCE/\ !['V_E].
MG>@Y&1TH I?V=_T^7G_?W_ZU']G?]/EY_P!_?_K5=HH I?V=_P!/EY_W]_\
MK4?V=_T^7G_?W_ZU7:* *7]G?]/EY_W]_P#K4?V=_P!/EY_W]_\ K5=HH I?
MV=_T^7G_ ']_^M1_9W_3Y>?]_?\ ZU7:* *7]G?]/EY_W]_^M1_9W_3Y>?\
M?W_ZU7:* *7]G?\ 3Y>?]_?_ *U']G?]/EY_W]_^M5VB@"E_9W_3Y>?]_?\
MZU']G?\ 3Y>?]_?_ *U7:* *7]G?]/EY_P!_?_K4?V=_T^7G_?W_ .M5VB@"
ME_9W_3Y>?]_?_K4?V=_T^7G_ ']_^M5VB@"E_9W_ $^7G_?W_P"M1_9W_3Y>
M?]_?_K5=HH I?V=_T^7G_?W_ .M1_9W_ $^7G_?W_P"M5VB@"E_9W_3Y>?\
M?W_ZU']G?]/EY_W]_P#K5=HH I?V=_T^7G_?W_ZU']G?]/EY_P!_?_K5=HH
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MIO\ "C_A+M%_Y^S_ -^F_P * -NBL3_A+M%_Y^S_ -^F_P */^$NT7_G[/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *SFT'268L=/@R>3\E:-% &;_PC^D?] ^#_OFC_A'](_Z!
M\'_?-:5% &;_ ,(_I'_0/@_[YH_X1_2/^@?!_P!\UI44 9O_  C^D?\ 0/@_
M[YH_X1_2/^@?!_WS6E10!F_\(_I'_0/@_P"^:/\ A'](_P"@?!_WS6E10!F_
M\(_I'_0/@_[YH_X1_2/^@?!_WS6E10!F_P#"/Z1_T#X/^^:/^$?TC_H'P?\
M?-:5% &;_P (_I'_ $#X/^^:/^$?TC_H'P?]\UI44 5+72[&RD,EM:Q1.1@L
MJ\XJW110 4444 %%%% 'BUS_ ,?,G^\:O6NDK=6]NWVM4GN"XBB,9()7U;MG
MZ51N?^/F3_>-7TU5HM,M;.&9XL-)YS*HSM8CH>O3- $,^F20:=:WA=2)S@H!
MS'G[N?J 35J;0A'-Y<=X)-MRMM(3&5VLW0CGD4^?6;>Y^V0-;)'!(JB)T4[\
MI]S/..F1^-2SZ[#=W;/.\K1Q7BSVY*\A,_,I_#!'TH I_P!C,LZP23JDS"1_
M+VY(102"?3..!^-*-#D)TX^<NR] ^8+_ *MB,X(^E3'5;6:^^W2AUN,2QN57
MB12I"M['D _G3['6K>WN[7S5=[9;>-) !RLB9PP_/'T)H H2Z<D%E#-)<XFG
M3?%&(R0PSC&[IGVJ5](022VR7BO>Q(6:$(=I(&64-W('\J?;W]M:Z?+&L\\K
M.G%O)&-B29SO!SV]A3GO[!+RXU&%IS<RJY6!D 5&8$$EL\@9..* &'0Y!-9+
MYZF.ZCWAPOW#MW;2/7&/SID6F0RH7^U$+%;K-.43>5+'   Z\$9]*MVNMV\-
MV/,5WMOLZ+TY614V@C]1]#69ILD4$OF/=SVLB@;)(4W?4$9% !:V:76HBU2X
M'EG<1,$/( )SCKVJQ'I"W#V[6]VLL$SF/S-A4HP4M@K[@4Y-0M?^$@>\\MHK
M9BW"J,C*D9Q]3G%26NH65@UO#"TTD2RF665T ).PJ %STYH JRZ='!:P/)<X
MFG19$C\L[2"<?>Z9HOM/BM;DVT5R\]P)?+*>25&>G!SSS4\-[:V^EO )KB;>
MJ[8)(QMB?()8-GV/3UYJW<:M:OJGV[[9<W 1WDAMY(L*K8^7G/3.* *CZ&Z:
MK]C^T*R>49O-1"<J <X'<Y!&/:HHM/M94N)1?-Y$6P;Q 226SQMSQC%3_P!H
MVMU!;B8O9SV[MY;VJ$X!Y[G/7/?O5DZQ;,]SLNKBW>18A]HCB&Z0KG)(!&,Y
M'Y4 8$@59&5&+H#A6*X)'T[4VGS$&>0J[2 L2'88+>Y%,H [CPMXJSLT_4).
M>D4S']#_ (UVU<#X6\+?:=E_?I^YZQQG^/W/M_/Z=>^H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH X26+P>)7#S3[\\\-U_*F>5X,_Y[3_DW^%<K=_\ 'Y-_OFIM
M,L?[0O!"THAC"EGD(R%'0?J0/QH Z3RO!G_/:?\ )O\ "CRO!G_/:?\ )O\
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MS_X#O_A1_:<']RY_\!W_ ,* +E%4_P"TX/[ES_X#O_A1_:<']RY_\!W_ ,*
M+E%4_P"TX/[ES_X#O_A1_:<']RY_\!W_ ,* +E%4_P"TX/[ES_X#O_A1_:<'
M]RY_\!W_ ,* +E%4_P"TX/[ES_X#O_A1_:<']RY_\!W_ ,* +E%4_P"TX/[E
MS_X#O_A1_:<']RY_\!W_ ,* +E%4_P"TX/[ES_X#O_A1_:<']RY_\!W_ ,*
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M?* 7G&&SZ=3Q5:O0_P"P/#O_ #YWG_?N7_"I(=%\/P3+*ME=%E.0&BE(_+%
M&9X6\+>;LO[]/DZQ1,/O>Y]OY_S[JJ7]IP?\\[G_ ,!W_P *7^TX/[ES_P"
M[_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"
MC^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG
M!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P"
M[_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"
MC^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG
M!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P"
M[_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"
MC^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG
M!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P"
M[_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"
MC^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG
M!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P"
M[_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"
MC^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG
M!_<N?_ =_P#"C^TX/[ES_P" [_X4 7**I_VG!_<N?_ =_P#"C^TX/[ES_P"
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M_P#OH_X4?8=>_P"?Z/\ [Z/^%;]%'UB79?<'U6/\S^]G+7KZSIHCDFNU8,<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<ZO'+);L]RIM7P-VP1*?DPO0D9.#DT >DT444 8/B?\ X][?_?-;W:L'Q/\
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MSSE_-O\ &CV_]U_<'U=?SQ^\YRBNCW^'/^><OYM_C1O\.?\ /.7\V_QH]O\
MW7]P?5U_/'[SG**Z/?X<_P"><OYM_C1O\.?\\Y?S;_&CV_\ =?W!]77\\?O,
M_2-(DU&;)RL"GYF_H*[:&&.WA6*)0J*, "HK%K9K.,VF/)QP!V^OO5FO,Q%:
M525GHD>OA</&E&ZU;ZA1117.=04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %83_\C=%_N'_T$UNUA/\
M\C=%_N'_ -!-;T/M>C.;$_8_Q(W:;(@EB>,E@&4J2IP1GT-.HK Z3)'AK2UT
MG3],6%EMM/>*2V"N0R-']TYZGW]<G/6JY\':*UEI-J;9C'I,PGLSYC;HW&>^
M<D<]#[5O44 8X\,:6NAVNCK"XM+5XY(<2'>KHP<-NZYW#)/?)]:=!X:TJVGU
M>>*VVR:L<WAW'Y_EV_AQGIW)-:U% '-VW@?2;>VBM3+J$]K$T3);W%[))&/+
M.4&UCC (''L*U[+2K33[R^N;9&1[V02S+N.TN%"[@.@) &<=<5=HH Q]<\-V
M7B%8DO9;Q4B(8)!<O$I8$,"0I&2" 0>U5KGP5HUY<K/<)<R,4C28&Y?;<B/[
MAE&<2$>I_&NAHH PO^$0T<ZR=3,,OFF?[5Y7GOY/G8QYGEYV[L=\>_6C3?"&
MCZ3J"WMK#+YD8<0)).[I;ASEQ&I.$R?3Z=*W:* "BBB@#!\3_P#'O;_[YK>[
M5@^)_P#CWM_]\UO=JWJ?PH?,YJ?\>?R"BBBL#I"BBB@#C?%/_(5'_7)?YFL4
M LP51DDX K:\4_\ (5'_ %R7^9K+M)DM[I)G4ML^8#_:[?K7N4-**MV/G<0D
MZ\D^Y9ETS9>QP),&1E),F.%VYW?EBF);6LY?R)I?DC=R'0#H,COWJ6/53L7S
MHE9E<D;%"@JPPP..YZYJ*.XM+>0&*.9D9623>P!VD8P,=Z%[3J-^SOIL-BMX
M/LT4TSR@22,F$ .",>OUJP=/MC<7,2/<O]G'S!4!+'(' JM-<1>5##"K^7&Q
M<E\98G'ITZ5,M]%]JO9&$RK<="A 9?FS3?/NOZU_R$G3V?\ 6G^976!'OE@#
M/&C.%S(,,OU%27]FEJR!/,!(.]),93GC./7K38;B."_6<"21 3]\C=R,9SZU
M/<W\,]F8 LQ?@^:V,OCIN^@/6FW/F5MA)0<7?<B%CNTU;I7RV\ADQT7(&?S-
M3G38D\\L;AQ',8AY2 G &<FH(+X0); (3Y;/O!Z.K8R*F>_@E\X-]HC$DYE'
MED9P1C!J7[2Y4?96\_\ @%<6BF2S7>V+C&3CI\Q%6(=,CEC!\R4,S2 ,$RB[
M?[Q[9ID5W;*+=I8Y3);D[-I ##.1GTY]*6+4O+6%&#F/<_G(#PX;M1+VG3^M
M_P#@!'V2W_K;_@C4M+<"!)YW2690PVJ"J ],_P#UJDCTQ&5$>219W:10 N5!
M7U-,%U:,89)HI3)"H4!2-K@=,^E))J,DEND1>107=I@IP&W'-#]H]@7LEO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "LC4=$:]O!<QW)B;&.%_P#KUHW$!G"@3RQ8[QD#/Y@U2FBBMR!-JERA
M/0%U_P#B:J-5TWS)V,ZE.$XVGL4_^$>N?^@G)^1_QH_X1ZY_Z"<GY'_&I_,M
M/^@Q/_WVO_Q-'F6G_08G_P"^U_\ B:OZ]+^9?@8?5J']-_YD'_"/7/\ T$Y/
MR/\ C1_PCUS_ -!.3\C_ (U/YEI_T&)_^^U_^)H\RT_Z#$__ 'VO_P 31]>E
M_,OP#ZM0_IO_ #(/^$>N?^@G)^1_QH_X1ZY_Z"<GY'_&I_,M/^@Q/_WVO_Q-
M'F6G_08G_P"^U_\ B:/KTOYE^ ?5J']-_P"9!_PCUS_T$Y/R/^-'_"/7/_03
MD_(_XU/YEI_T&)_^^U_^)H\RT_Z#$_\ WVO_ ,31]>E_,OP#ZM0_IO\ S(/^
M$>N?^@G)^1_QH_X1ZY_Z"<GY'_&I_,M/^@Q/_P!]K_\ $T>9:?\ 08G_ .^U
M_P#B:/KTOYE^ ?5J']-_YD'_  CUS_T$Y/R/^-'_  CUS_T$Y/R/^-3^9:?]
M!B?_ +[7_P")H\RT_P"@Q/\ ]]K_ /$T?7I?S+\ ^K4/Z;_S(/\ A'KG_H)R
M?D?\:/\ A'KG_H)R?D?\:G\RT_Z#$_\ WVO_ ,31YEI_T&)_^^U_^)H^O2_F
M7X!]6H?TW_F5SX:D=E\V_9U!Z%3_ (UT%9'F6G_08G_[[7_XFK0L&(R+^[(_
MWE_^)J)5W5W=[&U*E3IWY"[15+^SW_Y_[O\ [Z7_ .)H_L]_^?\ N_\ OI?_
M (FI-2[15+^SW_Y_[O\ [Z7_ .)H_L]_^?\ N_\ OI?_ (F@#/U?0YM1O!,D
MB*-@7#$^_M[U0_X12Y_Y[1?F?\*T+BYMK:9HI-2O0Z]<%?\ "H_[0L_^@E??
MFO\ A6D<QY%RJ2T.*>&H2DY2W]2G_P (I<_\]HOS/^%'_"*7/_/:+\S_ (5<
M_M"S_P"@E??FO^%']H6?_02OOS7_  I_VF_YD3]4PW],I_\ "*7/_/:+\S_A
M1_PBES_SVB_,_P"%7/[0L_\ H)7WYK_A1_:%G_T$K[\U_P */[3?\R#ZIAOZ
M93_X12Y_Y[1?F?\ "C_A%+G_ )[1?F?\*N?VA9_]!*^_-?\ "C^T+/\ Z"5]
M^:_X4?VF_P"9!]4PW],I_P#"*7/_ #VB_,_X4?\ "*7/_/:+\S_A5S^T+/\
MZ"5]^:_X4?VA9_\ 02OOS7_"C^TW_,@^J8;^F4_^$4N?^>T7YG_"C_A%+G_G
MM%^9_P *N?VA9_\ 02OOS7_"C^T+/_H)7WYK_A1_:;_F0?5,-_3*?_"*7/\
MSVB_,_X4?\(I<_\ /:+\S_A5S^T+/_H)7WYK_A1_:%G_ -!*^_-?\*/[3?\
M,@^J8;^F4_\ A%+G_GM%^9_PH_X12Y_Y[1?F?\*N?VA9_P#02OOS7_"C^T+/
M_H)7WYK_ (4?VF_YD'U3#?TRG_PBES_SVB_,_P"%'_"*7/\ SVB_,_X5K6@B
MO58P:E=DKU!90?Y59_L]_P#G_N_^^E_^)K2..J25TRE@:#U2_$P/^$4N?^>T
M7YG_  H_X12Y_P">T7YG_"M_^SW_ .?^[_[Z7_XFC^SW_P"?^[_[Z7_XFG]<
MJ]P^H4>Q@?\ "*7/_/:+\S_A1_PBES_SWB_,_P"%;_\ 9[_\_P#=_P#?2_\
MQ-']GO\ \_\ =_\ ?2__ !-'URKW#ZA1[#-+TJ+38<##2M]Y_P"@K0JE_9[_
M //_ '?_ 'TO_P 31_9[_P#/_=_]]+_\37/*3F^:1UPA&$>6.Q=HJE_9[_\
M/_=_]]+_ /$T?V>__/\ W?\ WTO_ ,34E%VBJ7]GO_S_ -W_ -]+_P#$T?V>
M_P#S_P!W_P!]+_\ $T 7:*I?V>__ #_W?_?2_P#Q-']GO_S_ -W_ -]+_P#$
MT 7:*I?V>_\ S_W?_?2__$T?V>__ #_W?_?2_P#Q- %VBJ7]GO\ \_\ =_\
M?2__ !-']GO_ ,_]W_WTO_Q- %VBJ7]GO_S_ -W_ -]+_P#$T?V>_P#S_P!W
M_P!]+_\ $T 7:*I?V>__ #_W?_?2_P#Q-']GO_S_ -W_ -]+_P#$T 7:*I?V
M>_\ S_W?_?2__$T?V>__ #_W?_?2_P#Q- %VBJ7]GO\ \_\ =_\ ?2__ !-'
M]GO_ ,_]W_WTO_Q- %VBJ7]GO_S_ -W_ -]+_P#$T?V>_P#S_P!W_P!]+_\
M$T 7:*I?V>__ #_W?_?2_P#Q-']GO_S_ -W_ -]+_P#$T 7:*I?V>_\ S_W?
M_?2__$T?V>__ #_W?_?2_P#Q- %VBJ7]GO\ \_\ =_\ ?2__ !-']GO_ ,_]
MW_WTO_Q- %VBJ7]GO_S_ -W_ -]+_P#$T?V>_P#S_P!W_P!]+_\ $T 7:*I?
MV>__ #_W?_?2_P#Q-']GO_S_ -W_ -]+_P#$T 7:*I?V>_\ S_W?_?2__$T?
MV>__ #_W?_?2_P#Q- %VBJ7]GO\ \_\ =_\ ?2__ !-']GO_ ,_]W_WTO_Q-
M %VBJ7]GO_S_ -W_ -]+_P#$T?V>_P#S_P!W_P!]+_\ $T 7:*I?V>__ #_W
M?_?2_P#Q-']GO_S_ -W_ -]+_P#$T 7:*I?V>_\ S_W?_?2__$T?V>__ #_W
M?_?2_P#Q- %VBJ7]GO\ \_\ =_\ ?2__ !-']GO_ ,_]W_WTO_Q- %VBJ7]G
MO_S_ -W_ -]+_P#$T?V>_P#S_P!W_P!]+_\ $T 7:*I?V>__ #_W?_?2_P#Q
M-']GO_S_ -W_ -]+_P#$T 7:*B@A,"%3-++DYS(02/R J6@ HHHH **** "L
M'584GURUCD&490",X[FMZL2__P"1AL_]U?YFN?$J\$O-?F9U-BU_8>G_ //$
M_P#?9_QH_L/3_P#GB?\ OL_XUHT5?L:?\J^XKDCV,[^P]/\ ^>)_[[/^-']A
MZ?\ \\3_ -]G_&M&BCV-/^5?<')'L9W]AZ?_ ,\3_P!]G_&C^P]/_P">)_[[
M/^-:-%'L:?\ *ON#DCV,[^P]/_YXG_OL_P"-']AZ?_SQ/_?9_P :T:*/8T_Y
M5]P<D>QG?V'I_P#SQ/\ WV?\:/[#T_\ YXG_ +[/^-:-%'L:?\J^X.2/8SO[
M#T__ )XG_OL_XT?V'I__ #Q/_?9_QK1HH]C3_E7W!R1[&=_8>G_\\3_WV?\
M&C^P]/\ ^>)_[[/^-:-%'L:?\J^X.2/8Y_5],M;2T22&,JWF 9W$]C6W;?\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJS:SIUOJBZ9+=(M\T#7*P8)8QJ<%A^-,_M[2SIMGJ O$-I>M&EO( 3YC/]P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &(O
MA735\4-XB*R-?F,1AF<D <\8].1],5!JG]NR:MMLA?1VORKOB-L5]SAP6_\
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MNNOM!LM0O/M4IN$E,7DN89WC$D>2=K 'D9)_,UH111P0I#$BI'&H5$48"@<
M"@#A+G6+RXUG3["&YG%]!=06MQB?:&(4/*_E!<%2N1EB!Z=*JV#LJPZA97>H
M3SW-_=W4]OYQ8;8@V(V4]#Q$OK7I%% 'G:ZO>?94U#3]5N+V5K!WNP/FB2=P
MHB55Q\K!R>.N <]JZ+0X;NVUV^M9-0NKN&"V@5VN"#NF.XL5P !\NW(''-=%
M10!Y[8W37VMRW-AJ-R;ZXU<B2U3A([:/",74CH53()[L,5K^$+W4-8M;:ZN)
MY?(M8C;/N&#<3@[78^R[<#U);T%=2Z"2-D)(W#&5."/H:CM+2"QM(K6VC$<,
M2A$4=@* .5L9+J!M<\1R-;FS,LT@C,!,I2%=BX;=T)0GIW]ZRHY; :-H1MO]
M(DTUUO+NZ@3=M;:<H&[O([[=H[$YKT6B@#AM#AU&W\9P7.J6'D7=_9SF:02B
M0%E>,J@QT"J2!Z\GUKN:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (D PP# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HK'\0:GJNG0P+H^BOJ=U.Y0*9A%'$
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M5+0VND76H31>4UQ( 8X8$=PJ[G(Y8D\*,^^* .VHIDTT=O!)/,ZQQ1J7=V.
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MCDC?.UE; ]"""*ZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M LH(!(]2,T >9:GJ=NVL>"I-6TTZ["GAY9GLY7C&'?:!*!(P5VX((ZCK2_\
M".+H7PO\UK*UM)+_ ,06]P(H&5S%$;A=D;.O#;1GN<9KJ/$G@>[_ .$BL;^Q
MT+2];TNUT\6,.F7TNP6^#G>A8,#D8!SSQ5SPEX 6TT[4H];LK***]OH[R+3+
M-V\BT* ;=IXR<C)P * ,ZT\,Z-KWQC\6RZMI\-X;>VLQ&DR[D&Z,@G:>"<
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M/_?J3_XN@#Z?HKY@_P"&C/%O_0/TG_OU)_\ %T?\-&>+?^@?I/\ WZD_^+H
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M#_AHSQ;_ - _2?\ OU)_\71_PT9XM_Z!^D_]^I/_ (N@#Z?HKY@_X:,\6_\
M0/TG_OU)_P#%T?\ #1GBW_H'Z3_WZD_^+H ^GZ*^8/\ AHSQ;_T#])_[]2?_
M !='_#1GBW_H'Z3_ -^I/_BZ /I^BOF#_AHSQ;_T#])_[]2?_%T?\-&>+?\
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M&>+?^@?I/_?J3_XN@#Z?HKY@_P"&C/%O_0/TG_OU)_\ %T?\-&>+?^@?I/\
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M*%6,]F14445PF@4444 %%%% !1110 4444 %%%% !1110 4444 %%%*!32N
M8I*?M/I2$5HZ;2%<;11160PHHHH *<G^L7ZBFTY/]8OU% 'WS;_\>T7^X/Y5
M)4=O_P >T7^X/Y5)0 4444 ?"?B/_D9]6_Z_9O\ T,UF5I^(_P#D9]6_Z_9O
M_0S690 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%+115) % &:55W' %:FGZ'>WS#R;=W![@5TT,/.J]%H9U*D(*\G8JV]J\S (
MN36BNBW&,[*[70_"KVH4S1$'OD5U2:1;E,%!7T%+"0A"[/ Q.<QC*T-4>,W&
MF31+DIQ6<Z%37M]WX>@FC*A1DUQ>L>"YP6>",GV K+$8*,U[IMA,XIS=IZ'
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MCYZNX&M[AXV&"IP:K&KVIW N;Z64<!F)J@:^CQBC&HU$^RI-N*<MPHHHKB-
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M0TY<T5(2G)_K%^HIM.3_ %B_45QFA]\V_P#Q[1?[@_E4E1V__'M%_N#^524
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3T.QO)+2%]9"B!VE.R-VQ\DAQ\K#<N1SC(K'M] U"Y\3)X>2'&HM=?9/+8X
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MLC#8P?E)&.1SP/2NGUCQ_P";I)L-&758&DN$GDN[[4#<3#8&"(AP-JC<WN:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3_XJC_A4'@'_ *%NW_[^2?\ Q5=O10!Q'_"H/ /_ $+=O_W\D_\ BJ/^%0>
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M_H6[?_OY)_\ %5V]% '$?\*@\ _]"W;_ /?R3_XJC_A4'@'_ *%NW_[^2?\
MQ5=O10!Q'_"H/ /_ $+=O_W\D_\ BJ/^%0> ?^A;M_\ OY)_\57;T4 <1_PJ
M#P#_ -"W;_\ ?R3_ .*H_P"%0> ?^A;M_P#OY)_\57;T4 <1_P *@\ _]"W;
M_P#?R3_XJC_A4'@'_H6[?_OY)_\ %5V]% '$?\*@\ _]"W;_ /?R3_XJC_A4
M'@'_ *%NW_[^2?\ Q5=O10!Q'_"H/ /_ $+=O_W\D_\ BJ/^%0> ?^A;M_\
MOY)_\57;T4 <1_PJ#P#_ -"W;_\ ?R3_ .*H_P"%0> ?^A;M_P#OY)_\57;T
M4 <1_P *@\ _]"W;_P#?R3_XJC_A4'@'_H6[?_OY)_\ %5V]% '$?\*@\ _]
M"W;_ /?R3_XJC_A4'@'_ *%NW_[^2?\ Q5=O10!Q'_"H/ /_ $+=O_W\D_\
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MXP0/F(!))9CT':MN?_CWE_W#_*@!?-C_ +Z_G1YL?]]?SHB \I./X13\#TH
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M]2G^Z*>>E,B_U*?[HH ?1110 4444 %%%% $<W^I;Z5)4<W^I;Z5)0 4444
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M_P"^10!)14>R3_GJ?^^11LD_YZG_ +Y% $E%1[)/^>I_[Y%&R3_GJ?\ OD4
M2'I3(O\ 4I_NBD*/C_6G_OD4V)7\I,2'H.PH FHJ/9)_SU/_ 'R*-DG_ #U/
M_?(H DHJ/9)_SU/_ 'R*-DG_ #U/_?(H DHJ/9)_SU/_ 'R*-DG_ #U/_?(H
M )O]2WTJ2LO6+F[LK&2>*-)D12SAGV$?3@YJW;_:WBS<;(Y,_=1MPQ]<"@"S
M135##JV[\*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2
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MGI_7:QM0Q4J,KP2)K/2X(;6))HUDD50&+?,,^V:NHB1C"*JCT Q2>:/[C_\
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M([N2!DBN%M1%*1P^U&!P?8G]:X_1M -O8VNA:O#XFD>&X4,D)S:/MDWK(&'
M7A6()!!R*]1HH XS3;F\\.ZGK%G-HVH79O-0:ZMY[6(-'(L@489B0$*D$'=C
M@#&:Q9]%EL[[7;/48_$DD%_=RSQC3/FAFBD RIX^5ARIW8X .:]-HH X(WPT
M'Q_<I'I5]=6ZZ/:Q;K9/->+#S;0RYR0?49Y'/7-1+IFI:?X=T>\ETZ=I(M;D
MU&>S@ >2&.5I3M '4KYBY ]Z[E+"V34I=06("ZEB6%Y,GE%+%1CIP6;\ZLT
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MW%M$(E"0W))D08Z-DDY^I- ',Q>$_$>G6ZZ;H_BO[-I*#9"DUBLL\"=E20L
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M* "HW_UL?U/\JDJ-_P#6Q_4_RH DHHHH **** "BBB@ I@_US_[H_K3Z8/\
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M/C4O[1&D6GVOS/-\SRQ]_P#O8Z;O?K6S0 4444 %%%% !1110 4444 %%%%
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M*J!$XQM &X]STXKO/#%W;W_AC3;JU6=89+=2JSR%Y%XZ,Q)+$'OWK@K?1O\
MA)/%%H?%&GPVUSJ%D;V"72;Z>($*%1HY1D!F"R@;AC(R.F*].M;6"RM(;6VB
M6*"%!''&@P%4#  H EHHHH **** "HY_^/>7_</\JDIDW^HD_P!T_P J *UB
M-\D\O^T(Q]%'^)-4;BZE&N0RC3KUXXHY(RZH,$DK@CGIP:O:6<Z?&_\ ?+-^
M9-7*RH_PT^^OWZEU/B:"BBBM2 HHHH *9+]T?[P_G3Z9+]T?[P_G0 ^BBB@
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M]T?E0!']I@_Y[1_]]"C[3!_SVC_[Z%2;5_NC\J-J_P!T?E0!']I@_P">T?\
MWT*/M,'_ #VC_P"^A4FU?[H_*C:O]T?E0!']I@_Y[1_]]"F/<0F2,^='U/\
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M +Z%2;5_NC\J-J_W1^5 $$UQ 8F FC)Q_>%/^TP?\]H_^^A4FU?[H_*C:O\
M='Y4 (DB2#*.K8]#FG4@ '0 4M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %8OB'6+G3?[/M;"**2^U"Y%O#YQ(1,
M*SL[8Y("J>!U)%;58OB'2+G4A87-A+%%?:?<BXA\X$H_RLC*V.0"K'D="!0
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M<&MFL;0M*NK&?4;[4)87O=0F6200 ^7&JH$55SR>%R2>Y-;- !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M86@@,21D%7WL[,IR>&+<YR>!S0!>N]6L[*YBM[AW1Y65%;RF*!F.%!8# )/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>avxl-20200630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9KhZw7xRiXgen8uCa3dcOaaE+cPtw5NxKYkhv2d8fZlq7yQowFfslSUUFPYmAZQF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:avxl="http://anavex.com/20200630" elementFormDefault="qualified" targetNamespace="http://anavex.com/20200630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000011 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000017 - Disclosure - Commitments and Contingencies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" id="CommitmentsAndContingenciesDetails1">
	  <link:definition>00000018 - Disclosure - Commitments and Contingencies (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" id="CommitmentsAndContingenciesDetails2">
	  <link:definition>00000019 - Disclosure - Commitments and Contingencies (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" id="CommitmentsAndContingenciesDetails3">
	  <link:definition>00000020 - Disclosure - Commitments and Contingencies (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" id="CommitmentsAndContingenciesDetails4">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20200630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="avxl_CommonSharesToBeIssuedMember" name="CommonSharesToBeIssuedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ClinicalStudyGrantMember" name="ClinicalStudyGrantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreementMember" name="PurchaseAgreementMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueAcquisitions2" name="StockIssuedDuringPeriodValueAcquisitions2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesAcquisitions2" name="StockIssuedDuringPeriodSharesAcquisitions2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" name="SharesIssuedPursuantToCashlessExerciseOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" name="SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" name="SharesIssuedPursuantToCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" name="SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingAgreementsAbstract" name="DisclosureEquityOfferingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentsIncentiveIncome" name="ResearchAndDevelopmentsIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_AgreementTerm" name="AgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_RemainingAllocatedShareBasedCompensationExpense" name="RemainingAllocatedShareBasedCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>avxl-20200630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200630.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200630.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>avxl-20200630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200630.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200630.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="loc_avxlCommonSharesToBeIssuedMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_avxlCommonSharesToBeIssuedMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlAgreementTerm_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_90" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_40" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_40" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense_80" xlink:type="arc" order="5" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>avxl-20200630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="avxl_CommonSharesToBeIssuedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommonSharesToBeIssuedMember" xlink:to="avxl_CommonSharesToBeIssuedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommonSharesToBeIssuedMember_lbl" xml:lang="en-US">Common Shares To Be Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ClinicalStudyGrantMember" xlink:label="avxl_ClinicalStudyGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ClinicalStudyGrantMember_lbl" xml:lang="en-US">Clinical Study Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp;amp;amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreementMember" xlink:label="avxl_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreementMember_lbl" xml:lang="en-US">2015 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">&#160;Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares, authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares, issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain (loss), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Deferred financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance Beginning (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">&#160;&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueAcquisitions2_lbl" xml:lang="en-US">&#160;&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:to="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesAcquisitions2_lbl" xml:lang="en-US">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">&#160;&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">&#160;&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1_lbl" xml:lang="en-US">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptions_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of options (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:to="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares_lbl" xml:lang="en-US">Shares issued pursuant to cashless exercise of warrants (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance Ending (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income Disclosure [TextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:to="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements [TextBlock]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentsIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Gross sale proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_AgreementTerm" xlink:label="avxl_AgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_AgreementTerm_lbl" xml:lang="en-US">Agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of share issued</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationDescription_lbl" xml:lang="en-US">Description of purchases price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Exercisable at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ClinicalStudyGrantMember" xlink:to="avxl_ClinicalStudyGrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ClinicalStudyGrantMember_doc" xml:lang="en-US">Information by clinical study grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreementMember" xlink:to="avxl_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreementMember_doc" xml:lang="en-US">Terms of the purchase agreement under purchase agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_AgreementTerm" xlink:to="avxl_AgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_AgreementTerm_doc" xml:lang="en-US">Terms of the agreement under agreements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:to="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_RemainingAllocatedShareBasedCompensationExpense_doc" xml:lang="en-US">It represents as a remaining stock based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1_2_lbl" xml:lang="en-US">CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentsIncentiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentsIncentiveIncome_2_lbl" xml:lang="en-US">ResearchAndDevelopmentsIncentiveIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>avxl-20200630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.4a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20200630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20200630.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20200630.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20200630.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingencies" xlink:href="avxl-20200630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20200630.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20200630.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20200630.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20200630.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="avxl-20200630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommonSharesToBeIssuedMember" xlink:label="loc_avxlCommonSharesToBeIssuedMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_avxlCommonSharesToBeIssuedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesAcquisitions2" xlink:label="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesAcquisitions2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptions" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfOptionsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:label="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlSharesIssuedPursuantToCashlessExerciseOfWarrantsInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingencies" xlink:title="00000011 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000012 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesTables" xlink:title="00000013 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ResearchAndDevelopmentsIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentsIncentiveIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_avxlResearchAndDevelopmentsIncentiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000015 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:label="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ClinicalStudyGrantMember" xlink:label="loc_avxlClinicalStudyGrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_avxlClinicalStudyGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000016 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreementMember" xlink:label="loc_avxlPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_AgreementTerm" xlink:label="loc_avxlAgreementTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationDescription" xlink:label="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapUnrecordedUnconditionalPurchaseObligationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000017 - Disclosure - Commitments and Contingencies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails1" xlink:title="00000018 - Disclosure - Commitments and Contingencies (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails2" xlink:title="00000019 - Disclosure - Commitments and Contingencies (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails3" xlink:title="00000020 - Disclosure - Commitments and Contingencies (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetails4" xlink:title="00000021 - Disclosure - Commitments and Contingencies (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000022 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20200630.xsd#avxl_RemainingAllocatedShareBasedCompensationExpense" xlink:label="loc_avxlRemainingAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlRemainingAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>e2054_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20200630"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20200630.xsd" xlink:type="simple"/>
    <context id="From2019-10-01to2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-08-06</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avxl:CommonSharesToBeIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">avxl:ClinicalStudyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-19</startDate>
            <endDate>2015-10-21</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2018-10-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-10-01to2020-06-30">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-10-01to2020-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-10-01to2020-06-30">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2019-10-01to2020-06-30">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-10-01to2020-06-30">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:DeferredCostsCurrent
      contextRef="AsOf2019-09-30"
      id="xdx2ixbrl0056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-01to2020-06-30"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-01to2020-06-30"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-06-30"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0468"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_custom_CommonSharesToBeIssuedMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2019-10-01to2020-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2019-10-01to2020-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2019-10-01to2020-06-30">2020-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2019-10-01to2020-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2019-10-01to2020-06-30">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2019-10-01to2020-06-30">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-10-01to2020-06-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-10-01to2020-06-30">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-10-01to2020-06-30">51 West 52nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2019-10-01to2020-06-30">7th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2019-10-01to2020-06-30">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2019-10-01to2020-06-30">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2019-10-01to2020-06-30">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2019-10-01to2020-06-30">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-10-01to2020-06-30">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-10-01to2020-06-30">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2019-10-01to2020-06-30">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-10-01to2020-06-30">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-10-01to2020-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2019-10-01to2020-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-10-01to2020-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2019-10-01to2020-06-30">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2019-10-01to2020-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-10-01to2020-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2019-10-01to2020-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2020-08-06" decimals="INF" unitRef="Shares">60190619</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">27619145</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">3547972</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2642745</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">438631</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">500998</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24508</us-gaap:DeferredCostsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">31630256</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">25329373</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">31630256</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">25329373</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">3980204</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">3523332</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">2968994</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1516342</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">6949198</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5039674</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">60082291</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">60082291</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">52650251</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">52650251</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">60083</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">52652</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">178332979</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">153633807</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-153712004</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-133396760</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24681058</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">31630256</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">25329373</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1381477</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">1388729</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4453654</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">5211287</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">6725002</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">5758446</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">19126717</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">17549442</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">8106479</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">7147175</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">23580371</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">22760729</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">223999</avxl:NonOperatingIncomeFromGrant>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1319913</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">552335</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">2980456</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">1727007</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">56096</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">34838</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">172996</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">165103</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">36978</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">36978</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">248665</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-54546</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-24182</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-4854</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1624674</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">644549</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">3279158</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">2148233</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6481805</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-6502626</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-20301213</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-20612496</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">4817</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">19300</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">14031</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">76065</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-6521926</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-20688561</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-04-012019-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-10-012019-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">59105399</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-04-012019-06-30"
      decimals="INF"
      unitRef="Shares">49622465</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="Shares">57401387</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-10-012019-06-30"
      decimals="INF"
      unitRef="Shares">47691921</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-20688561</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">5194343</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">905227</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">1780150</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-62367</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-829576</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">456872</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">267061</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">1452652</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">184920</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-15032274</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-15992811</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">20490297</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">14361379</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">24508</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">50000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">20465789</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">14311379</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">5433515</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-1681432</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">22930638</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">27619145</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">21249206</us-gaap:Cash>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">58664946</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">58666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">171958462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-147225382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">24791746</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1400000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1400</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5123405</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">5124805</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16624</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">16</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-16</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1251129</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6486622</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60082291</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">178332979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-153712004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24681058</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">48173241</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">48175</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">138696975</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_custom_CommonSharesToBeIssuedMember"
      decimals="0"
      unitRef="USD">-292700</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-121268416</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">17184034</us-gaap:StockholdersEquity>
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2619403</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2619</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7833451</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2019-04-012019-06-30_custom_CommonSharesToBeIssuedMember"
      decimals="0"
      unitRef="USD">292700</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">8128770</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14070</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-14</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">375</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1163400</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">1163775</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">328157</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">328</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-328</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1234204</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">1234204</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6521926</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-6521926</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">51509871</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">51511</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">148927688</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-127790342</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">21188857</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">52650521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7364584</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7365</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">20482932</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">20490297</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">66465</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">65</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-65</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">721</avxl:SharesIssuedPursuantToCashlessExerciseOfOptionsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfOptions
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4216306</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">-20315244</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">60082291</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">60083</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">178332979</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-153712004</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">24681058</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">45933472</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">45935</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">129377542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-107101781</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">22321696</us-gaap:StockholdersEquity>
    <avxl:StockIssuedDuringPeriodSharesAcquisitions2
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4848995</avxl:StockIssuedDuringPeriodSharesAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4849</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">13192755</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:StockIssuedDuringPeriodValueAcquisitions2
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">13197604</avxl:StockIssuedDuringPeriodValueAcquisitions2>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">23701</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-27</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">375000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">375</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1163400</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">1163775</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">328157</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">324</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-324</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">546</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-1</avxl:SharesIssuedPursuantToCashlessExerciseOfWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5194343</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">5194343</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-20688561</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">-20688561</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">51509871</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">51511</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">148927688</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-127790342</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">21188857</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zQlXHVUG8wTg" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Note
1 	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_825_zIzBfC2Q1yPc"&gt;Business Description and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex
Life Sciences Corp. (the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#x2019;s lead compound ANAVEX&#xae;2-73
is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
results for the nine months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year
ending September 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&#160;The actual amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#x201c;WHO&#x201d;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to
curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition
for the year ending September 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 27, 2020, the President of the United States signed into law the &#x201c;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#x201d; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#x2019;s interim condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="text-align: justify; margin-right: 0; margin-left: 42.55pt"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Adjustment
of Prior Period Financial Statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
previously disclosed in Note 1 to the Company&#x2019;s consolidated financial statements included in the Company&#x2019;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial. These adjustments
were identified in connection with the preparation of the consolidated financial statements for the year ended September 30, 2019
and related to the timing of recognition of research and development incentive income. Previously the Company accounted for research
and development incentive income when received in cash. During the year ended September 30, 2019, based on a continuing assessment
regarding the Company&#x2019;s eligibility for the incentive programs under which it was receiving such income, the Company determined
that the income should have been accrued and recorded in the period in which the qualifying research and development expenditures
were incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
interim condensed consolidated financial statements for the three and nine months ended June 30, 2020 have been similarly adjusted
to reflect the adjusted research and development incentive income for the three and nine months accordingly in the amount of $&lt;span id="xdx_900_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20190401__20190630_pp0p0" title="Research and development incentive income"&gt;552,335&lt;/span&gt;
and $&lt;span id="xdx_904_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20181001__20190630_pp0p0" title="Research and development incentive income"&gt;1,477,007&lt;/span&gt;, respectively and should be read in conjunction with Note 1 to the Company&#x2019;s consolidated financial statements
for the year ended September 30, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;










&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
June 30, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
and Diluted Loss per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2020, loss per share excludes &lt;span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200630_pii" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt; (September 30, 2019 &#x2013; &lt;span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares"&gt;8,812,933&lt;/span&gt;) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/span&gt;&lt;/p&gt;








&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <avxl:ResearchAndDevelopmentsIncentiveIncome
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">552335</avxl:ResearchAndDevelopmentsIncentiveIncome>
    <avxl:ResearchAndDevelopmentsIncentiveIncome
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">1477007</avxl:ResearchAndDevelopmentsIncentiveIncome>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="Shares">10576266</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="From2018-10-012019-09-30"
      decimals="INF"
      unitRef="Shares">8812933</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqagfZL73Wy6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
2	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82E_z85hjqJ0aMAj"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znN3K39uB8bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;












</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znN3K39uB8bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;












</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_809_ecustom--OtherIncomeDisclosureTextBlock_zeLtjRD503Ad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
3	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_825_zxassuBqGV39"&gt;Other Income&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
Income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $&lt;span id="xdx_900_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Grant income"&gt;597,886&lt;/span&gt;. The grant was received in
equal quarterly installments over a period of two years commencing during the year ended September 30, 2018 in exchange for a
commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the three and nine months ended June 30, 2020, the Company recognized $&lt;span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20200401__20200630_pp0p0" title="Grant income"&gt;0&lt;/span&gt; and $&lt;span title="Grant income"&gt;&lt;span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_zzQ6UnSjeSfa"&gt;149,888&lt;/span&gt;&lt;/span&gt;, respectively (2019: $&lt;span title="Grant income"&gt;&lt;span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_c20190401__20190630_zehAlWHgYVT8"&gt;74,944&lt;/span&gt;&lt;/span&gt;
and $&lt;span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20181001__20190630_pp0p0" title="Grant income"&gt;223,999&lt;/span&gt;, respectively) of this grant on its statement of operations within grant income. As at June 30, 2020, the Company
had recognized the full amount of grant funding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development incentive income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#x201c;NYC Biotech credit&#x201d;), and the Australian research and development tax incentive credit (the &#x201c;Australia R&amp;amp;D
credit&#x201d;) through a program administered through the Australian Tax Office (the &#x201c;ATO&#x201d;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#x2019;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#x201c;Anavex Australia&#x201d;).&#160;Research and development incentive income
during the three and nine months ended June 30, 2020 and 2019 represents the receipt by the Company&#x2019;s Australian subsidiary,
of the Australian research and development incentive credit, (the &#x201c;ATO R&amp;amp;D Credit&#x201d;), as well as receipt by the
Company of the New York City Biotechnology Credit (&#x201c;NYC Biotech credit&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended June 30, 2020, the Company recorded research and development incentive income of $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630_zIgqvw7r8Uwc" title="Research and development incentive income"&gt;1,319,913&lt;/span&gt; (AUD
&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630__srt--CurrencyAxis__currency--AUD_zRFY0EmyPBc3" title="Research and development incentive income"&gt;1,923,000&lt;/span&gt;) and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income"&gt;2,980,456&lt;/span&gt; (AUD &lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;4,471,000&lt;/span&gt;), respectively (2019: $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20190401__20190630_pp0p0" title="Research and development incentive income"&gt;552,335&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630_pp0p0" title="Research and development incentive income"&gt;1,727,007&lt;/span&gt;, respectively) in respect of the ATO R&amp;amp;D
Credit for eligible research and development expenses incurred during the period (2019: In respect of the ATO R&amp;amp;D Credit for
eligible research and development expenses incurred during the period and the NYC Biotech credit).&lt;/span&gt;&lt;/p&gt;








&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2016-10-012017-09-30_custom_ClinicalStudyGrantMember"
      decimals="0"
      unitRef="USD">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">149888</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">223999</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1319913</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-04-012020-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">1923000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">2980456</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2018-10-012019-06-30_currency_AUD"
      decimals="0"
      unitRef="USD">4471000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">552335</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">1727007</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_80C_ecustom--EquityOfferingAgreementsTextBlock_zfIUaaCpRYtc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
4	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_824_z5LW55hRLcJ2"&gt;Equity Offering Agreements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales
Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has entered into an Amended and Restated&#160;Sales Agreement dated May 1, 2020 (the &#x201c;Sales Agreement&#x201d;) with
Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;), pursuant to which the Company
may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds"&gt;50,000,000&lt;/span&gt; from time to time through the
Sales Agents (the &#x201c;Offering&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Upon
delivery of a placement notice based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has agreed to pay the Sales Agents commissions for their services of up to &lt;span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zVfgMLXdiCy3" title="Percentage of gross proceeds from sales"&gt;3.0&lt;/span&gt;% of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. As of June 30, 2020, no shares had been sold pursuant to the Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2015
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 21, 2015, the Company entered into a $&lt;span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; purchase agreement (the &#x201c;2015 Purchase Agreement&#x201d;) with Lincoln
Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $&lt;span title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; in value of its shares of common stock from time to time over a &lt;span id="xdx_905_ecustom--AgreementTerm_dtM_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7MmdbFAlQ6f" title="Agreement term"&gt;36&lt;/span&gt;-month period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended June 30, 2019, the Company issued an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"&gt;4,872,696&lt;/span&gt; shares of common stock under the 2015 Purchase
Agreement, including &lt;span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"&gt;4,848,995&lt;/span&gt; shares of common stock for an aggregate purchase price of $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;13,197,604&lt;/span&gt; and &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"&gt;23,701&lt;/span&gt; commitment shares.
At June 30, 2020 and September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.&lt;/span&gt;&lt;/p&gt;














&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 7, 2019, the Company entered into a $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; purchase agreement (the &#x201c;2019 Purchase Agreement&#x201d;) with Lincoln
Park, as amended on July 1, 2020 (the &#x201c;Amendment Date&#x201d;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $&lt;span title="Total number of shares obligated to purchase"&gt;50,000,000&lt;/span&gt; in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the &lt;span id="xdx_907_ecustom--AgreementTerm_dtMp_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBxgIhrXnQY1" title="Agreement term"&gt;36&lt;/span&gt;-month anniversary of June
12, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price"&gt;The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#x201c;Regular Purchase&#x201d;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#x2019;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of share issued"&gt;12,016,457&lt;/span&gt; shares
of Common Stock, representing &lt;span id="xdx_903_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXmKUzpOCcwh" title="Percentage of gross proceeds from sales"&gt;19.99&lt;/span&gt;% of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#x2019;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#x2019;s outstanding shares of Common Stock at any given time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"&gt;324,383&lt;/span&gt; shares of common stock
as a commitment fee and agreed to issue up to &lt;span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchases at the Company&#x2019;s
discretion the $50,000,000 aggregate commitment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended June 30, 2020, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"&gt;7,431,049&lt;/span&gt; (2019: &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z0O1oNJCqhY9" title="Number of share issued"&gt;703,157&lt;/span&gt;) shares of common
stock under the 2019 Purchase Agreement, including &lt;span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"&gt;7,364,584&lt;/span&gt; (2019: &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price"&gt;375,000&lt;/span&gt;) shares of common stock for an aggregate purchase
price of $&lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;20,490,297&lt;/span&gt; (2019: $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;1,163,775&lt;/span&gt;) and &lt;span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"&gt;66,465&lt;/span&gt; (2019: &lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"&gt;328,157&lt;/span&gt;) commitment shares. At June 30, 2020, an amount of $&lt;span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"&gt;24,875,198&lt;/span&gt;
remained available under the 2019 Purchase Agreement, as amended.&lt;/span&gt;&lt;/p&gt;












</avxl:EquityOfferingAgreementsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2019-10-012020-06-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2015-10-192015-10-21_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4872696</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4848995</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">13197604</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreementMember_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">23701</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <avxl:AgreementTerm contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">P36M</avxl:AgreementTerm>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationDescription contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#x201c;Regular Purchase&#x201d;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#x2019;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</us-gaap:UnrecordedUnconditionalPurchaseObligationDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12016457</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Pure">0.1999</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7431049</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">703157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">7364584</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">375000</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">20490297</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">1163775</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">66465</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2018-10-012019-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">328157</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2019-10-012020-06-30_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24875198</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2019-10-01to2020-06-30">&lt;p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_z3AXoOb8dNzg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
5 	&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82E_zQuSaGcTyW5k"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;a)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Leases
                                         &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended June 30, 2020, the Company incurred office lease expense of $&lt;span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense"&gt;58,554&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense"&gt;169,469&lt;/span&gt;, respectively
(2019: $&lt;span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20190401__20190630_pp0p0" title="Lease expense"&gt;49,546&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20181001__20190630_pp0p0" title="Lease expense"&gt;127,807&lt;/span&gt;, respectively).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Litigation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
                                         Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the status of the Company&#x2019;s outstanding share purchase warrants is presented below:&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zZWKgXFSWzT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B6_zn2zABSpv8jk" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Exercise
    Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_ziqb9BiyeLV3" style="width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font-size: 10pt"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3JnLXGCxB3l" style="width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3bxlKyoKPB3" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXh8ABBOisha" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z0sX98riAYsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font-size: 10pt"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zTGK6luJQFc1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/&gt;

&lt;p id="xdx_8A3_zA2ymSIfOUE3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
June 30, 2020, the Company had share purchase warrants outstanding as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zLDXHvnaDEi2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_z6nL5KtxiWed" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zxZCX8kPYXRb" style="width: 56%; text-align: right" title="Expiry Date"&gt;June 30, 2021&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zzBBoNDn6kaj" style="text-align: right; padding-bottom: 1pt"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p id="xdx_8A1_zraAxYp4CsLc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"/&gt;
















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#x2013;based
                                         Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2015
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 18, 2015, the Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) approved a 2015 Omnibus Incentive Plan (the
&#x201c;2015 Plan&#x201d;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
maximum number of our common shares reserved for issue under the plan is &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event
of a change of the Company&#x2019;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member" title="Description of grant option"&gt;The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#x2019;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"&gt;6,000,000 &lt;/span&gt;additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#x2019;s 2007 Stock Option
Plan (the &#x201c;2007 Plan&#x201d;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"&gt;The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#x2019;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;












&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A summary of the status of Company&#x2019;s outstanding stock purchase options is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zVxhk4ylQtie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;span id="xdx_8B1_zU7BoFNDLJTf" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average
    Exercise Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average
    Grant Date Fair Value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Aggregate intrinsic value
    ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 32%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zNpPtqZQ9cM9" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;8,462,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrgt4hrjcQb8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zojP64cEmKH8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;4,115,032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRrVn3O8MER" style="text-align: right" title="Options Granted"&gt;&lt;span style="font-size: 10pt"&gt;1,695,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUYkLwAkzy1h" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-size: 10pt"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zI05EiVc7nhk" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font-size: 10pt"&gt;2.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOq12yM1C5dj" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(68,332&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCDVrzUaXet4" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMp17Cuyenmk" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font-size: 10pt"&gt;(13,335&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQGq44vAnB" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zsY9J8uI8cq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;10,076,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zskENi1W2Ndj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyGaUEQJF8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font-size: 10pt"&gt;17,818,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVQgEmFvYhy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;7,284,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4p8P2cxHTc3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgVoSUSIbc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;12,366,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zFroywHDE9c5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#x2019;s stock for the options that were in-the-money at June 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and nine months ended June 30, 2020, the Company recognized stock-based compensation expense of $&lt;span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zLf59z9vH5cd" title="Stock-based compensation expense"&gt;1,251,129&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200630_zfrDE5KDVRvh" title="Stock-based compensation expense"&gt;4,216,306&lt;/span&gt;,
respectively (2019: $&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20190401__20190630_zX06LvO8MMj5" title="Stock-based compensation expense"&gt;1,234,204&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20181001__20190630_zkHo8rdFi9x5" title="Stock-based compensation expense"&gt;5,194,343&lt;/span&gt; respectively) in connection with the issuance and vesting 	of stock options and
warrants in exchange for services. These amounts have been included in general and 	administrative expenses and research and
development expenses on the Company&#x2019;s interim condensed consolidated statements of 	operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zbZwBCbJCER6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BD_zAFP6YFvHpw5" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Nine months ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;575,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;579,636&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,863,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,586,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;675,678&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;654,568&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,352,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,608,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,251,129&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,234,204&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;4,216,306&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;5,194,343&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

&lt;p id="xdx_8AD_zmmI9ahJzyV1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;An
amount of approximately $&lt;span id="xdx_90F_ecustom--RemainingAllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" title="Remaining stock based compensation"&gt;4,858,000&lt;/span&gt; in stock-based compensation is expected to be recorded over the remaining vesting period 	of
such options through fiscal 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5XfDOXZ76L9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20191001__20200630_zj8evM8GyvQ" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20181001__20190630_zLYDbvHNkIS2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B3_zUBTrSrAcebb" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_zMdHMs6CGSt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zTZvz2UAK5m3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_zLNt6k3EXijf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;97.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;105.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_uPure_zk0oLLbp6t8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A0_z7WTMrNZJ5Z6" style="margin-top: 0; margin-bottom: 0"/&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">58554</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">169469</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">49546</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">127807</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2019-10-01to2020-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zZWKgXFSWzT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;span id="xdx_8B6_zn2zABSpv8jk" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average Exercise
    Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 35%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_ziqb9BiyeLV3" style="width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font-size: 10pt"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3JnLXGCxB3l" style="width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3bxlKyoKPB3" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXh8ABBOisha" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z0sX98riAYsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font-size: 10pt"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zTGK6luJQFc1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/&gt;

</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2019-10-012020-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2019-10-012020-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2019-10-01to2020-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zLDXHvnaDEi2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_z6nL5KtxiWed" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;Expiry Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"&gt;&lt;span style="font-size: 10pt"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zxZCX8kPYXRb" style="width: 56%; text-align: right" title="Expiry Date"&gt;June 30, 2021&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font-size: 10pt"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zzBBoNDn6kaj" style="text-align: right; padding-bottom: 1pt"&gt;May 6, 2024&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: left" title="Number"&gt;&lt;span style="font-size: 10pt"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-06-30_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-06-30_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-06-30" decimals="INF" unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member">The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#x2019;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2019Member">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#x2019;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2019-10-01to2020-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zVxhk4ylQtie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: left"&gt;&lt;span id="xdx_8B1_zU7BoFNDLJTf" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average
    Exercise Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Weighted Average
    Grant Date Fair Value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Aggregate intrinsic value
    ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 32%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zNpPtqZQ9cM9" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;8,462,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrgt4hrjcQb8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 13%; padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zojP64cEmKH8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font-size: 10pt"&gt;4,115,032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRrVn3O8MER" style="text-align: right" title="Options Granted"&gt;&lt;span style="font-size: 10pt"&gt;1,695,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUYkLwAkzy1h" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font-size: 10pt"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zI05EiVc7nhk" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font-size: 10pt"&gt;2.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOq12yM1C5dj" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;(68,332&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCDVrzUaXet4" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font-size: 10pt"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMp17Cuyenmk" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"&gt;&lt;span style="font-size: 10pt"&gt;(13,335&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQGq44vAnB" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font-size: 10pt"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zsY9J8uI8cq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;10,076,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zskENi1W2Ndj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyGaUEQJF8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font-size: 10pt"&gt;17,818,714&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
                                         June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVQgEmFvYhy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font-size: 10pt"&gt;7,284,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4p8P2cxHTc3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;3.67&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgVoSUSIbc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"&gt;&lt;span style="font-size: 10pt"&gt;12,366,473&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">68332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">13335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">17818714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">7284183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-06-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">12366473</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">1234204</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">5194343</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2019-10-01to2020-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zbZwBCbJCER6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8BD_zAFP6YFvHpw5" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Three months ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Nine months ended June 30,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;575,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;579,636&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,863,869&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,586,223&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;675,678&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;654,568&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,352,437&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;2,608,120&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;Total share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,251,129&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;1,234,204&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;4,216,306&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font-size: 10pt"&gt;5,194,343&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">575451</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-04-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">579636</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1863869</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2586223</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">675678</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-04-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">654568</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2352437</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">2608120</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1251129</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">1234204</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4216306</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-10-012019-06-30"
      decimals="0"
      unitRef="USD">5194343</us-gaap:AllocatedShareBasedCompensationExpense>
    <avxl:RemainingAllocatedShareBasedCompensationExpense
      contextRef="From2019-10-01to2020-06-30"
      decimals="0"
      unitRef="USD">4858000</avxl:RemainingAllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-10-01to2020-06-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5XfDOXZ76L9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20191001__20200630_zj8evM8GyvQ" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20181001__20190630_zLYDbvHNkIS2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B3_zUBTrSrAcebb" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_zMdHMs6CGSt9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest
    rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zTZvz2UAK5m3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.53&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.59&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_zLNt6k3EXijf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;97.80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;105.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_uPure_zk0oLLbp6t8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="Pure">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2018-10-012019-06-30"
      decimals="INF"
      unitRef="Pure">0.0291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-01to2020-06-30">P5Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-10-012019-06-30">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="Pure">0.9780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2018-10-012019-06-30"
      decimals="INF"
      unitRef="Pure">1.0596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-01to2020-06-30"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-10-012019-06-30"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175597485000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Aug. 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">51 West 52nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,190,619<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175597417176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,619,145<span></span>
</td>
<td class="nump">$ 22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">3,547,972<span></span>
</td>
<td class="nump">2,642,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">438,631<span></span>
</td>
<td class="nump">500,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="nump">24,508<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">31,630,256<span></span>
</td>
<td class="nump">25,329,373<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">31,630,256<span></span>
</td>
<td class="nump">25,329,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,980,204<span></span>
</td>
<td class="nump">3,523,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,968,994<span></span>
</td>
<td class="nump">1,516,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">6,949,198<span></span>
</td>
<td class="nump">5,039,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)</a></td>
<td class="nump">60,083<span></span>
</td>
<td class="nump">52,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">178,332,979<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(153,712,004)<span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">24,681,058<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">&#160;Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 31,630,256<span></span>
</td>
<td class="nump">$ 25,329,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175604933512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="nump">52,650,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175600980808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,381,477<span></span>
</td>
<td class="nump">$ 1,388,729<span></span>
</td>
<td class="nump">$ 4,453,654<span></span>
</td>
<td class="nump">$ 5,211,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,725,002<span></span>
</td>
<td class="nump">5,758,446<span></span>
</td>
<td class="nump">19,126,717<span></span>
</td>
<td class="nump">17,549,442<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(8,106,479)<span></span>
</td>
<td class="num">(7,147,175)<span></span>
</td>
<td class="num">(23,580,371)<span></span>
</td>
<td class="num">(22,760,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,944<span></span>
</td>
<td class="nump">149,888<span></span>
</td>
<td class="nump">223,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">1,319,913<span></span>
</td>
<td class="nump">552,335<span></span>
</td>
<td class="nump">2,980,456<span></span>
</td>
<td class="nump">1,727,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income, net</a></td>
<td class="nump">56,096<span></span>
</td>
<td class="nump">34,838<span></span>
</td>
<td class="nump">172,996<span></span>
</td>
<td class="nump">165,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="nump">248,665<span></span>
</td>
<td class="num">(54,546)<span></span>
</td>
<td class="num">(24,182)<span></span>
</td>
<td class="num">(4,854)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,624,674<span></span>
</td>
<td class="nump">644,549<span></span>
</td>
<td class="nump">3,279,158<span></span>
</td>
<td class="nump">2,148,233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(6,481,805)<span></span>
</td>
<td class="num">(6,502,626)<span></span>
</td>
<td class="num">(20,301,213)<span></span>
</td>
<td class="num">(20,612,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(4,817)<span></span>
</td>
<td class="num">(19,300)<span></span>
</td>
<td class="num">(14,031)<span></span>
</td>
<td class="num">(76,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (6,486,622)<span></span>
</td>
<td class="num">$ (6,521,926)<span></span>
</td>
<td class="num">$ (20,315,244)<span></span>
</td>
<td class="num">$ (20,688,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">59,105,399<span></span>
</td>
<td class="nump">49,622,465<span></span>
</td>
<td class="nump">57,401,387<span></span>
</td>
<td class="nump">47,691,921<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603120424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,315,244)<span></span>
</td>
<td class="num">$ (20,688,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,216,306<span></span>
</td>
<td class="nump">5,194,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(905,227)<span></span>
</td>
<td class="num">(1,780,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">62,367<span></span>
</td>
<td class="nump">829,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">456,872<span></span>
</td>
<td class="nump">267,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">1,452,652<span></span>
</td>
<td class="nump">184,920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,032,274)<span></span>
</td>
<td class="num">(15,992,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">20,490,297<span></span>
</td>
<td class="nump">14,361,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred financing charges</a></td>
<td class="num">(24,508)<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,465,789<span></span>
</td>
<td class="nump">14,311,379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (decrease) in cash and cash equivalents during the period</a></td>
<td class="nump">5,433,515<span></span>
</td>
<td class="num">(1,681,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">22,185,630<span></span>
</td>
<td class="nump">22,930,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 27,619,145<span></span>
</td>
<td class="nump">$ 21,249,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175595549032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Common Shares To Be Issued [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2018</a></td>
<td class="nump">$ 45,935<span></span>
</td>
<td class="nump">$ 129,377,542<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (107,101,781)<span></span>
</td>
<td class="nump">$ 22,321,696<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2018</a></td>
<td class="nump">45,933,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">23,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="nump">13,192,755<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,197,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">4,848,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">1,163,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,163,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="num">(324)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">328,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants', window );">Shares issued pursuant to cashless exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares', window );">Shares issued pursuant to cashless exercise of warrants (in shares)</a></td>
<td class="nump">546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,194,343<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,194,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,688,561)<span></span>
</td>
<td class="num">(20,688,561)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 51,511<span></span>
</td>
<td class="nump">148,927,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(127,790,342)<span></span>
</td>
<td class="nump">21,188,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Jun. 30, 2019</a></td>
<td class="nump">51,509,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 48,175<span></span>
</td>
<td class="nump">138,696,975<span></span>
</td>
<td class="num">(292,700)<span></span>
</td>
<td class="num">(121,268,416)<span></span>
</td>
<td class="nump">17,184,034<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Mar. 31, 2019</a></td>
<td class="nump">48,173,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">14,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueAcquisitions2', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 2,619<span></span>
</td>
<td class="nump">7,833,451<span></span>
</td>
<td class="nump">292,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,128,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2', window );">Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">2,619,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">1,163,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,163,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="num">(328)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">328,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,234,204<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,234,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,521,926)<span></span>
</td>
<td class="num">(6,521,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 51,511<span></span>
</td>
<td class="nump">148,927,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(127,790,342)<span></span>
</td>
<td class="nump">21,188,857<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Jun. 30, 2019</a></td>
<td class="nump">51,509,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">153,633,807<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(133,396,760)<span></span>
</td>
<td class="nump">20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 7,365<span></span>
</td>
<td class="nump">20,482,932<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,490,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">7,364,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">66,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,315,244)<span></span>
</td>
<td class="num">(20,315,244)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 60,083<span></span>
</td>
<td class="nump">178,332,979<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(153,712,004)<span></span>
</td>
<td class="nump">24,681,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Jun. 30, 2020</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 58,666<span></span>
</td>
<td class="nump">171,958,462<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(147,225,382)<span></span>
</td>
<td class="nump">24,791,746<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Beginning (in shares) at Mar. 31, 2020</a></td>
<td class="nump">58,664,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">5,123,405<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,124,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1', window );">Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)</a></td>
<td class="nump">16,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions', window );">Shares issued pursuant to cashless exercise of options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares', window );">Shares issued pursuant to cashless exercise of options (in shares)</a></td>
<td class="nump">721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,251,129<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,251,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,486,622)<span></span>
</td>
<td class="num">(6,486,622)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 60,083<span></span>
</td>
<td class="nump">$ 178,332,979<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (153,712,004)<span></span>
</td>
<td class="nump">$ 24,681,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance Ending (in shares) at Jun. 30, 2020</a></td>
<td class="nump">60,082,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueAcquisitions2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueAcquisitions2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603841224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zQlXHVUG8wTg" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Note
1 	<span style="text-decoration: underline"><span id="xdx_825_zIzBfC2Q1yPc">Business Description and Basis of Presentation</span></span></b></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged in the development of differentiated
therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. Anavex
analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic
benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The Company&#8217;s lead compound ANAVEX&#174;2-73
is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and potentially other central nervous system
diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in
the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2019 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2019 filed with the SEC on December 16, 2019. The Company follows the same accounting policies
in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Operating
results for the nine months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year
ending September 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least the next two years after the date that these interim condensed consolidated
financial statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials
is uncertain.&#160;The assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to
change.&#160;The actual amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but
not limited to the design, timing and duration of future clinical trials, the progress of the Company&#8217;s research and development
programs and the level of financial resources available. The Company has the ability to adjust its operating plan spending levels
based on the timing of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the Sales Agreement and the 2019 Purchase Agreement (each as defined below), there can be no assurance
that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable
terms. If we are not able to obtain the additional financing on a timely basis, if and when it is needed, we will be forced to
delay or scale down some or all of our research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. Given the daily evolution of the COVID-19 situation, and the global responses to
curb its spread, the Company is not able to estimate the effects of COVID-19 on its results of operations or financial condition
for the year ending September 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 12pt 42.6pt; text-align: justify; text-indent: -0.05pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2020, the President of the United States signed into law the &#8220;Coronavirus Aid, Relief, and Economic Security (CARES)
Act.&#8221; The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer
side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to
the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections
to tax depreciation methods for qualified improvement property. The enactment of the CARES Act did not have any material impact
on the Company&#8217;s interim condensed consolidated financial statements.</span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="text-align: justify; margin-right: 0; margin-left: 42.55pt"/>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Adjustment
of Prior Period Financial Statements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">As
previously disclosed in Note 1 to the Company&#8217;s consolidated financial statements included in the Company&#8217;s annual
report on Form 10-K for the year ended September 30, 2019, the Company adjusted amounts to previously reported consolidated financial
statements which were immaterial. These adjustments
were identified in connection with the preparation of the consolidated financial statements for the year ended September 30, 2019
and related to the timing of recognition of research and development incentive income. Previously the Company accounted for research
and development incentive income when received in cash. During the year ended September 30, 2019, based on a continuing assessment
regarding the Company&#8217;s eligibility for the incentive programs under which it was receiving such income, the Company determined
that the income should have been accrued and recorded in the period in which the qualifying research and development expenditures
were incurred.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
interim condensed consolidated financial statements for the three and nine months ended June 30, 2020 have been similarly adjusted
to reflect the adjusted research and development incentive income for the three and nine months accordingly in the amount of $<span id="xdx_900_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20190401__20190630_pp0p0" title="Research and development incentive income">552,335</span>
and $<span id="xdx_904_ecustom--ResearchAndDevelopmentsIncentiveIncome_c20181001__20190630_pp0p0" title="Research and development incentive income">1,477,007</span>, respectively and should be read in conjunction with Note 1 to the Company&#8217;s consolidated financial statements
for the year ended September 30, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">Principles of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; text-align: justify; margin-right: 0; margin-left: 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited, a company incorporated under the laws of Australia, Anavex Germany GmbH, a company incorporated under the
laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province of Ontario, Canada. All inter-company
transactions and balances have been eliminated.</span></p>










<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - 	quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active 		markets, quoted prices
for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - 	assets and liabilities whose significant value drivers are unobservable by little or no market activity and that are significant
to the fair value of the assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.55pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2020 and September 30, 2019, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common
shares outstanding during the period. Diluted loss per common share is computed similar to basic loss per common share except
that the denominator is increased to include the weighted average number of all potentially dilutive securities convertible into
shares of common stock that were outstanding during the period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2020, loss per share excludes <span id="xdx_905_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20191001__20200630_pii" title="Loss per share for potentially dilutive common shares">10,576,266</span> (September 30, 2019 &#8211; <span id="xdx_900_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_c20181001__20190930_pii" title="Loss per share for potentially dilutive common shares">8,812,933</span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>








<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175683955704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Accounting Standards Update and Change in Accounting Principle [Text Block]</a></td>
<td class="text"><p id="xdx_808_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zqagfZL73Wy6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
2	<span style="text-decoration: underline"><span id="xdx_82E_z85hjqJ0aMAj">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znN3K39uB8bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>












<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603727336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income Disclosure [TextBlock]</a></td>
<td class="text"><p id="xdx_809_ecustom--OtherIncomeDisclosureTextBlock_zeLtjRD503Ad" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
3	<span style="text-decoration: underline"><span id="xdx_825_zxassuBqGV39">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
Income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_900_ecustom--NonOperatingIncomeFromGrant_c20161001__20170930__srt--ProductOrServiceAxis__custom--ClinicalStudyGrantMember_pp0p0" title="Grant income">597,886</span>. The grant was received in
equal quarterly installments over a period of two years commencing during the year ended September 30, 2018 in exchange for a
commitment to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. During the three and nine months ended June 30, 2020, the Company recognized $<span id="xdx_90A_ecustom--NonOperatingIncomeFromGrant_c20200401__20200630_pp0p0" title="Grant income">0</span> and $<span title="Grant income"><span id="xdx_905_ecustom--NonOperatingIncomeFromGrant_c20191001__20200630_zzQ6UnSjeSfa">149,888</span></span>, respectively (2019: $<span title="Grant income"><span id="xdx_903_ecustom--NonOperatingIncomeFromGrant_c20190401__20190630_zehAlWHgYVT8">74,944</span></span>
and $<span id="xdx_909_ecustom--NonOperatingIncomeFromGrant_c20181001__20190630_pp0p0" title="Grant income">223,999</span>, respectively) of this grant on its statement of operations within grant income. As at June 30, 2020, the Company
had recognized the full amount of grant funding.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is eligible to obtain certain research and development tax credits, including the New York City Biotechnology Tax Credit
(&#8220;NYC Biotech credit&#8221;), and the Australian research and development tax incentive credit (the &#8220;Australia R&amp;D
credit&#8221;) through a program administered through the Australian Tax Office (the &#8220;ATO&#8221;), which provides for a
cash refund based on a percentage of certain research and development activities undertaken in Australia by the Company&#8217;s
wholly owned subsidiary, Anavex Australia Pty Ltd. (&#8220;Anavex Australia&#8221;).&#160;Research and development incentive income
during the three and nine months ended June 30, 2020 and 2019 represents the receipt by the Company&#8217;s Australian subsidiary,
of the Australian research and development incentive credit, (the &#8220;ATO R&amp;D Credit&#8221;), as well as receipt by the
Company of the New York City Biotechnology Credit (&#8220;NYC Biotech credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company recorded research and development incentive income of $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630_zIgqvw7r8Uwc" title="Research and development incentive income">1,319,913</span> (AUD
<span id="xdx_904_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20200401__20200630__srt--CurrencyAxis__currency--AUD_zRFY0EmyPBc3" title="Research and development incentive income">1,923,000</span>) and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20200630_pp0p0" title="Research and development incentive income">2,980,456</span> (AUD <span id="xdx_903_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">4,471,000</span>), respectively (2019: $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20190401__20190630_pp0p0" title="Research and development incentive income">552,335</span> and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20181001__20190630_pp0p0" title="Research and development incentive income">1,727,007</span>, respectively) in respect of the ATO R&amp;D
Credit for eligible research and development expenses incurred during the period (2019: In respect of the ATO R&amp;D Credit for
eligible research and development expenses incurred during the period and the NYC Biotech credit).</span></p>








<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175598804008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingAgreementsAbstract', window );"><strong>Equity Offering Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements [TextBlock]</a></td>
<td class="text"><p id="xdx_80C_ecustom--EquityOfferingAgreementsTextBlock_zfIUaaCpRYtc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
4	<span style="text-decoration: underline"><span id="xdx_824_z5LW55hRLcJ2">Equity Offering Agreements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into an Amended and Restated&#160;Sales Agreement dated May 1, 2020 (the &#8220;Sales Agreement&#8221;) with
Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;), pursuant to which the Company
may offer and sell shares of common stock, for aggregate gross sale proceeds of up to $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20200429__20200501__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pp0p0" title="Gross sale proceeds">50,000,000</span> from time to time through the
Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zVfgMLXdiCy3" title="Percentage of gross proceeds from sales">3.0</span>% of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. As of June 30, 2020, no shares had been sold pursuant to the Offering.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 21, 2015, the Company entered into a $<span id="xdx_90C_ecustom--ValueOfSharesObligatedToPurchase_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase">50,000,000</span> purchase agreement (the &#8220;2015 Purchase Agreement&#8221;) with Lincoln
Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;), pursuant to which the Company could sell and issue to Lincoln Park, and Lincoln
Park was obligated to purchase, up to $<span title="Total number of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time over a <span id="xdx_905_ecustom--AgreementTerm_dtM_c20151019__20151021__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7MmdbFAlQ6f" title="Agreement term">36</span>-month period.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended June 30, 2019, the Company issued an aggregate of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued">4,872,696</span> shares of common stock under the 2015 Purchase
Agreement, including <span id="xdx_900_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price">4,848,995</span> shares of common stock for an aggregate purchase price of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">13,197,604</span> and <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment">23,701</span> commitment shares.
At June 30, 2020 and September 30, 2019, all remaining purchase amounts available for issuance under the 2015 Purchase Agreement
had been utilized and the 2015 Purchase Agreement has expired pursuant to its terms. As such, no further shares will be sold under
the 2015 Purchase Agreement.</span></p>














<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Total number of shares obligated to purchase">50,000,000</span> purchase agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln
Park, as amended on July 1, 2020 (the &#8220;Amendment Date&#8221;), pursuant to which the Company may sell and issue to Lincoln
Park, and Lincoln Park is obligated to purchase, up to $<span title="Total number of shares obligated to purchase">50,000,000</span> in value of its shares of common stock from time to time from
June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019 Purchase Agreement
was filed with the SEC, until July 1, 2022, which is the first day of the next month following the <span id="xdx_907_ecustom--AgreementTerm_dtMp_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zBxgIhrXnQY1" title="Agreement term">36</span>-month anniversary of June
12, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--UnrecordedUnconditionalPurchaseObligationDescription_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember" title="Description of purchases price">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s sale of shares of Common Stock to Lincoln Park subsequent to the Amendment Date is limited to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pii" title="Number of share issued">12,016,457</span> shares
of Common Stock, representing <span id="xdx_903_ecustom--PercentageOfGrossProceedsFromSales_pii_dp_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXmKUzpOCcwh" title="Percentage of gross proceeds from sales">19.99</span>% of the shares of the Common Stock outstanding on the Amendment Date unless (i) shareholder
approval is obtained to issue more than such amount or (ii) the average price of all applicable sales of Common Stock to Lincoln
Park under the 2019 Purchase Agreement after the Amendment Date equals or exceeds the lower of (A) the closing price of the Common
Stock on the Nasdaq Capital Market immediately preceding the Amendment Date or (B) the average of the closing prices of the Common
Stock on the Nasdaq Capital Market for the five Business Days immediately preceding the Amendment Date, and it also limits the
Company&#8217;s sale of shares to Lincoln Park to the extent it would cause Lincoln Park to beneficially own more than 4.99% of
the Company&#8217;s outstanding shares of Common Stock at any given time.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued">324,383</span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchases at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 12pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the nine months ended June 30, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued">7,431,049</span> (2019: <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z0O1oNJCqhY9" title="Number of share issued">703,157</span>) shares of common
stock under the 2019 Purchase Agreement, including <span id="xdx_908_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price">7,364,584</span> (2019: <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues4_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for aggregate purchase price">375,000</span>) shares of common stock for an aggregate purchase
price of $<span id="xdx_90C_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">20,490,297</span> (2019: $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">1,163,775</span>) and <span id="xdx_906_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment">66,465</span> (2019: <span id="xdx_90E_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20181001__20190630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment">328,157</span>) commitment shares. At June 30, 2020, an amount of $<span id="xdx_90D_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20191001__20200630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available">24,875,198</span>
remained available under the 2019 Purchase Agreement, as amended.</span></p>












<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603062312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
<td class="text"><p id="xdx_807_eus-gaap--CommitmentsDisclosureTextBlock_z3AXoOb8dNzg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5 	<span style="text-decoration: underline"><span id="xdx_82E_zQuSaGcTyW5k">Commitments and Contingencies</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>a)</i></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Leases
                                         </span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company incurred office lease expense of $<span id="xdx_906_eus-gaap--LeaseAndRentalExpense_c20200401__20200630_pp0p0" title="Lease expense">58,554</span> and $<span id="xdx_90B_eus-gaap--LeaseAndRentalExpense_c20191001__20200630_pp0p0" title="Lease expense">169,469</span>, respectively
(2019: $<span id="xdx_907_eus-gaap--LeaseAndRentalExpense_c20190401__20190630_pp0p0" title="Lease expense">49,546</span> and $<span id="xdx_903_eus-gaap--LeaseAndRentalExpense_c20181001__20190630_pp0p0" title="Lease expense">127,807</span>, respectively).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 60.75pt; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span><span style="font-size: 10pt"><br/></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zZWKgXFSWzT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B6_zn2zABSpv8jk" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 35%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_ziqb9BiyeLV3" style="width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font-size: 10pt">350,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3JnLXGCxB3l" style="width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font-size: 10pt">4.19</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3bxlKyoKPB3" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"><span style="font-size: 10pt">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXh8ABBOisha" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-size: 10pt">3.17</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z0sX98riAYsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font-size: 10pt">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zTGK6luJQFc1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font-size: 10pt">3.88</span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/>

<p id="xdx_8A3_zA2ymSIfOUE3" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2020, the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"/>

<table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zLDXHvnaDEi2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_z6nL5KtxiWed" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Number</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Exercise Price</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: left" title="Number"><span style="font-size: 10pt">350,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"><span style="font-size: 10pt">4.19</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zxZCX8kPYXRb" style="width: 56%; text-align: right" title="Expiry Date">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: left" title="Number"><span style="font-size: 10pt">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font-size: 10pt">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zzBBoNDn6kaj" style="text-align: right; padding-bottom: 1pt">May 6, 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: left" title="Number"><span style="font-size: 10pt">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p id="xdx_8A1_zraAxYp4CsLc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 6pt 58.5pt; text-align: justify; text-indent: -0.8pt"/>
















<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 66pt; text-align: justify; text-indent: -1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors (the &#8220;Board&#8221;) approved a 2015 Omnibus Incentive Plan (the
&#8220;2015 Plan&#8221;), which provides for the grant of stock options and restricted stock awards to directors, officers, employees
and consultants of the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan is <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. As a result of the adoption of the 2015 Plan, no further option awards were
granted under any previously existing stock option plan. Stock option awards previously granted under the previously existing
stock option plans remain outstanding in accordance with their terms.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2015 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member" title="Description of grant option">The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.</span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance">6,000,000 </span>additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 67.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.</span></span></p>












<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>





<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zVxhk4ylQtie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span id="xdx_8B1_zU7BoFNDLJTf" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Grant Date Fair Value ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate intrinsic value
    ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 32%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         September 30, 2019</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zNpPtqZQ9cM9" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Options Outstanding at beginning"><span style="font-size: 10pt">8,462,933</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrgt4hrjcQb8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font-size: 10pt">3.58</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 13%; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zojP64cEmKH8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font-size: 10pt">4,115,032</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRrVn3O8MER" style="text-align: right" title="Options Granted"><span style="font-size: 10pt">1,695,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUYkLwAkzy1h" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-size: 10pt">2.96</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zI05EiVc7nhk" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font-size: 10pt">2.27</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOq12yM1C5dj" style="text-align: right" title="Options Forfeited"><span style="font-size: 10pt">(68,332</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCDVrzUaXet4" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-size: 10pt">3.01</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMp17Cuyenmk" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font-size: 10pt">(13,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQGq44vAnB" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font-size: 10pt">3.15</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zsY9J8uI8cq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font-size: 10pt">10,076,266</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zskENi1W2Ndj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font-size: 10pt">3.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyGaUEQJF8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font-size: 10pt">17,818,714</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVQgEmFvYhy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-size: 10pt">7,284,183</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4p8P2cxHTc3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font-size: 10pt">3.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgVoSUSIbc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font-size: 10pt">12,366,473</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_8A8_zFroywHDE9c5" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at June 30, 2020.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and nine months ended June 30, 2020, the Company recognized stock-based compensation expense of $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20200401__20200630_zLf59z9vH5cd" title="Stock-based compensation expense">1,251,129</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20191001__20200630_zfrDE5KDVRvh" title="Stock-based compensation expense">4,216,306</span>,
respectively (2019: $<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20190401__20190630_zX06LvO8MMj5" title="Stock-based compensation expense">1,234,204</span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20181001__20190630_zkHo8rdFi9x5" title="Stock-based compensation expense">5,194,343</span> respectively) in connection with the issuance and vesting 	of stock options and
warrants in exchange for services. These amounts have been included in general and 	administrative expenses and research and
development expenses on the Company&#8217;s interim condensed consolidated statements of 	operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zbZwBCbJCER6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zAFP6YFvHpw5" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Three months ended June 30,</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Nine months ended June 30,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">General and administrative</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">575,451</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">579,636</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,863,869</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,586,223</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">675,678</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">654,568</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,352,437</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,608,120</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,251,129</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,234,204</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">4,216,306</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">5,194,343</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<p id="xdx_8AD_zmmI9ahJzyV1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_90F_ecustom--RemainingAllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" title="Remaining stock based compensation">4,858,000</span> in stock-based compensation is expected to be recorded over the remaining vesting period 	of
such options through fiscal 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black Scholes option pricing model based on the following
weighted average assumptions:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify; text-indent: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5XfDOXZ76L9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20191001__20200630_zj8evM8GyvQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20181001__20190630_zLYDbvHNkIS2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zUBTrSrAcebb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_zMdHMs6CGSt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1.57</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2.91</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_407_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zTZvz2UAK5m3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5.53</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5.59</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_zLNt6k3EXijf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97.80</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">105.96</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_uPure_zk0oLLbp6t8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p id="xdx_8A0_z7WTMrNZJ5Z6" style="margin-top: 0; margin-bottom: 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603078200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_znN3K39uB8bg" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Recently
Adopted Accounting Pronouncements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, Topic 842, Leases was issued to replace the leases requirements in Topic 840, Leases. The main difference
between previous U.S. GAAP and Topic 842 is the recognition of lease assets and lease liabilities by lessees for those leases
classified as operating leases under previous U.S. GAAP. A lessee should recognize in the balance sheet a liability to make
lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the
lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class
of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize
lease expense for such leases generally on a straight-line basis over the lease term. The accounting applied by a lessor is
largely unchanged from that applied under previous U.S. GAAP. The Company elected to the package of practical expedients
permitted under the transition guidance that allowed, among other things, the historical lease classifications to be carried
forward without reassessment. Further, the Company elected to not recognize lease assets and lease liabilities for leases
with a term of 12 months or less. The adoption of this standard on October 1, 2019 did not have any impact on the Company's
results of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2018, the FASB issued ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based
Payment Accounting, which simplifies the accounting for share-based payments to nonemployees for goods and services by aligning
it with the accounting for share-based payments to employees, with certain exceptions. The new guidance was effective for the
Company beginning on October 1, 2019 and was required to be applied retrospectively with the cumulative effect recognized at the
date of initial application. The adoption of this standard on October 1, 2019 did not have any impact on the Company's results
of operations, financial condition, cash flows, and financial statement disclosures.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes (ASC 740)", which is intended
to simplify various aspects related to accounting for income taxes by removing certain exceptions to the general principles in
Topic 740 and clarifying and amending existing guidance to improve consistent application. ASU 2019-12 is effective for the Company
on October 1, 2021. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on its consolidated
financial statements but does not expect such guidance to have a material impact.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>












<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603607272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zZWKgXFSWzT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span style="font-size: 10pt"><b>&#160;<span id="xdx_8B6_zn2zABSpv8jk" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average Exercise
    Price ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 35%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_ziqb9BiyeLV3" style="width: 20%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font-size: 10pt">350,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3JnLXGCxB3l" style="width: 20%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font-size: 10pt">4.19</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z3bxlKyoKPB3" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"><span style="font-size: 10pt">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zXh8ABBOisha" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-size: 10pt">3.17</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z0sX98riAYsd" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font-size: 10pt">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zTGK6luJQFc1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font-size: 10pt">3.88</span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_zLDXHvnaDEi2" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_z6nL5KtxiWed" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Number</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Exercise Price</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt">Expiry Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: left" title="Number"><span style="font-size: 10pt">350,000</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 12%; text-align: right" title="Exercise Price"><span style="font-size: 10pt">4.19</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 8%"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zxZCX8kPYXRb" style="width: 56%; text-align: right" title="Expiry Date">June 30, 2021</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: left" title="Number"><span style="font-size: 10pt">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font-size: 10pt">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20200630__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zzBBoNDn6kaj" style="text-align: right; padding-bottom: 1pt">May 6, 2024</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20200630_pii" style="border-bottom: Black 2.5pt double; text-align: left" title="Number"><span style="font-size: 10pt">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zVxhk4ylQtie" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 2)">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: left"><span id="xdx_8B1_zU7BoFNDLJTf" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Number of Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Weighted Average
    Grant Date Fair Value ($)</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>Aggregate intrinsic value
    ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; width: 32%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         September 30, 2019</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zNpPtqZQ9cM9" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Options Outstanding at beginning"><span style="font-size: 10pt">8,462,933</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zrgt4hrjcQb8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font-size: 10pt">3.58</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 13%; padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 5%; padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20190930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zojP64cEmKH8" style="border-bottom: Black 1pt solid; width: 13%; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font-size: 10pt">4,115,032</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRrVn3O8MER" style="text-align: right" title="Options Granted"><span style="font-size: 10pt">1,695,000</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zUYkLwAkzy1h" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font-size: 10pt">2.96</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zI05EiVc7nhk" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font-size: 10pt">2.27</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zOq12yM1C5dj" style="text-align: right" title="Options Forfeited"><span style="font-size: 10pt">(68,332</span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zCDVrzUaXet4" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font-size: 10pt">3.01</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zMp17Cuyenmk" style="border-bottom: Black 1pt solid; text-align: right" title="Options Exercised"><span style="font-size: 10pt">(13,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pii_c20191001__20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zeQGq44vAnB" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font-size: 10pt">3.15</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zsY9J8uI8cq3" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable at ending"><span style="font-size: 10pt">10,076,266</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zskENi1W2Ndj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font-size: 10pt">3.48</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zyGaUEQJF8Ha" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font-size: 10pt">17,818,714</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
                                         June 30, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zVQgEmFvYhy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font-size: 10pt">7,284,183</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z4p8P2cxHTc3" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Exercisable at ending"><span style="font-size: 10pt">3.67</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: right"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20200630__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zkgVoSUSIbc5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable at ending"><span style="font-size: 10pt">12,366,473</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zbZwBCbJCER6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63.8pt; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - Commitments and Contingencies (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8BD_zAFP6YFvHpw5" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Three months ended June 30,</b></span></td><td><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="7" style="text-align: center"><span style="font-size: 10pt"><b>Nine months ended June 30,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 10pt"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left"><span style="font-size: 10pt">General and administrative</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">575,451</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">579,636</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,863,869</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,586,223</span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Research and development</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">675,678</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">654,568</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,352,437</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">2,608,120</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,251,129</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20190401__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">1,234,204</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_985_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">4,216,306</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AllocatedShareBasedCompensationExpense_c20181001__20190630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font-size: 10pt">5,194,343</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&#160;</span></td></tr>
</table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z5XfDOXZ76L9" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Commitments and Contingencies (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_490_20191001__20200630_zj8evM8GyvQ" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_499_20181001__20190630_zLYDbvHNkIS2" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zUBTrSrAcebb" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td><td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_zMdHMs6CGSt9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest
    rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1.57</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 8%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2.91</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_407_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_zTZvz2UAK5m3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5.53</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5.59</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_zLNt6k3EXijf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">97.80</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">105.96</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_uPure_zk0oLLbp6t8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">0.00</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603874808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentsIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">$ 552,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,477,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,576,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,812,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentsIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentsIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175681215272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74,944<span></span>
</td>
<td class="nump">$ 149,888<span></span>
</td>
<td class="nump">$ 223,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,319,913<span></span>
</td>
<td class="nump">$ 552,335<span></span>
</td>
<td class="nump">$ 2,980,456<span></span>
</td>
<td class="nump">1,727,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,923,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,471,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember', window );">Clinical Study Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems', window );"><strong>SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=avxl_ClinicalStudyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175600152040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Oct. 21, 2015</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,490,297<span></span>
</td>
<td class="nump">$ 14,361,379<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp;amp;amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember', window );">2015 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,872,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,848,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,197,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_AgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,431,049<span></span>
</td>
<td class="nump">703,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,364,584<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,490,297<span></span>
</td>
<td class="nump">$ 1,163,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,465<span></span>
</td>
<td class="nump">328,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription', window );">Description of purchases price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company may direct Lincoln Park, at its sole discretion, and subject to certain conditions, to purchase up to 200,000 shares of
common stock on any business day (a &#8220;Regular Purchase&#8221;). The amount of a Regular Purchase may be increased under certain
circumstances up to 250,000 shares, provided that Lincoln Park&#8217;s committed obligation for Regular Purchases on any business
day shall not exceed $2,000,000. In the event we purchase the full amount allowed for a Regular Purchase on any given business
day, we may also direct Lincoln Park to purchase additional amounts as accelerated and additional accelerated purchases. The purchase
price of shares of common stock related to the future funding will be based on the then prevailing market prices of such shares
at the time of sales as described in the 2019 Purchase Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,875,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,016,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Terms of the agreement under agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603973016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Purchase Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning | shares</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted | shares</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price Granted | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending | shares</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending | $ / shares</a></td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175597711592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175597388760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 2) - 2015 Omnibus Incentive Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning | shares</a></td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning | $</a></td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted | shares</a></td>
<td class="nump">1,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited | shares</a></td>
<td class="num">(68,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised | shares</a></td>
<td class="num">(13,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Exercisable at ending | shares</a></td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending | $</a></td>
<td class="nump">$ 17,818,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable | shares</a></td>
<td class="nump">7,284,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable at ending</a></td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable at ending | $</a></td>
<td class="nump">$ 12,366,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175682709608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 1,251,129<span></span>
</td>
<td class="nump">$ 1,234,204<span></span>
</td>
<td class="nump">$ 4,216,306<span></span>
</td>
<td class="nump">$ 5,194,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">575,451<span></span>
</td>
<td class="nump">579,636<span></span>
</td>
<td class="nump">1,863,869<span></span>
</td>
<td class="nump">2,586,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 675,678<span></span>
</td>
<td class="nump">$ 654,568<span></span>
</td>
<td class="nump">$ 2,352,437<span></span>
</td>
<td class="nump">$ 2,608,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175603969368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details 4)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">97.80%<span></span>
</td>
<td class="nump">105.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140175600113416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 58,554<span></span>
</td>
<td class="nump">$ 49,546<span></span>
</td>
<td class="nump">$ 169,469<span></span>
</td>
<td class="nump">$ 127,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,251,129<span></span>
</td>
<td class="nump">$ 1,234,204<span></span>
</td>
<td class="nump">4,216,306<span></span>
</td>
<td class="nump">$ 5,194,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_RemainingAllocatedShareBasedCompensationExpense', window );">Remaining stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,858,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
exercise price will be determined by the Board at the time of grant shall be at least equal to the fair market value on such date.
If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair market value
of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2015 Plan for an exercise
period of up to ten years from the date of grant of the option or such lesser periods as may be determined by the Board, subject
to earlier termination in accordance with the terms of the 2015 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market value
on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than 110% of fair
market value of the Company&#8217;s shares of common stock on the grant date. Stock options may be granted under the 2019 Plan
for an exercise period of up to ten years from the date of grant of the option or such lesser periods as may be determined by
the Board, subject to earlier termination in accordance with the terms of the 2019 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_RemainingAllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a remaining stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_RemainingAllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIXTL?AK#<B[?IM$-+CN@5I+ABCB951J\U<C@=9,+O068^TI4>VB-CNUY'"1
MP,_%,+K2XZU&'N]&+ S)59K [:1R'&MT:M;!5NGQ5B./GT1<KO27]044H!F
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M3^,Z$/XK5G4>0-K2V+FC4JFTH.UJN8C"V6<W<5N?3>QN[%#X]V><E+2;&_!
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M=#8N>&ULQ9QM<]K*%<>_R@[MM,G,)6@?):4V,PZ"QNV-[1JGG4ZG+Q18VTP
M<25AI]^^*R LVB=+\B;WC<W#[MF_SCE>_<YA\=ESEG\M'CDOP;?5<EV<]Q[+
M<O-^,"AFCWR5%N^R#5^+=^ZS?)66XFG^,"@V.4_GNTFKY0 % 1NLTL6Z-SS;
MO7:3#\^R;;E<K/E-#HKM:I7F__O E]GS>0_VOK]PNWAX+*L7!L.S3?K I[S\
MO+G)Q;/!T<I\L>+K8I&M0<[OSWL7\/V$TFK";L0_%_RY.'D,JDOYDF5?JR>7
M\_->4"GB2SXK*Q.I^/7$1WRYK"P)';\=C/:.:U833Q]_MS[97;RXF"]IP4?9
M\E^+>?EXWHMZ8,[OT^VRO,V>/_+#!>T$SK)EL?L)G@]C@QZ8;8LR6QTF"P6K
MQ7K_._UV<,3)!(0L$]!A E(F8&:9@ \3<-,)Y#"!J))"RP1ZF$"5"1!;)K##
M!+;S_=Y9.T\G:9D.S_+L&>35:&&M>K +UVZV</!B7676M,S%NPLQKQQ>7MV-
M;R\_@='U53*^FHZ3ZM'T^M?+Y.)./)G>B5^?QE=WX'H"1A\OKOXZGH++*_'Z
M]>CO'Z]_3<:WTS^#\3\^7][]&[SYO$ZW\T7)YV]!'WR>)N#-']^>#4HALUIL
M,#M(^K"7A"R21MEJ)7)N6F:SK^ _G_CJ"\__:S S<INYF LI(GG3);A)%_/^
M8@U&Z691BN<.HTDS;8]IS@MPEX$/'%P6Q9;/74;';J.WO!1;@# Q3O/U8OU0
MN&Q-W+;N,G&!]6D#D1+'O$#'O$ [.\1BYP-_6*PK,>+O=IFN9_P7\)0NMQRD
M)9CRS3N @U\ "F!DBN_>--N9KK:VIR&A,:9G@Z?3\.FC((IQ&%*"ZB,3I]1J
M[WU?;-(9/^^)S;7@^1/O#8$I#/J*?1B$,(!A!.M+3O2A"&$$6<R. VM^Q4>_
M8K=?]]X$TK]O1&(6NWQZV\BY>_M4<2XF(3(K(T=EI+T;__0'R(*_[']6N;\H
MQ5VE/.@UJ2.ZWT(E[D2[@+XZ)ND@U1AQ3W8FK[=3BPD]QH0ZL^6PSRSV.\QV
M/>=YE1<4W&SSV:.XH8*+AYSS74SZ0 O0:6Z9@D6U2" <!M"<1^RHF;TNCX[:
M[5G$] TD(K&21TQ3#S&,44B5C2;IH->83)[L3,S"0Q80L^?#H^=#C]FBA.&E
M7 GU;2<B41Q3L^;HJ#GZX=D2:=F"0_5F$^D^APR3(%!RI8-:8ZYXLC,QZPY#
MB]OCH]OC+JD2>TF56-,LXA&<N+HF&08258.?<(<Z+%)+%T24=#D,JMVDM%%)
M%[W&;/%E:.+!4#TX)W4$])A1K6]5A]5K284B2$-+4DG.A6[0K>O>;/-BFPI5
M909F:?&XY$4!^#>>SQ;B"K)[\)SFN7C?G%D&HE7S"NEY!=6L\H6[O@Q-/!BJ
M1T?2,G3C<L?HO)A-.D138B%[* $:.C%P+W;7YYB#6;;:\'615A6H48$G,AU!
M':<IC DF6$TK7TSMR]"D@?1Z)"0V0S<W7_$2++/"_%?JG-K&\YX,);X,C:$.
M]'T4L"BB3*UO&PVM>U\6 -!)PL/Q>FYN'/QMNS[6MK$Q-CKX4TBAMHL:"%JP
M* J%?C7K?<&_8<T^1&$8!UCM5TP,8Q&$D7"N[78E$1^Z&?][_^#@8Z5Y\+*#
M=8P7#@[B*+1%78(\=#*MLV/T*<V%+NC0I3,\B:!&\=" PSAB,8O5H8EA:!^)
M%%&)?VP:"!%$+"*0J8$UK!_"B(@<L+A/ CET$_F+C:&7?:AS=^5#@:V6V"))
MWNAGD#?2R1NJX(T,X*T.2KJH-3<$?7&W!T/UT$CN1IVXVU>+".G<#4D06FHY
M=-)>[L",+>M^9&C2,JBVB9".W&&$,:$J=QL&&C>,+E=F3AI]P0BB*+1Z5V(S
M:H/-GCM!2(?GRNUB$[3(E@"-7MF";I(4>@=:[P8AG3S-[: N@LT[C2]HMDBW
M=H20A&;4J=GLIR>$=-YT-860A$WTRG9SLUN3#IX816K6&!!0&Y5TT6M.&5_]
M9@^&ZL&1M(HZ=:1]-8603K.NIA"2+(O<+-NFDG>;:E%/(@-<(E%<!!K^^&I2
M^S(T:2"]'@F)Q<B-Q:Y*WCVUC><]&4I\&1HCG>7[C"(8([4D:3*R_DFUI'[L
MI-97U/%8)WU3'8]UV+?5\6ZI+3QK6--:QQO&NNMX++$=N[']E74\UK'<7<=C
M2>;8S\D/LRX=R2D2Z:@&7B=?2#'#. K4DP!NM6T";VJ]8XQC%K) #;RA% A0
M%+,XMKCWY/R'QP,@9A\;FM?"QX'XH[>(DP".?SR 8QW 0\Q4 L<ZQHJ[181B
MK![^Z2+9G "^$-RL/0Y0;-L6)(/CWY'!L<[@(C*$1I:[-)80CG\&A&,=PO6\
M,3"X.BCIHM:<,KX0W(.A>F@D@N/?%<&QCN",$68I1K$D<-R P)M_\)=M*CPW
M9Y7>6M8XQ-0"5G/*%RM[,%3WJ61IW.;01U.?OI@!.H"&MCL1D>Q)W.S9I@)S
MFVI1!Q"=]PB"# <*=">^5AS[,C1I(+T>"4FJQ$VJK@K,/;6-YST92GP9&A.=
ML/LHP) BHM3CDT9#Z]Z7-$[<--ZD!D.!,38ZBK,@B)1C 2-B0/&J/RY@)E:S
MWA>*&];L"_X/(0K49L?$,!81%L& 1A;?2A0GS5#\Q1K,XF"=PRL'(Q3;=K^3
MH]CNDR0-/TNUZ-(!G$:,,37PAD9R"&-!@TQ%<+?:-H$WG/V&)$2(XD@MO@UC
M$0EC&-H.ZA!)V<1-V6T^:[7X6$?IRL<DMHJ3+$U^_/EIHI,TU#[<&!&=I6G5
MM@M4GNZBV!Q_7SQMEDZBP *>1/(R\<G++2LPHM-R%1?KQR!$\C)YY3GJ9M_>
M,+"RMF^88%D#)%\M:E^&)AX,U4,CL9OX/&O=N@(C.G]#QI"%/*@D<-J P+U4
M8-1P[D-)*FKJRBHYY=;;(J=\&9IX,%0/CH1RVN;4AZ]2CNH@:RWEJ$18VN"$
M=<-2SFVJ14%!#5B+*(1(A5I?*XY]&9HTD%Z/A 1>Z@9>5RGGGMK&\YX,);X,
MC:D.ZGU&!*XAE3F;C*S[7B(]=2-]]T*.ZCQO*N0,PVR%G%MJ&\_J:UH+.<-8
M=R%'3[XEV8SG.Q9R5(=Y2R$W./FB??6/%T2=("J( BSYO9@:O N%C7S_OPSV
M3\ILL_ON_9>L++/5[N$C3P4!5 /$^_=95GY_4GV=__@?)8;_!U!+ P04
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MZ\G#/*4#.>N7Q?.0A/@USV-3?>'@<304 !MG"Z_UQJ/Y4E'?JIJ8*'%"U!
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MTH,1E16@_;6D6#<3:V#_!)W_#5!+ P04    "  &@091B$$/ZZ<&   O$
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M*BL\E$$= *:1,UE)Z^"9.X4E0%=XJ\0V.5<N.7?8#G$0>T<BZ[J#E;XU^&#
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M9>J<ELHPGL?(PMA9O)F,15,8;:D["L[Z*FE&6^C<R>NRUC+:2Y9W%8!A$"*
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MT'<3$-2KJUU(^O^L/TKUE32W/\P<<JCU(*',!MHU(CY.<WCM&@:'UU3%'0W
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M!", W\^%T)L+<YI<_4/C[']02P,$%     @ !H$&427FAFG) @  Z@<  !D
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ME)?,LF%?JPUH9TW17,.7ZKT)CDLW*7=6TU].?G8X44)P2RI; TRF,%'2<KE
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M\,V,+F/4SH#^SY6RNXY+4%[OPU]02P,$%     @ !H$&48JT##J] @  Y0@
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MQZV^.H$P _3[->?JU# !ZLO8[!]02P,$%     @ !H$&46D#\P,@ P  0@H
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MS4P]\H!K@/H^8TQN.MJ@>3:._@!02P,$%     @ !H$&42#<FX:H @  M0<
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MY)!JBD3305FY>W8CT=S:KEF8N@K*3C#?<RGQV+$+M)5Z_@=02P,$%     @
M!H$&4;0_-34 !0  BA$  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
MS5A9;^,V$'[WKR#< [M UKIM*W4,)':*IMBT0=QM'Q9]H*6QQ482O21EQ_^^
M0\J6+UG9-HO%YB$6J?EFOKEX:+#BXDDF (H\9VDNK]J)4HM+RY)1 AF5';Z
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MZ])"L APMTY3,@4\FR@0N#]C;#!A*@%RPW6"J#(#A8>K'0&,9HG"MRDN<HK
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MCPE0K"DM@.]GG*OM0!NH/K\,_P502P,$%     @ !H$&48J&/D\S @  VPD
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M%     @ !H$&49>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ !H$&4<3,]D%4!0  A18  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  :!!E&P0ODDE@0  "4/   8
M              " @9<-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  &@0914+Y8 \D"   G"   &               @(%C$@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ !H$&4:-K1\^;!0
MRA0  !@              ("!8A4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    (  :!!E&?A353OP0  #X/   8              " @3,;
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  &@091[SBR
M1' )  !=0@  &               @($H(   >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ !H$&47Z;,M.I$0  A2\  !@
M ("!SBD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (  :!
M!E%C:^AYH08  !,0   8              " @:T[  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  &@091-_;OE%T$  "."@  &
M        @(&$0@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ !H$&48A!#^NG!@  +Q   !D              ("!%T<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  &@091[JQ,'AH)  #E&
M&0              @('U30  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    (  :!!E&/M8ZU@@8  -4/   9              " @497  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ !H$&45MHO +(
M!   !PT  !D              ("!_UT  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  &@091T'19)-P"  "4!P  &0
M@('^8@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (  :!
M!E%L:MUJ3 ,  % +   9              " @1%F  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ !H$&48(?T<=L!@  W!@  !D
M         ("!E&D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  &@091)>:&:<D"  #J!P  &0              @($W<   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  :!!E&*M PZO0(  .4(
M   9              " @3=S  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ !H$&45G'X[O= P  F T  !D              ("!*W8
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  &@091:0/S
M R #  !""@  &0              @($_>@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    (  :!!E$@W)N&J (  +4'   9
M  " @99]  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M!H$&4;0_-34 !0  BA$  !D              ("!=8   'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  &@091BH8^3S,"  #;"0  #0
M            @ &LA0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  :!!E&7
MBKL<P    !,"   +              "  0J(  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    (  :!!E&4=!I#BP(  *L/   /              "  ?.(  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  &@091X!='6"T!  #Y#0  &@
M        @ &KBP  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  &@091KQ%I,&@!   $#P  $P              @ $0C0  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     '@ >  D(  "IC@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>209</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments and Contingencies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails1</Role>
      <ShortName>Commitments and Contingencies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments and Contingencies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails2</Role>
      <ShortName>Commitments and Contingencies (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments and Contingencies (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails3</Role>
      <ShortName>Commitments and Contingencies (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetails4</Role>
      <ShortName>Commitments and Contingencies (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e2054.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e2054.htm">e2054.htm</File>
    <File>avxl-20200630.xsd</File>
    <File>avxl-20200630_cal.xml</File>
    <File>avxl-20200630_def.xml</File>
    <File>avxl-20200630_lab.xml</File>
    <File>avxl-20200630_pre.xml</File>
    <File>e2054ex_311.htm</File>
    <File>e2054ex_312.htm</File>
    <File>e2054ex_321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>40
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e2054.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "contextCount": 80,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20200630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20200630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "e2054.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20200630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20200630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20200630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 237,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20200630": 29,
    "http://fasb.org/us-gaap/2020-01-31": 40,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 74
   },
   "keyCustom": 28,
   "keyStandard": 181,
   "memberCustom": 12,
   "memberStandard": 6,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20200630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Equity Offering Agreements",
     "role": "http://anavex.com/role/EquityOfferingAgreements",
     "shortName": "Equity Offering Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments and Contingencies",
     "role": "http://anavex.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Recent Accounting Pronouncements (Policies)",
     "role": "http://anavex.com/role/RecentAccountingPronouncementsPolicies",
     "shortName": "Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-04-012019-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ResearchAndDevelopmentsIncentiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Business Description and Basis of Presentation (Details Narrative)",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative",
     "shortName": "Business Description and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-04-012019-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:ResearchAndDevelopmentsIncentiveIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:NonOperatingIncomeFromGrant",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Equity Offering Agreements (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
     "shortName": "Equity Offering Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-292020-05-01_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2019-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2019-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Commitments and Contingencies (Details 1)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
     "shortName": "Commitments and Contingencies (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2019-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments and Contingencies (Details 2)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
     "shortName": "Commitments and Contingencies (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2019-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments and Contingencies (Details 3)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
     "shortName": "Commitments and Contingencies (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments and Contingencies (Details 4)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetails4",
     "shortName": "Commitments and Contingencies (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2020-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2020-04-012020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2018-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "AsOf2018-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description and Basis of Presentation",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "shortName": "Business Description and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://anavex.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2054.htm",
      "contextRef": "From2019-10-01to2020-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "avxl_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the agreement under agreements.",
        "label": "Agreement term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald &amp;amp;amp; Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ClinicalStudyGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by clinical study grant.",
        "label": "Clinical Study Grant [Member]"
       }
      }
     },
     "localname": "ClinicalStudyGrantMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1",
        "verboseLabel": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement1",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued under 2019 Purchase Agreement - Commitment shares (in shares)"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement1",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued under 2015 Purchase Agreement - Commitment shares (in shares)"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_CommonSharesToBeIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Shares To Be Issued [Member]"
       }
      }
     },
     "localname": "CommonSharesToBeIssuedMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_DisclosureEquityOfferingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Offering Agreements"
       }
      }
     },
     "localname": "DisclosureEquityOfferingAgreementsAbstract",
     "nsuri": "http://anavex.com/20200630",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20200630",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Offering Agreements [TextBlock]"
       }
      }
     },
     "localname": "EquityOfferingAgreementsTextBlock",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income Disclosure [TextBlock]"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Terms of the purchase agreement under purchase agreements.",
        "label": "2015 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_RemainingAllocatedShareBasedCompensationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents as a remaining stock based compensation.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "RemainingAllocatedShareBasedCompensationExpense",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ResearchAndDevelopmentsIncentiveIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ResearchAndDevelopmentsIncentiveIncome",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentsIncentiveIncome",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptions",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfOptionsInShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of options (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfOptionsInShares",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of warrants"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfWarrants",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued pursuant to cashless exercise of warrants (in shares)"
       }
      }
     },
     "localname": "SharesIssuedPursuantToCashlessExerciseOfWarrantsInShares",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesAcquisitions2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shares issued under 2015 Purchase Agreement - Purchase shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions2",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueAcquisitions2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions2",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to stock option.",
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Total number of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20200630",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r207",
      "r209",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r74",
      "r98",
      "r99",
      "r165",
      "r185",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r74",
      "r98",
      "r99",
      "r165",
      "r185",
      "r186"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-17, Insurance Companies, Reinsurance [Line Items]"
       }
      }
     },
     "localname": "ReinsurancePremiumsForInsuranceCompaniesByProductSegmentLineItems",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r104",
      "r106",
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r106",
      "r125",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r39",
      "r67",
      "r69",
      "r72",
      "r76",
      "r148",
      "r150",
      "r154",
      "r170",
      "r178"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r23",
      "r39",
      "r76",
      "r148",
      "r150",
      "r154"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r107",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r14",
      "r195",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r14",
      "r38"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Increase (decrease) in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r85",
      "r173",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common shares, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r40",
      "r139",
      "r145",
      "r146"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r47",
      "r54",
      "r56",
      "r66",
      "r77",
      "r96",
      "r97",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain (loss), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r36",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on settlement of accounts payable"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r67",
      "r68",
      "r70",
      "r71",
      "r73",
      "r169",
      "r174",
      "r177",
      "r184"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r21",
      "r172",
      "r182"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in non-cash working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r39",
      "r76",
      "r154",
      "r171",
      "r180"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r39",
      "r76",
      "r149",
      "r150",
      "r151",
      "r154"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r24",
      "r25",
      "r27",
      "r37",
      "r39",
      "r46",
      "r50",
      "r51",
      "r52",
      "r53",
      "r55",
      "r56",
      "r63",
      "r67",
      "r68",
      "r70",
      "r71",
      "r73",
      "r76",
      "r154",
      "r175",
      "r183"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r44",
      "r45",
      "r48",
      "r49",
      "r57",
      "r58",
      "r59",
      "r78",
      "r79",
      "r100",
      "r101",
      "r102",
      "r103",
      "r130",
      "r142",
      "r143",
      "r144",
      "r166",
      "r167",
      "r168",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Deferred financing charges"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r107",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r5",
      "r80",
      "r81"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares",
        "verboseLabel": "Gross sale proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r136",
      "r197"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r97",
      "r131",
      "r179",
      "r190",
      "r194"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r47",
      "r54",
      "r56",
      "r77",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r187",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r106",
      "r124",
      "r133"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r107",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r105",
      "r108"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Description of grant option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2",
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price Exercisable at ending"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r111",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Exercisable at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r105",
      "r109"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails",
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r120",
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable at ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance Ending (in shares)",
        "periodStartLabel": "Balance Beginning (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r41",
      "r42",
      "r43",
      "r47",
      "r54",
      "r56",
      "r66",
      "r77",
      "r96",
      "r97",
      "r127",
      "r128",
      "r129",
      "r140",
      "r141",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r66",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r7",
      "r8",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Shares issued under 2019 Purchase Agreement - Purchase shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r96",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of share issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r96",
      "r97",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r20",
      "r96",
      "r97"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "verboseLabel": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r39",
      "r75",
      "r76",
      "r154"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationDescription": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of an unconditional purchase obligation that is not recognized as a liability on the balance sheet.",
        "label": "Description of purchases price"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Expiry Date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsAndContingenciesDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r198": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r199": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r201": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r202": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r203": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r204": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r205": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r206": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r207": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r208": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r209": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r211": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r212": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r213": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r214": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r215": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r216": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>41
<FILENAME>0001731122-20-000807-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-20-000807-xbrl.zip
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MO]0R&F,J7"U**O<8N*3W+PN2-GI1CTI3Q"V=GM4I)(:._L4>E6QWAXAZ.^!
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M7Q-+VR26RW0LY18$KU@N36+)SVBMQ I!$U,\J06;./5'_;<$<.5_4$L#!!0
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MC(KVR\_.]T?1899%BCZO=Z ?0C9U\5N'6!\&5NKB-;;X[,.![9"*I918P-8
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M:\G==]=QX8!(5(EK%ED+LF2I?_WAA621!$""5220I9F.&4NJR@2>!!XDWA+
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MI6+@WMM@2C$_'J<)4N]NI P\JC2!]3H:*>V?&#=IEN/X_T:KSBF[7M@+2;2
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M775I\.WV ;-BO%[G&>]9&3SS.GJGDN,-"@L#6ML4'1J "&@!T[1E(3214#U
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M(M1PB<NC&)HOLN:1;P+9,<<S97H'ZM:$D8-V<%T7#Y*)<A&;P%?74Q&J3I*
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MBFMPQF'96,M4.6%EES>\Z2=B7J<RB;M=J.H&W5RITLMZ9YHE0'6M2HH7+#I
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ML)\+OLK;;22<+(?SI/LH;1W7@!(G_!5;F[+V$#A^U['IT1;R$AQ^9]K.:$J
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M9&"SZ1IP^T79/B5/I+5<,.W6@$A+^Y%@G8>@UR0[YN0W:1P%S_+?'59L#,D
M69WI--)R)4:;!AC^;@F\S6C^ME.2Q\]H%J8K_L188R&EGBH,8M\&#R1<QSQ^
ME\_*]&\#%G>Q/HO[S?HXOE.*3@\][FYZ(VYB^^3 -(+=;5""D(H4^594$4_(
MU60,!@\[E&=OJO#"=!/2,57T;&6C,*\\_E.&3=9B2CKIOF-:[J)G=S1W$SV[
M94+>R3T&^BY:.Z#RV+Y>Q*\5!S8^IW%\D5(&.QSHWRU3\>/3!YFH]^-627BG
M]VZXNXA=(S#*>)H;DH]TR&QL7I\O5W'Z3,IP64/_%0LL(A2C"*7]@X0RM%8\
MD&#? D;/ST];F:C8]*UJY,P MK]I+.QJJ0N2$(ICL9:#PV641'S51KP@VWC
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MRK!!)NRYC1ZKLH2SY$<-:SRC9(FC!.%'',4\2 9&[ZX+PFR$1F_V4+./S_I
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MP8F (>FVR-L$_@4_1<OULO:V>"!2WCS]+--#\Y2BN4@11462,/B^=7]Q1K*
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MA(ZS+N4&>ZR/&C5F26A7.WTZ,!M)-]2.)B-6@*2XITJZ9K-IS.]Z*V9HVOY
M$0)4#69LZMW8A20J13V5^:<T24LLEPD;ZI&.,Q1&84!UT(]1V4*K:2"I@EX7
M2IV7S4Q8+1(&O_^0[R')*Q#7#%_!&S9T_DC8P)U(N3O\1++SIYQB-J&-$DR?
MQ06)S#"QV)O&L7PX05QRI:O8";,#1 T75JKS*\DGGNL/<L=NDS':Y(SN1=8E
M_T3F!ZB9&2IS\T3*8DA5%4_11CZ2A,PC+:^Z-0!1PQ)HNW8+M5JME?X<O2YT
M?7F0UEI 8\^RMF0@]BC9F.$LBOF.D*X2MTL)4.7N:$#O%?B;& RY(UQ_8N8
MB63%X*I(V%^70OGM'&=$_KQ,:G[N,PE(]&BZKMI2%5"5#T6L<=M"#[TN4_B!
M+QG7O3/:) .F1F\H6>$H[!C"]>F KD,#5,O**[1+#PVFTF9!P/<-LAO\;-\
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M4LL#T:JA[#;JGCRT'EPM1I+OG%$<Y'<I<T0\;O$BI2(<,FO$=V.:Z'<R1LT
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MY0Z,BADD7E-&W+D?QZS:ZRBEF<A527TAB)#C@CSP,C/K14ZG5B/8]QB:$ML
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MQGXYB6;-32?.]2@I548SBUMA1((%ZB#19*1<&^W9RRX&26N<M+/\?/$9L06
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M"&19V0B,<"P=(R#AQ-!T;@DW-9TZ)\>H#\^!/:3B64%(30G"-1VY9%GWWF*
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MY4JR(ZP!DE]FB*&-%A"Z#VR@[:,7VXU>V/T(R'WA$LU$N.ZBWD>S=HP?PC6
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M'E?*9I;=V'M']US/K3:"V2IS]_6U+@OV1-"J$25?*PS]ZF!Z:R^Y/7@6\$U
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MV1'0L2U6V%ZMU$+J1KOAID';IQB6#=BZ.MYU"QNJGUJ9?.%MV"DFD\HRR63
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M!E")RJLX,/R2=,3O(RYV*Z;>Y,3N19+%6[P60ZF9D)=UX+/0Q\X@CYW#.\&
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MG0#C=K$)[V+I"W*0(8*7.QC"8VVL:EU05"#F(FJ!AG(ON2_)\ @ ($L$]M:
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M/K!HP(3P#L! ^B]^0>46\9F=L)<SHS6"Q>E>8%+)!P8F^J=!-GX+(D 5!11
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MPE]/>ZV1O+586,QK95ACW'<;=]HF@9L.;D?6Z/[OZP__U =N-0]SLW8 E.4
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M3T?W[[[<7^X.K=Z&#1Z.42,ZO';_V:OOW:WIV)?7UTA&V8^5P1.>."'">>+
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MZT7<+"L_.0S$>^Y57_%Q>G]]<JD:.>U4)^9<GGRS?^PYD9USG3_$='GR:5W
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MI#0FB+'X8-LUG?Y6*K=2N:KTK=FQN[$99 0SM-MQ@!_!9$&[M]636XE\C@@
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MP&["#X>&"C[<<8U-8 X<"]&TN"JX<[9WYP0^17IWZ-#C"J@Q@J3 Z17G"M0
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M#;R>:,X3*?PTQ5FB.KMGU;%K))Y/H.R%30#Y<_U["@$P/T?<AR>#@(7&5YM
MM]1,@)B@*:XL\EJTCPME(5WNDA["<ZY-+RR/GV[1UN7*?GRSY_^V_OROT^\:
M8=#^WU^</@CS;:52W?DRZ/X"AS3ZWU]^,7[[,\67O?8+M@9F;8_(N!(MB>I!
MW/$AJ@XR.;%,Q^GVS7*5C+5!!!;9B^OJU4M#WF4)4R*S(%^_?G7>O*K2Y0>&
M;]M'2FJ*?E>OY,4G;$0*T2([.U[E&'&)D2:XW0,S,$ .!GE-DK7J]'&H)IB
M<#%S,7#R%;_?CU&143:-WH1/=D.P4+T[W[T3MC>2RK<#9\#1;@P04B*%CA]'
M)[V8G$$,/9/U(FBHD0P;WMD#2\$';1HZD@+2Z>,#*'K9]BFJC<MH8V0X]KAT
MZ;YG>[Q*:-[O&*_A.D$3 N\I6&>7LM9\X8B4N+AMDMW #(AX +*F@"44D5*&
MVT*L+%U((OIN6Z3"$R85&@6NX36L'WS"PJ@C!O61_ )NBM0SC4O,2L+Z&Z<R
M*7'C]U$C#7I#X\7EZ<U+ \\@11O;M'L&> JVM/LUHB(+Y,OR0[MLV0.D=(:]
MFV([PGI@.BX2WA);^T$B=AC?!8%OPR"N+EZ*">%.L]75"N &WBS+:1OT7+N@
M9ZVR#7JN[X%9J_&-FR2UC$FR1M;HVB\FFGA_'HL+O5CX*[EI__N;LW#C[N>2
MU'/3&Q8+*OB'80Z1%!^"_P87++G&*J#1[L'M[[25M8,1.:??,EW.TV+:6AI>
M<,]3MKO#UR_?(&3B#&S+,:. 0R;TWF+!=;[:Z; +/@R<(+0^T#L:F&$_Y/2
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MSD"97M-VD2$6:&'T87IQH#7;AB&(GX6"8!9CZC1(+,M+&1T<3A7UUV*GT B
M;9$'2]5"ZI*9V(],(Z.,2S8G=1-$&4ILF2)O@<J)"(#,$#P656B)(?K$?@)3
M&&Q_$B\4/[9]IRZ,>"19^UX/HX84CW4PFFVRV0WGUFSYKA.A@T;/JAZ6JWM[
M+U7P%>$Q\J#08+) '\HZ$$H()+%3=A$'GS;;HWNG35W]7!^A0"&CM6'!T5"3
M$>[-B@ZNU?CPLCFG#G7JIA&8>4M19"1'\Q3L\G;(Y<119%.M;3-&+([KF-P
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MKD/62<!*C#:G3FZH++E?G&JF L]*GC*Y-58Y_8+-"GZLU?A().#N&P2.35E
M*J<]/KV\N;@">VOOH/8'5HJ)_CF7<!]A;A9O2XS3CYFO9"&K&+7($L>>\RWF
M] 'CA 49(R,EB$XR#C@AB;3PDH:<#.#$V,5[,?4#:L3>LA5-BG +DOZ<A%;N
MM^ V[F.CSQXY'@DA/,4_\UI6%@M@WH/&UTW(*>T1-5LQ>9K>ADT^;9QB?\?X
MB V(6A22%<X$!4UA.V#]D#&O"PN"O/>9N:-QR0$:RE8(XU.LG"(KA$NLW;/[
M?%($]XTBZ4YU7Y+T1K@*2'_TP@^<KF"BUV;SDGNBBM#ON7S/G1/$:*$DZW7=
MO,*"P0_EFO'B^.+#ZY-R]?"ER.Z,4? C.P[84^ $8"\ W;+&!JL^S%@R,K&^
MD)2/ZCF"Z1UW-67O>-3B'O[GSKD3VB.PJ1,\)\+^PA6$[T1:%P";5PB[%U%O
M>JI+'2*(%(2<*+Q ](5=1M%S.0A5I(ZMHYR H,UH"DFGP.R#>F4HGK[46^7U
MZ/$=RWL#+4\STIG"I'6=-(?D2T]B/.G4R : "VWF]W-MP=2\#%AP+UIP--H@
M^MCP^N5Z!]PV>JWQ,O31<L*49#;8HK4W>$3[4.*=2CHMR*M98R/;*K&G!4ZS
M967"@0_4@L_+U4TV38KC1]8,R#LSA4A!+!S\?Q"8###5T.D#,S MV&;%GTA=
MD(V_3F\RJ#_I,!.2@N*)DJJAQ&4U"068Q&T8=%'Z@@ H6X)6FDX?B2%:&<C@
MPITX\C'*UH9;-XRI%%9<Q*(_Y, 1"PD6*4]Z'XZ&A]:?:XE@(2Y#UR;&%^9,
M-*T[INY+=5FQ[RC;NV-\L.%CKEV6]#^\.OBL=-RS8R,+SL0ADCF&#2"1%70X
ML.D).\:-C&P+IIY9J,\.WG',$Z5M/OEF[< F,YM,RXDKE=KCU/XF8)*^'Z/1
MER9*E"V/2&8X"F,PV!/'U=BIBV'-D&&P^P.RJ& #_K^Z_BW8%5@$RHQKQ5KS
M"60LQ5(P:8AE2#Q,DT)^(=O,85OT*P7[45!!E;2^+XR+P%9!'M.\6<EWT([U
MNE$/#?549620A)Q3/*$9+Z#YD -/+OP"3KP8)<:Z'G[L=;' <[^^^G4+/]@(
M^,'>%GZPO@=FK<;WLY<;8\0)KR,$@,683[9L;)S=DLP? MJOD?D;62Y_1<^4
MHAQ [VRS%/E:C8_EDCDG:.MD#5VC)%$""E!PP8""$PR7GFB @AF--F97^'!X
M?;QM9YK+$HQTG2;_<'R LSI^P,>O,(AXJ<IG!"JU6'AQ1<3DVJSFXW2 )UZ>
MI+ZG&JH, K!.$"J T Q8_P1WP6$^!GS;7#J8::JB7LH18B+L&&^ NI7[1X]/
MDET2^E5C7D$84%:LSC K?A.@[90G(%,33GE-<Z3*%@] 1NCI(H:#T08AOY_!
MT'3 %G,=(H85+1% 8$3>7'\].Y@DDA3ZOP?I@R--J0>P[RBX'7O8I8& PY@+
ML&U+V=:IP8983!:STD<V]S(FU6 $'B-89,GY5E ?+ZAX<4\IYJ&J%<U[#[.T
MM(D;)2(+JBP%P0X2 $27N^8=R1"<Y_0QH<$.:1ZH/DFL7$]Z+U'ZA!CASA03
M46S#MF;5%&E]0R<5%2&5$./XJ@<DI1AEQ_S9%'+[:_B $_:,9I=:=^%I/&>D
M/'SJDG*%O&AP0XJ#< +'!@M]7C1/SR^O7Y:H?ZXHJV"4"-MOI=EDK-4]69@I
M^(4F5X9.#RWEWE.S^U7EU4"DB$OT^A'> 83ZJS()O3!BT:2KI;'"\&(!7-Q,
M@CYTB"ZE'?B@L& S'<Y8*:S4DZH4%(RG-=S<BH6U&A]:FC-:/K*VX>!,.)V'
M&C>4.^M(X)>J0"0%(CO>$/^LTB[% L="N<6(J;4O)NU"+:')WL38:N24S3YF
M.]OB7U@?'KNA3#[0SRQ[0"V+N1^R3..C5X3$*5;,+;:C4+P*#A*<:TE,.):1
M$+5,HLN2^*CH$W1>+>\9'&[-0=5F8MA3(W')VNDK8,74FZG=0ZW8%[!C3- (
M:G.*V4W"G[)Y;NK(5FRII^VG<=.MU?<;,^+DG&O'"K40.Q.$$;=G3-UIF:V2
MQ6(Z(#=C38,:L4S1.I*[+ E;AJ.MU%4G!8F8%H\&S2":5.L7J! UL-O, 0K
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M2(;4;W<0Z#1 %(7G>V4?)%(V9.#2_1G#%@?>CSDM41=<UJ);1*)3)J;LZ;[
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MVQX(:00]B&2MD@:$/WDG&U0G3T-SF8H@0+2P9U)ZRO(DI*F+J4J9IU:M8/.
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MX/>P&AVN5VR:LO(&/#YR""5R@F.DQ/M%F/8\M-G(]UHE+DP%S3*R16@4TH_
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M7BY,@#O<HNO@1K$_-JK[;61?$9-W>:\L;:3Y5ECN@Q">7B4C51KHZP(E&;0
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MM=M,+#PHY%+3K$FO\?\'4$L#!!0    (  :!!E%N0SYQ,@<  #$<   /
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M_2Y=S?OK^>,$H., '/?#"W^')A.^$6U- $;?X-&P:44LJSZX9T$ JA3W>PB
M]00!F)_"-.RH$(#FEO&_0Z(-3G)U$X!R,=P6O#[\>Q#)& U22&]T8S#M7.S'
MRN\5%_X''!%%_)EL."8?'&?&6A& )UD:^)7QO<9?;;(!HC9])O\%X%\ _@7@
M7P#^!>!? /X%X'\@ &NM$]^6]'?N7)OQ9#+W=967UDR3"L0MS4RS*I N&W!]
M?27X4CO$7ZI?GD'G_-ZNEOIHR))6 CQ43Y\CJ5CHMQ:<"C_MPXW8B,5Z=!
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M(W9)_.-@GS)KQ-TPT:%6-%SL'7'&1YE,:(7'CI&70P_2 LIJRU ]/XQO_$8
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MP^'4; /R#0E6.#PT[J228Y.1I+WLKKFB$)+/,-%L:F)$TW]>>TF:3 M?[K_
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M:<%5MC;F>R+Y)G/M"AI$/*-+_E><&557I.>5@90;<JE,Z=[%'_@D6.0G.52
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M4FJR0<.57T?9OW.?XAE"1AT0'U3Q=?\N;(D![=LP7=]'5F.R>KHX"4+WU!Q
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M]*;JRN?B,3/Q=9JUN-B/"O;ITSD:SUM)C$0T>*>,E);<2^609GA>26G/0?Z
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M.#9O)GAOQ::<JP2-+$Q(.^U/$GB5),FK)270[/>H7-[,;XC>(2BX,YU;0<!
M;>KEIR/H':9B9#/5FF]SECG1\,WY&>FTG-U",&%^6$S"02\+=NJ*?5SA&/)K
M7I):?,]#9C:L7GSG]S+B.2QEY[KJ<VI>TP_U\7:Q&*/[J)U;>1ZC *OQ*4G[
M.]R6XK65T4=9REC+U7T&Q]M:RL5/^YQ+UN:F%G0"QAG>VK\O<)+#-1.FCP*,
MY<C-+62X?&=U"@CHE8?&O5JH%M@V;W+(N5)R;DGS^HJ&77J1*\J/>*#L(<U'
M_Q4-/5R'&T_TFV:LOT%\H-7K-)8GB+[*_3.7[:S_C&-M_V'9C5Y'<^,'&H@-
M;O>)"8$[8Q=?\"$]54Z%3K39W5  ?22DP<:.M^W\P<Z#@;=FA+H+#+=D)<_>
M@VX JV*%>) ^:Q1P![W+_EQ>BOL2T;MD:5<B*=+4/U_=!VG*#%,IC6Y5?%W[
MD8RMZL5]HDWXS>4U""$PO5>'WB7%,^'Q<)8_B^S0> 4KBR&-TLU2W#>LOBC@
M+KBYP*8E3KS&1DTGOWM).\J,XZN)C.>K)"L<L\X=2_@1=,]A)_6/4H'/O*(5
M_UL!+!:7\&^&/)W&[TGF7VF%OERLK^EY)ADQM?PL?(NU\L0Q20FP=3<B0@%)
M@T@E)-F?17+_ZXFVW$EHFZG221D3KCSM,(4$B-_+Q@N"VNI?KP&7"W0]%-S#
MQHIP'&7<N0 \/?W+1KHFO^ ZO_;3I7GN("@>DBE^L<>P=L DL&"^LI:WQSJ2
MPX%N,NL>D[*R8QPP\==ZH+.[06WR;'^J*I2U[GT'\9;KJ^CEESW:T4T7.4QC
MEQ*Z.(Q,<YH_T(3[?3LZ2"9^]1>JR",H"P@:Z700<#,HTG[<]D$_JF_(63WQ
M]LRYXL:#-;L5QGTW23_!D 6B/>)[R9<+V3]#]\<A';"FS+* STM;-R.J[9JQ
M[W^6/VXO$%F[9_J!@YN=B]=K[(@&P6MS SCZ#@#$'[1)9AW([;Z99(&Z!EAU
M#HXDI@\G_P]DUY$2[]2_P%5".R4HTP/WET)DXA]S079HT3N;+Y>:!@HH^XY<
M[$/BP$[4_IL_$@O=1H+0T]1K.%[QH+0X2<"?,<E2==IF\0&QM\<R?91KWZ<3
M'UE+6\62;B>(&_?)8TB1F"C::7*#'F^!=Y*)C;QEFHY$7X*@EPS$G*J#[LH<
MJE-3B1,[JQD8K!;:.9#Q3K%-A.10QA"C9XWSS"GA^B_U4\]QFF'[RV@T[K.(
M ><+6R[1U=ZJ8H-U0C=/67K>P^XQA.PVYEY;.RJQ*3)"9!P.W]$5"U K!VCF
MD\H'(,8OW)!>VZ#M2=BL[!%^ &2Y=Q^)Z$*2876-KQWU,]4];MJ[7US3F93I
M<\"PV[9D;3R2.G.I=S_/CW5$G@'G5IHPKO-X#62#A!@%]"4N(\XQB68:=[;A
MI].0F6I(DZ^PP/"[E"F!_*G!OEMO\P:(A#J5)1=V!W+Z.!/&<[MQ^R?:)]KO
M"]UB$//$.=.V0[R<G3G=KT,!,"=,0IPQ.K2"H:)]Y\?<)ZKX5-DSLFY,E=$#
MG29*^?S)^)$)^V'*4:;[:B5\8 .]P'';1HU37[;6M(5YW(7=H#44\'=J6HK4
M*E%2]]PYMC'LN.NO'E& WSFY.S/RR?-<,9C:BK&Z/M LA.'SC5?47BUGYV>N
M!86_U@?].H1ZAC:7FMW(>TK2ZUK([F81$T)C&!.\)X.B.4U'\"HD.2=SK[QW
MWTJ6>QECI;F<+'98$/FWS5T_DEM,$#$P,/!*ID@P*5T=VM7,_?IK?[)O]7N!
M<+O8OAE>?_S^!JL<O/@^5=+UG<KX$B1"0KGX8?.V)]1A&7Z>DXXV5?A^-0IH
M1&\^A.#->Z!J9Q3@NXT>8J>@S)_L..Q_'OW/H_]ZCX(NO:YZT$X#..Y_>GP6
M%/VGU[=\2/WN@9+UTTUFTD4GOL95J,(*.P$*6+ /1C2C7;2X&1+;2KM(X6*A
M,LU-US>( "/T4K*" C#?;O'^Z88<)DVO$V-QC#]L!N_;?H(_YK)]B@S[\?67
M/XOZ!VJ'@:[@9]Y:H&[DD;'W_^V-67)ZG/7&,438EANW :Q]!P4915XJ*(#N
M"$T;-[VIJ;O_."1_4H."4[YU,]VN"1,!EH7YB,GR8;[]NDK]E:;B*#:2[C3H
MLN[,SH<9%.!$<KZ ANO,0: %%MAAMY9%VJ5G>S+R^V(E_?.UQ(ZG3^H]-*P]
MF5@9FO.-"BL<0VKBH#_7H__Y1BVTE\&&-M@] S\>V %N<A]F6PRF[,^^N<5R
ME32PXP*58X2,Z+FFIPA]ITI9BQ[\"_1$P0$%5.,C]C 'H/XL9T]\MG!S"G]8
MB;--<YW*&(NA$C_(2XN ,9+[F_TKV1M%P<\X6A(\5%?[]5O(%;:MKT-F66'(
M!?KCCA^G:OXLY\1YT8_S->W?K0P&8%1$SP!0X/**3>F$NVN$W.G5-*0:;<T-
MFRB*HX=K<]?WD.&9*(! "04<WT0!#2H_WH'^>3?B'57F+,U7YRRGFD5 \3CR
M0$ LSMPJ1JJ'\S;/GNRQW_<*[U:(E/Q@<F*"3,[<C9IP2^35>!2P)8D&%]#=
MU)]O<BK.O*ZY>RZ8SS@LV6]0N_:?:-H&@TL_7[IKPD!!G%G\.,@F$6^SDUG[
M2M3I.] _45'12NY9/?<BP[HF+#;^GX^(2;_L\"J$Q=NF<I_/^9]*E"?"@FF,
M)%\+^<0>TO08@F@';4=B7A'_7A0(D*;73H=_.LR9Z>[I^Z<RI:X=P#Y(E.N?
MQDZMBM1Y?-"YISODU;6^Q:Y0-TZP4!EK$1A4D^#'7C/@0K]);;A(6+,S^4RE
MW'TL3ZCT.+5X]?NNS^@DVM6(]4&;+5\=QFS_LZ]?UIVI/&84$%[#?4R"]+/U
MH+?M3QB#%B,9[?NER5\.D&G'K4CP4L!(GTCE$.25X\<-3 ^Z7>&GI4>.FSX^
MX31?\6$:>:SP]:D K8Q;=>T09P'GUB7:P8FZ=// ,*> 5\@N3L#S OEB[ES&
M$-S-TSQNHLW:QW+ V$_XHN">3*QN#.TEH8_51WI%2;>&#CTO2Y!51T]O*P]N
MV0L\>/=J62:?,/N(BW87V9A,HI!2U_:(8KZQ9&W3,W_,L-GZPOBDC7:*W!,+
MZG9"REG]3[@X;R@7-,45!K_0\>W<&GK>->%?"ZOE5;2D_1PR?AN><BO!/)O*
MV#&:^:LJ?KZ:D9N[Y1PM^V</:L.U4<%CP5&M53$>.9J.AN=81@86ONJ2K7QJ
M)V_VU6+AAME?<J;U)%XM!M^[%?G4_&VTNJ&'Q-R$^PH^)3_6*IEVK*[MJ+;>
M1EQ&1ERWJYFFH-;FA<[T.G/:G$)*T7AG2P[)A1!CC23"$?M"A[+<*0-; N?<
M-H[HC6,V.S".Z^>KT,A+7\,C7T7>IXM$>S%X)($H8'YZ!K&O/Y6+WX("=K<=
MD*?Y6\/U*K-22\Z/D6)(R=^/MV*UGJ0B'P2C (,O9LWLDF).F=,R1.P%P_%R
M%+Y@AEC7L!H5E=ZL[9UE^'[,OL-NH=X[_<>*4;#P.>U4CP*#5=O)#L^=4:&K
M;XM*'IIJX&\1\\"S.[+2:RZ4^R;OXX;0'A/CW17'OU,N=.*,=.\ZK3SIAS5#
M]WO!/;#6W"11)]#ZD@IC(<2:?GW!0M;=EJAS5X\W+-[5HN,SKK%CFU[8)H\L
M30>NLI^&9I=\Q$7A/H5O,[-]I\O<2S/S,BB &-(G#!%$+U8^_1 .6.''^GCD
M"TRT(*^2^H,\$S";/"5_X>?)^VV9- M(?ODL29&JI*D)S[P0=:5JXRKF3)_R
MS#^$>8>D0?O;3D@[)'_U/#SL[#2J@ZN< >$5<J] CY+YG1#KAP)*P;M8N:0V
M)4UV([?>IJA2$:/!_[;S=MS07XIDGV:T W%D2T@MESZ.O>R1P7>CY<$I'NG^
M\]-*R[/']MMZ>^PN+EASZI<LMSV14:5_)0A;H.C>W><+P]7SQV@<BSFH^)><
M"AT0H\>DAR[PW?->IZ"5XW_4=!B& G]X=+]M^Y^V(@X[!D_2:X/[Z.N660K"
M( &@Y018/.0=-5P8\R8</@&W0F^34Y!GWH80,9_]A)0:\3\E=?C=/%(G4( +
MXO,/8;H1#'*1:O',[-C06%ARP3BE6:6_:>"#E!" C?UZA>V]G@RQA&?X#H7U
MNH5\I'J:3)8ILH7^S:T?[,L=,!GS>UW^,Y(1_,-E H*_ZX=400ZNZ9>_1@%[
M0M+(64S*80>I30^^^&M'H)9WXT_?,@7.,_E:L"DDD$*EE%.*1!Z%S^9S/D\$
M/=+1M2L[#E(T+I!BD#U6]H!"#!(.<Y8_C[/K6@MF? OQ>-3DR;<DN#)IV> D
M*TY2[J!VGW*^^8;>BFN-2-/<P/!\!(V<6VXJ_N7: C>BR!GFD43\-V6YUH?N
M<Q43=_*<7[C10Q<G3AR3$CL$\J4!9]=I_ &[S91RWK5KXRW]O/J31AV,9EW"
MDN6A=R_2>!*.E@SD\Y]WK<>;FWM^PRWEFB^K4JWU72$ +&D=M:V2B;R=FUV-
M;NE$'.E_D7MK_-Z@3D'G2N/[-',_+/QRK>H=K7?N3J633-TAZOP?J6,FG!C.
MWZ@ER,EFPVT_I?C>A<U>Z>\M<>$C:K"&;AII)R%5$D/<DXQ<M]J\/ ]3E7;>
MA*6M7?*T)6HP-VDA8-Q:M:=9;+%1OL8\N#I0:?7C[T0B>LR'Z^IAYTN5M5H_
M+U$>T*: [J5,N#O<+X@EC_@]YFWBNUT5N+\LP@F\9$N&W4TN(W\/NZ+N,0JX
MI89>JF).X[K*8CFW(BS5)R2,0>.;9Z/54@IL4V&)+8SK'1*+L<][8HH;(_%D
MU!]]G'5==EL,,M77ZP6WQX$CA)QH@15>T>-LLV'E+_LI6A9.,E\("8N:<4*7
M"VQ8MC@Y%_!8ELPMS",] =?P$"*W3Y[*J3Z]9T\%V5](]) -BB7+,]RY@N/'
MLWZ8BZ]2(43!PS )^];638[%X82/G:OD2!%%=#?WU+'8"4QEZK@ZF/ZHLM\[
MYTCF&MOD<Y;[%J>E2OM;L'Q(N_S@-Q2@!XDU-)9MT,$1L^JEX"7B14C+0YY$
MY[T4:Y03'7AD(3Q_[W!=Z<W</>Z19XSA6""O=Y,AEA+EXCUPOF\?L;O!KY8J
M>$]6:U=(].SZ8O5-F/ IO-O]0S<%[*/V)MK-VZ3;J> ]RL_'(OLX[&ED>=ZZ
MRQ$T4G5DW6RXPE1T426ZKXXN-#\D*';[>TSOY:.W+9&QLM$RSV3NVH#+JM6.
MM/;1KHCV]2#S4L/-X!#S^<QN:9V 1Z$ZG_>9B'IN$EUCJ874>3Z))9\J"7:-
M%GX4O; Q?I^(+QRJ[,UJ.E17[D\I'.9\VDY"3%U^]2@1E(\"ON-Z1\R<32 O
M#I558N,FN<D_46VV\<LB>80"#G/D#EHL'KHSZDZEJ6(O2H(?/Z+0"C&)L$KG
M??#IOKI@%2W?JOR=5,;H55)W,@K7CZR-=FW\(*NC"QO1*&"D<41-ROIRRX $
M-<(TF>I12"%8E4V>_T2BG[..5WE/EBHRBF;G(@Z]WM-QZ/CU):' A^H%5]A\
M.V6G.K:#I'Q@3Y-<M.G,)?2^[Q$#?:L/CA(ES[F@HX?)P9G(K3L?.JA%%+XH
MS%/+R"XK18Q/XQ+P#Q!TXC=E:#KQ8FTK*^[<#C0GW@ADBU!VKC+VT?AFSVE/
M)L_A=#J+39N'78P#G T>;V=!2RN@(W[C>E)BMQ;=-<I2F"[65C-DIT<J\^C*
M\[RG(FT?$R'#M]_N30TZDN,PNIC8/Z[TY<-\B!FYL4T0C>Q"6*F[D1JU#-QL
M=+V'9-QHA6&C^NDQ[D!+DE-:IL?#4-^P.AU+^EF-Y=</BJZTG(;C"],*,]"G
MZWCNJ"N]'.YL(:\G=,L 3^4O%+<7GWJ:$397.,DS3,0Q]'F[HD>8]5S"4 @%
M^"FFVY2LEBYX]0O-J.AM_5LR]$I,,O3EZ)&]*>7BA^FQH7?9JP?*A@?M*O X
M&9R6Q7S(.T)#A,YE70U%XMHV8E92@O95-/XEN)-!K?_&T8Y!FY/I4S-_%+ ^
M\JX%[UFR"H?.-A4.Z*. @E5*Y4VE'(-/XE@N*&#.)E5ST*MCK#?]GK)@TA?0
MB6P!9(69>0&#O_\H9NYS@E9X0(@C&%R)SB(3@<>,B2Q  8&Y9P>P6!\\>JU/
M""&D.?U.F %Z<U!6^>V R$\W*DMZD*^FD/--R$F<6)?*&9$*)B0 !5R3'4V'
M=^V0Y*HBT3X#+\F_CWOJ^@#2X@1_. N"]J9B\>$,HZ"#:Y$_3J[\47Q\&@T]
MH(0BS\'(.V&\@\A7US"A"2B@I?]P%<(+QUD; F6@@.Y72-)UZ!E!QX]3/W\4
ML^&_R!IKC0(DT0LS)L9BSNI'U[$.;>@'(4N8S\H>]B%P%WX[X?)'>0CYB[R8
M,Q+):,")B;K8Y??V '?#@+-RDE78/MH5?.VQC/1S\I'%))OXHVP#^47FG]0H
M4<^]!/;UU@LXF#F-ZGN3Y@H61"1*KFB@M?V<//PGPC(.RI#@\Q+0-%H#*9I3
MAE,;=@I1(FX+F#1]I3-(R!:Z0^F8#B'[(*<HH!:3&!PM;+; _X8@F0@!EHI7
MJ[O&^#;5V(!' CE]*(4D582>;E(L09K*N+CL\C.LTH8*I0H-R%$ 8=CY@SZD
MG_9,'":5!DU;N%,V)S'K;):"LOK,$-H]OIC>!S\*WO_Q4=X8T/XX=S>:S@#Y
MM12ML:CC)<R+:'\H K<0)H!N"S+N<!H.TFB&//KWU@25S>S?/,N@/K, G4AS
M09;+P+$_CK*05:/!6K^/)9QM^1=J#DR>2^_3PA,U1 ;&QH;OS@RRHH F5F<4
M()X"[_N1*^]W ;1_H?]DB;86]FU,Y,*F$+Q=(OL-,E;E3P6%_<2_^A?B2Z S
M K"/+9(,8@U;DCQ\)'30"=D)0D^F/BL8'R8I^Q_,-?M^(K;2Q61 /=_'O-96
MPDRF'!-8!B;V2'T9Z2E]"L6DZON=><$OU'\.##U:L>^]'U]&\$)_4B;]G]S)
M\ZUNUVO=M=$V+U35E41J6IYC4HPBMY%G:.LJ"Q5)BQID-;825X<_(OEK_;)#
M?JX1MH%)GWH..U]%&RK$('=2XI-L\<M_&-/I'V(XH !+&!R-LC')Z3&S 8%V
MZ-$;L1LFL_V/M83MF"1+;8-/<2!ET*2Q66'&'6T"^83I_T^Z(TPN4\0,X@"]
MH#AW*CO$R1K<HI2-%OV1_QB3B/48@LF]O\L/^87?T ?#E&S(WXIP_W_3Q-<+
MF$3*/[&G_X48RS7H;X4%_D> _Q'@/T0 EEMW;SWF+UE8YKTB!_?-MOKCJ$(>
MK189U* \5/*#!1 R7YV_U@)# >%O^A##R"?5NVP[BCT^3UP$.2$FF,\/HK>R
M&4NX%;(9\QU!],;8T'<R\H[<IQ6Z5UA5('?$!RLZ0 &G<Y#M4B3_SS5L98)^
MY"Q]YB1;G(@(P'QZ$+W%>4-W4\])T+MM$C/R'#2OQZ_V6Q[15Q'B(=L;XB#D
M"^CY!@99C'E X+N@8[2+<*,_)<Q,Y51[DB9\P_)O9"+[D>;T^T*8F>A/'&2/
MZ*!H[UT%<01I+;-*_9%[%9_1DVKF)P:@/[L@D"I-]Z-KP@QCRX?>O",#_8QO
M>/.7L!);C@0J[5  71$*J()UEL+1<. FNEI!ZNF-KQ4H($P',@E>U!T,>F?-
MF)]RFY6U]FJ_-/F #2:CCJ/>#-P_\VSHSLB]>;#(=\:\^*:GC%@3S!4V=@[(
M!X,(&V&F\FH"QAZV]BL,;%DWOQM?\=0.$'7N&IJ%7&.(Z$\M"5TH$NTE/%8;
M0]X3X!^WE1)M-;_P4.9^HTOC@K?U'O@+-Y0T4.OZ_:Q&KQGNJ3[0,O]\5DO/
M"RJ=M!ROU%#-MY_A) >9-MY-_>SRMC3R@5S8/96N/:]?MM[ORY<;(0U.J] =
M:^^]LL0+P)U[!-WM"@AB0W)Y5 DO4$[B\4$5BHYW!0ZTZ:T2PQE)%DMV4B?B
MKOKJDFUQ1E/.1S'.T,0"4>-.(KOJG!&.#>KQ)OL)F[V\+W!V;L<ZNQQEF?'R
M\:\H;(F/9L$]AJ-KKE0GJO!.X!IA-1/AA)^H*U X)%L[@386#1>W[KYZ,J+!
M[+J5X)H1SQ3@7OU1)O=6B)WAE[=K/A]67%@_A6I?A27M,=@?X@CC1>OF,S^F
MLC:3#D^\:+ SULX@@<9<KB/Q ;5V>(EB,HSNF9=N1&$-7[)DN'E.*&EK=V0F
M7/,4F^PEA9?E2(;BF'1?XI+2%=6L*RS&*WAWO7LD:7:>LMXN^51UE5PM@8N$
M3(#XY5:HYX6WS<M*90JPIMCQ2:_,G=L)3V]=5899F]X\7Y">N3<?QSAT?9;Q
M:DO6M%64 O'ILM@9A$UGFT$_?O2J(F4"//15^+[E2-C4C.1YNH:_1:V.NDK4
M1Q972@3K<73*6%OYQVW<V5%;[GL+ZLUBCN# Q"2-#M&WIR6R!AZO>I1<W'"/
M\EXF9C#IIK&&W0W%<Y\_&TJGTYZ,9R>WLT\O2[0(+&H^+.A3'C(=NCE9=^^\
M STG1@IN9)371 ^X1-]I)ADI)'G['!JNL78/Q@!+R5X=?^WQFGHP -S0 $78
M5!NUF*<5A+8,:DM*DVD2_2O<E3_<EJLH "E##3K6/HV;R$.O4Z>43]%K%GC)
MEDBVJ5Y[R?*QF7T02WX/(7A\A'X"/(8";,+.I=K/5="S-+AKJM)M4$S3?%<P
MF"EJ>,Z&5* ^O>V;I6/D8E<5UP!/PL++DU' =*0W1\P: :5X+R"VS.N=N0%9
M$SSU= P[M1V=SIJQJHE*"A???)>P=^=3CG@]G"T Q#EKE8E#^T8C:?;EYGVZ
M7,'23/VUX S%Y\%>7P4Z/_OIM&9>")A_A)P>Z(VWS+K4(AB3?T._'4O"##0)
MF(F-)H$E"SIRIUYT<DH(OAE4P^,";]X9X&A9*]Y<$%RE+Q3SU'H3F#[-'3PJ
M'3&M.?!<=PE6\3[[&W,"Z/FK*2&E@Z:O^%(4H7 !?G6%N&B3=VYB&0386%5<
M;N2MO++"N3=@P65*Q**M#?6$3T<$8TFIOKDM&S?2*A.T)?<IV_KO-*32!KRR
M**N+U!Q*U[_S=F5O=2,[8N(!WEZKDPZQSF[D>/X+R.=5Q^0U.M)=;&7[@8<U
MMB?!/@C=9VFBEJ+W><A!3:DCOB)9=0ZS'6(@NJKQ!-4QN0GRQ<Z*[:W-=6BF
MO8=FOOZ7&US^_(XVVJNX$5P[Z;I%L:U+C:+:XKT7G.A8OY9!+\&%J@<X-K>8
MDQZZ5$@HJK +M[IKBKX 7"D!U[0A%SG388':UI*&ZE<Z V9O6M(3 KI=]C53
M&.PU(M9\GA+1'"43-ZB06X7;$J1+?**L<],9%JR8VA"Z,/6N]NT"T<+0W9.^
M^U"U8!7%)8K'"B;OZ*:E)^>%@2B<XNWQJMRA.ETQT0S&L]>C-4]'%.]$C\AN
M[)$1TH'OL;0;Z="V6-S_XE(L+9@_7VUO$2I=TC^WESR=1L#%2.5&]^FQS?)P
MG*^(#4N*+V_=7R_D2+2W]MX#,JH&?V>E#VG+ VUQ[^4QP*T]& 1V2_184BKY
M,?]%W\O_;0$7+%9A=NI^E$+*\R#!;'U=W1:R=QVZ+B< &'VC@F[LI@3<Q^^6
M/>AE;XGA%JNN35">[)T'*_-,3CPPIXP'BNA=:L.:PLN.+[/A7>COUZ:E=Y-2
M;\MF*.'?S2EYQ(0GL([8V#_(:,MZ7:[!]JBX/2_$@QPW@;XW6)VB1N#I=\_7
M+[DJY0QN(;ZU5>/7LPSVIP4_[5ELIUEH>T/ML:M(,Z(ZS=3BX_,PON*]A-K,
MNG*PJOI.AZB<Q?T5 R?7\+8Y@D\L+O2U0V_8Y99J=2*T=8ZVW,(%-^E5.A.B
MGSV-[TEZ^ (RPA)V;YG&N8=[?/X=$UN?(V.\1MDZG*$2G'[-2)8EL2*<L3_9
M&)_ZY?).8[H5(_=SJQ(CFIX*TBOA"84,S #6^B/!G;+'_+RE'YLJV4,)/K<?
MKJH'5^GQ$+V$5_BK!85*8<LQC(03D7YVZN>[8D;Z[N1"H# SW4<R/7&<!U%D
M:CKO?T]-1V[:VZO_K46-:#G[@$SW6Y?GO2"F7H^DIEI1:LJ\FZ2MO)# VKC5
MYMDI;;?B=!%[E7:.IZ9%OK*4'2#WVDBMK)3ZMU^D=6D#&?/\@E@R[OXK3X?^
MLMC9%[GH1ERV']$EN)A#<-,S;KFE5E)H"H.YA++R9C8G2$Y79HY[Z"<JZ/?[
M8=MQ, ?%T_>(-,\X#2V'H\T ^('#^5+8[U1TTS'[-X_"MZS5=&&_5P!5/@4M
MIT)F^#T]P-VOQF6KTZ6?H #[,4B?#.8L.W(*C6&2WJ$ K_[-50@OB37=4A1Y
M/*+6!.UQ4B-/4\]=FY$>0HA]V<IT>+OX_P^^57U7(.WBH/4LI$P9)VQ^A/Z8
MXE2++C][?&H\[5GI]7VLUADS_>B9W762\V!XKHA32*[\EYF'C_2<79E2@MC3
MAC!;1KI$E*4C:[1.R>;0UNW4WQ#?RQ^A[&B V3.0<>CX<.\/@(GS(Z"]_^>;
MO\"%^,ASA]]1Z(]R_@V6W_+>?^Z@:W7[#3"2((YF?@>//\I_ 57ISS<Q7T7X
MH_@/^'('$R/_&Y;]K6C5+UN<"<_=(OX#.'__$3K_;Q#TWV[^$? V_HBFY__Y
MYF>DZC?>>TF:'==$<KU7/GLE)9\Q*EQ>WS@EB-7W7YVA1T-]0E)";$7]T?/)
MY+E4.YD.[NL]!9\H. A(*:A#>2:0N""14OFT8^S*(Y<8^)D4V@8)0:5YL.4!
M^O/O&@-=-*3\I7+AK:\XMAH!<7D!\D1$TB?2Z,ZU2Q^'*Z+?W/]._RCTH)IA
MS""W"/IM!+R_2H+884'VEF#2J$*V7VK9L!28Q%FGA$I;WS0NR5I[[=M(W_CJ
MI+^#[G-G+2D*L-2%]*6!CAM3ST6ZD-ZWT%9T03<E5.Z(6',L'Y%H@0(DWJ-5
MBQVVL<Y]>A" /"&;V32\!_9^/3..*+RW)[8XDV"YM2PNG/O<2;;(J>"+PQ]T
MD-];SN7_QBB7:LWH(O?U^A,SWV07QM^87X'\!>_K'N]"4T*.M*./V3*)3-[?
MPY_!R_N-G!SVNT[4?I(KX]K#)U8/WUIH$K53+P'+N&'*)(LJJ1'BKZ)<V2]+
MM-,$ZV!TX*&FUB5V]Y.[Q4/5!]%/ &PYP(<QK#<N2!];_BIZA%K)--2F)#F[
M1U;9RK[Z\]X4*]B*/9M+3\8.RA;,S=0W3$\['NF?;!!LVLMR[6AL['5/H=56
MKJKUE./>M*A^(-44R>K29N#K_ 703TFEN!+_RIXII#>'IJW*GE >F"_@)9$8
M9@)^7Z[_JURFW/[/AW>E7KS->^=C1OK&DA&KC_)@P9M'U08Z46(S\=3_P!7&
MMOUV@OSXWC-]%#!L2$Z&U?TB8FF$TT$F6#/<;!#DR<Z?>NS Z[\W'*;L/V99
M$SI7TIYTKA\QKQ2A3^FB_]%$-R7,5NPN0VT[[[U)N?MRJWZBVF[2@/O:3)<+
MQ,7.+-^H?+'A$WE^>0%\CI^%*>)12 ETVCSI'N"L4IYDRVIW""V;(:^OKFF(
MNT %+KU]%^>)L"FNSG;DJF%]U(<;WCD3$]DZ0Z7&$<JZP=<BU^0%3'W%IB_K
MJ]7'G>B >P,=:>MXJJ";6$QQ4M&/RUC8*1E?A@_4P$A.5]WR&*8F#?2^.#&\
MGA1<PI5)WW$<= 2%YX^SX/3FFY>,UDE$'WU^,L1=V##!GK(P7A@/<Q;:B9(F
MQ'-.(*PE7YR\[F&4[9X]V2(@.K7!]%0:EU[LK:\9\#ZG6BQAKC:(!:='@.3:
M9/<U!-><J'YF5141H^ 2RX>W<UWA4>J:"<?+L-N5Y5_YMW&_K1X?MSYVVM'K
M<V-8?O:$SNS:BH;0$KOI?G,%Q6C$9#?S99&+RP\3H^ZH)>"K/I-E7D^R505R
M  "K$:<<>';CRSI7ZIWRU!S]"3%'ZZ7#F"Z9J3M+7M]WDNV()*G3COACM$>C
M/1XLZ^C[1W_O(2^CR!OLN:B:?OM#%L>T94^(\^!-9Z-7(R'$]U;OT[GGVE8*
M5G*2)BWH=[@QFN?Y"5V1HE1WFU_L3HOPQOJ<2;]YL2S;+%*_+DX<I+"_$#=M
M$!^XP)A!3W7S F4K7]63FO5-O"[5NG.-C%DF'G<ND\3YJ[(1KD7XX1$0/CU2
M:9HK:3RWTQRS-*0I"?$!0F"6RR6XZYVE2M&;)4?O"T/7*RFA5J9D8H6+%SZK
M5U.9XF<JY!IOY!)_LG#+4A'O04P-'2$=32INCKW[<"#VL*%\E4P5/[&@T/U(
M8X@?H35WI%7D5HNS%,C\+(5)LZWS<\=\ 5:?S4K9/?O-\HEU78%+N57&%2\-
M"RZ*9H@&DS<"7K5.^#2CTF@[W'PW"+9UFARS$;IS-J]]6U%CEJ$B[.*7H5#_
MQS>3-GCTD%?JAP2"]6US Q?W.$T%^ZJ,)Y6)1\TV:I^)RSM(&BHF1P@^D)OD
MB;K'L&(CJBC'87>[O")$EDB!E,P5VU=8GXHKV<ZYQ4F@NI2WYV9(XZ/T6X;!
M;Z:^?F#.A'ATANICI5K)3"!N*PF,[&VMX4Z55R0DVV\S-$RE%@L72J-!M!TQ
MK<Q,ZS.#M6@ZZ2E$PI(U;LI]72/>+)ZO;!'XA<PCM7'_FF#?_TX7">K;_P)0
M2P,$%     @ !H$&4<_>\'@+A0  VZ8   T   !I;6%G95\P,#(N:G!G['ME
M5)S=LF;C#D&:X!#<W9T0/+B[:P=W"Q9(:-R#NTL'=[?@[NY.<)?)]QVYY]RY
M9]:]L^;/K'5VK_KU[MYOU99ZGJK:[^O\ZSK@C:RDC"0 "@H*X/'[!WA= H@#
M$.'A$>#A$!$0$)"0$)%1<=!045!0\;&P,7"("4A)B F(B,@HF6G(R!DIB(AH
M>>@86=DX.3E):?B$>-D%F3DXV?\8! H)"0D5!14/#0V/_1W1._;_<7OM & B
M0E/"H,) D0.@,:%@,*%>>P"D   4'-2?#?#7!@4- PL'CX"(A(SRNT/M&P T
M% P,-"P,'!PL[.^GOK^? V QX;#>L8G!8RL;(Y [XK 'Q&0C4KRO[ 2J3)Q1
M<I@X!2(AX[[%PR>@HJ:AI:/GY.+FX>7C%_\@(2DE+2.KJJ:NH:FEK6-J9FYA
M:65MX^SBZN;NX>D5]"4XY.NW4'!L7'Q"8M+WY)2<W+S\@L*BXI*JZIK:NOJ&
MQJ:N[I[>OOZ? X.34],SLW/S"XL;FUO;.[M[^P>'YQ>75]<WMW?W#W_8!06
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M*S2-U4_'V"7%%**2B_=S7P&4E85!>Q>PL3?90M=BPSY2=,B_DU9MP&G#^IB
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M1=B$_$L)-&*,LQ=\H^3K=;U]3ZA[*9^&94P'A&0XH88\MC'N9'W07@'&%J^
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M#->&[IYMU+%M1'39JW>6Y(\[I3"=.WM<E@.^>1#X63/$8T\^GD7HEL'NQ.X
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M$0&QR:O4H<=F%-[UAFFJ2[MTYV3##,5=+Z\4P.60/K;RK##UW?S\'?A6&G/
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ME#$&]5N<Y&.]L?PQC&TD4P3O+T*U,T=%Y:1YW7YVVMU58&]<]GN"-A4Q0DW
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M-82'8\@MO,F-IS;9Q=1.HXJM4I$,[=C"GC514T9ET8NT.0UH_QRJ7A6 E1Q
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M5H!PP)Q>#1UGE 1LW^SJ<;4PGT-63)MRG%GFJD71C;?C/^Q6F@+D>5"]D4/
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M&V)GRI7*)LNSH@7.8]VAUK(@:.[6Q.GSU6P#)DXRUZ4BB^ZO *M'J:4*GU<
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M'5E#6,^',-0I8R65#88C!>CZR0^[ HN>Z_A =AQ]B7>O5D#@U;G/AIC,B@^
M2^"C\:P>H7G62P,3=[@\X+:L[:3)&8\S&4]G!0N]3([?LU9@"<Z)9+W$V_'3
MIO^KTUEH<<S/,7$W&9=A?+VZJ@] 4QB][G;,W8@"QUY^F6KM!V9NDFY65$!R
MC:G :U$LXJ4'Z/Z:_=JP/!.#/9H3VS51)K.XE6XS<)T%U&X8E4H(H$A2#[N-
M,VM"PAD9V9HOG]F0L=P+9B?#RK&GKR]9M]UIF5PB--_HWN=7:XCR1B2"['4+
M[I[O5(4=%S!TNDAO+UZ,9$MC?B2H7B!N]S W-VRV]VH02GYO3*1X77UW:GH<
M/]%\D"&7[HWW]_S00*7\-4*&<WQ_1-RV5^"U\AG^ U 4L?VHFID^-14] !XO
M^+/.K&XVQS;3X']K.>.G! 2# 9-_!R4;,7Y0+VY3*/!F?/SW;6)O]-^X^ TC
M9T08Y3<NQ'_2\, "AOX:0Z$+<^W*JO%N16G\-T>:!LK]UP9'?N,^511@^\G3
M;P(P.Y6'X?\'##%]+8=?>-0/>BO99T_<;F[PASJ&^B>E] <"-%ZZPC/;>:$&
ML_O?VJ-Z=. 7I:*],929WMY3LT/^%@I%L)ZWQ&VY;[5?=%"R)[/[3EL$3*-<
M0^KH:\N:@PO[.$%59)B^%5$'\/-3IQS(C)_>4/KU5SG,I>4'O([L%5-VW(;"
MKBBZ#)$]/)ZN^DI'4E\#<C[/LTJH3Q4E'!*1++Z,D3F<F1;,H7L3[X0,QO]
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M96[$Z#:-,:2W]M'+'(N(UW5L-(^B4N:-"W/*VM1!'=.K>ZH;IJ )\L.-N1A
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M^VSM]IOG;R[2?/:)LY)397-*X;R9ML6QL@-_..@(P/7_;P( 4$L! A0#%
M  @ !H$&4:L_"8;O"0  55@  !$              ( !     &%V>&PM,C R
M,# V,S N>'-D4$L! A0#%     @ !H$&420D22DL"0  Y6(  !4
M     ( !'@H  &%V>&PM,C R,# V,S!?8V%L+GAM;%!+ 0(4 Q0    (  :!
M!E&\V?%L/Q$  #@. 0 5              "  7T3  !A=GAL+3(P,C P-C,P
M7V1E9BYX;6Q02P$"% ,4    "  &@091'#_5ZEPR  "AS@( %0
M    @ 'O)   879X;"TR,#(P,#8S,%]L86(N>&UL4$L! A0#%     @ !H$&
M4>K;+Z=<'P  /! " !4              ( !?E<  &%V>&PM,C R,# V,S!?
M<')E+GAM;%!+ 0(4 Q0    (  :!!E&PB4J+G (! &,S"0 )
M  "  0UW  !E,C U-"YH=&U02P$"% ,4    "  &@091;D,^<3('   Q'
M#P              @ '0>0$ 93(P-31E>%\S,3$N:'1M4$L! A0#%     @
M!H$&44( 2QY;!P  VQX   \              ( !+X$! &4R,#4T97A?,S$R
M+FAT;5!+ 0(4 Q0    (  :!!E$2ETH$2@8  -\9   /              "
M ;>( 0!E,C U-&5X7S,R,2YH=&U02P$"% ,4    "  &@091THKTS8A]  #V
MN0  #0              @ $NCP$ :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    (
M  :!!E'/WO!X"X4  -NF   -              "  >$, @!I;6%G95\P,#(N
9:G!G4$L%!@     +  L KP(  !>2 @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
